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Cannabis: The Evidence for Medical Use 
 
Executive Summary 
 
Cannabis has been used as a medical product for many centuries.  In recent 
decades it has been discovered that the human brain and other organs contain 
naturally occurring cannabinoid receptors as well chemicals that bind to those 
receptors.  This is called the endocannabinoid system.  It is known that the 
endocannabinoid system has a range of important natural functions, including 
modulation of pain, control of movement, protection of nerve cells and a role in 
natural brain adaptability (plasticity), as well as a role in various metabolic, immune 
and inflammatory processes and a possible role in the control of tumour growth.  
Plant cannabis probably works in man by “mimicking” the effects of the human 
endocannabinoid system. The main plant cannabinoids (phytocannabinoids) studied, 
and thought to be the most important in terms of efficacy, are tetrahydrocannabinol 
(THC) and cannabidiol (CBD), although many others exist and a role for them may 
become clearer in due course. 
 
In this paper we have analysed and graded the evidence for efficacy of cannabis and 
various licenced cannabis products for a number of different indications.  We have 
found good evidence for one or more of the cannabis products or “natural” cannabis 
in; the management of chronic pain, including neuropathic pain; spasticity; nausea 
and vomiting, particularly in the context of chemotherapy; and in the management of 
anxiety.  We have found moderate evidence in; sleep disorders; appetite stimulation 
in the context of chemotherapy; fibromyalgia; post-traumatic stress disorder; and for 
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some symptoms of Parkinson’s disease.  We have found some limited evidence of 
efficacy, but further studies are required, in; the management of agitation in 
dementia; epilepsy, particularly drug resistant childhood epilepsies; bladder 
dysfunction; glaucoma; and in Tourette’s syndrome.  We have found that there is a 
theoretical basis, but so far no convincing evidence of efficacy; for the management 
of dystonia; Huntington’s disease; headache; brain protection in the context of 
traumatic brain injury; depression; obsessive compulsive disorder; gastrointestinal 
disorders; anti-psychotic agent (CBD); and a role in cancer/tumour control.   
 
We have summarised the short term effects of cannabis, which are generally mild 
and well tolerated.  We have looked at the evidence for a causal link between 
cannabis use and schizophrenia and find that there is probably a link in those who 
start using cannabis at an early age and also if the individual has a genetic 
predisposition to psychosis.  Thus we recommend caution with regard to prescription 
of cannabis for such individuals.  We found there is a small dependency rate with 
cannabis at around 9%, which needs to be taken seriously but compares to a rate of 
around 32% for dependency in tobacco use and 15% dependency with regard to 
alcohol.  There may be a, as yet unproven, risk of respiratory cancer for smoked 
cannabis but nevertheless this route of administration is not recommended. The 
evidence for cognitive impairment in long term users is not clear but it is wise to be 
cautious in prescribing cannabis to younger people, given the possible susceptibility 
of the developing brain.   
 
Overall, we conclude there is considerable literature demonstrating the efficacy of 
cannabis and/or available cannabis products in a number of important indications. 
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Clearly there needs to be much further work with regard to the formulation of 
cannabis and the best THC:CBD ratio for different conditions and better and further 
studies are needed on both short and, more particularly, longer term effects.  We 
consider that these studies will be facilitated by legalisation of cannabis for medical 
indications in strictly controlled circumstances with a quality-controlled product and a 
secure supply chain.  
 [1] 
 
Cannabis: The Evidence for Medical Usage 
 
1. Introduction 
 
The authors have been asked by the All Party Parliamentary Group for Drug Policy 
Reform to carry out a review of the efficacy of cannabis for medical use.  Specifically, 
we have been asked to – 
 
 Examine those diseases and conditions where cannabis is identified as 
having an established or credibly potential treatment application. 
 To assess and grade the quality of the research related to each of those 
diseases and conditions. 
 To document the side effects of cannabis. 
 To comment on the impact of potential legalisation of cannabis in the United 
Kingdom on potential medical use and supporting research. 
 
The work was carried out in April and May 2016.  The authors have received a small 
grant from the APPG for Drug Policy Reform for this work.  The authors have 
received no other remuneration from any other source and have no commercial 
interests in cannabis or cannabis products.  The work has been carried out in a 
personal capacity and the evidence collated in this paper and the views expressed 
are those of the authors alone and do not represent the views of Newcastle 
University or Northumberland, Tyne & Wear NHS Foundation Trust. 
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2. Search Criteria and Grading of Evidence 
 
The authors have searched a number of established databases, including Medline, 
AMED, BNI, Cinahl, Embase and PsycINFO.  The search terms were cannabis (also 
refined to medicinal cannabis), marijuana, endocannabinoids, phytocannabinoids 
tetrahydrocannabinol (THC), cannabidiol (CBD) and relevant specific drug names, 
including Nabiximols (Sativex), Nabilone (Cesanet), Dronabinol (Marinol) and 
Cannador.  This search produced over 20,000 references although clearly there was 
significant overlap between the search terms.  The relevant papers that describe 
efficacy / safety under the different headings were then analysed and graded.   
 
The medicinal cannabis literature is far from satisfactory in that it contains many 
small scale studies as well as case reports and anecdotal evidence but very few 
good quality placebo-controlled double-blind trials. (this means that neither the 
investigator nor the participant knows whether they are taking the actual product or a 
placebo or other comparator). The authors recognise the difficulties of cannabis 
research, particularly given the illegality of cannabis in many countries.  We also 
recognise the value, in the early phase of drug studies, of small scale trials that may 
point towards potential efficacy and pave the way for larger scale studies.  However, 
in terms of the current strength of evidence we felt that it would be reasonable to 
adopt the grading system used by the American Academy of Neurology and used in 
the systematic review of medical marijuana for neurological conditions by the 
Academy (Koppel et al 2014). The American Academy’s grading scheme 
(paraphrased) is as follows: 
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Class I study: a randomised, controlled clinical trial with masked or objective 
outcome assessment, in a representative population.  Relevant baseline 
characteristics of the participants should be presented and should be substantially 
equivalent among treatment groups (or there is appropriate statistical adjustment for 
differences).  The following are also required: 
a) Allocation to the groups in a blind fashion (so that neither the patient nor the 
investigator are aware of the allocation) 
b) Primary outcome clearly defined 
c) Exclusion / inclusion criteria clearly defined 
d) Adequate accounting for dropouts (with at least 80% of enrolled subjects 
completing the study) with dropouts sufficiently low to have minimal potential 
for bias. 
e) For non-inferiority or equivalence trials claiming to prove efficacy for one or 
both drugs, other criteria are also required (see Koppel et al 2014) 
 
Class II study: a randomised, controlled clinical trial in a representative population 
with masked or objective outcome assessment that lacks one criterion a-e in Class I 
or a prospective matched cohort study with masked or objective outcome 
assessment in a representative population that meets b-e in Class I.  Relevant 
baseline characteristics are presented and substantially equivalent among treatment 
groups (or there is appropriate statistical adjustment for differences).   
 
Class III study: All other controlled trials (including well-defined natural history 
controls or patients serving as their own controls) in a representative population, 
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where outcome is independently assessed, or independently derived by objective 
outcome measurements. 
 
Class IV study: Studies not meeting Class I, II or III criteria, including consensus or 
expert opinion. 
 
Overall, the authors felt it would be helpful to grade the evidence for each indication 
into “good”, “moderate” or “some”.  We felt that it was reasonable to suggest that if 
there was evidence from at least two Class I studies for an indication backed up by a 
theoretical basis and other Class II/III/IV evidence then that would be deemed as 
being “good” evidence of efficacy.  If there was one Class I study or at least two 
Class II studies, backed up by Class III/IV studies and a theoretical basis, then this 
would be “moderate” evidence of efficacy. If there were no Class I studies and only 
a single Class II study but there was evidence from Class III/IV studies and a 
theoretical basis, then this would be “some” evidence of efficacy.  Lesser levels of 
evidence cannot lead to any recommendation. The authors wish to emphasise that 
“some” or “no” evidence of efficacy does not equate with poor efficacy but simply that 
there is currently insufficient data from studies to arrive at a definitive conclusion 
regarding the efficacy in that particular indication.   
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3. A Brief History of Medicinal Cannabis and its Regulation in the UK 
 
It is not the purpose of this review to give a detailed history of cannabis as a 
medicine but nevertheless some background information may be of interest.   
The medical use of cannabis dates back to around 4000 BCE in ancient China.  It is 
also known to have been used in ancient Egypt.  In addition, there is written 
documentation of use in India in at least the second millennium BCE.   
It is also clear that ancient Greek and Roman cultures used cannabis.  The first 
detailed account of the medical use of cannabis was in the first century CE when 
Dioscorides published his Materia Medica (Russo 2004a). Cannabis was 
recommended for the treatment of otalgia as well as for the use of joint pain, gout 
and burns.  At this time the medicinal gastrointestinal effects of cannabis were noted.  
Around the 10th century the use of cannabis was largely promulgated through the 
Arabic culture of the era.  It was around this time that it was used as an analgesic 
agent, including migraine.  However, cannabis went through periods when it was ‘out 
of fashion’.  Pope Innocent VIII in 1484 deemed it associated with witchcraft and 
cannabis consequently was less used.  Another period of prohibition was attempted 
after the Napoleonic invasion of Egypt.  However, by the late 19th century a number 
of cannabis indications were being explored and it was used throughout Europe for 
migraine, neuropathic and musculoskeletal pain and as an aid to childbirth.  
Obviously the psychoactive properties were also known and it is felt that it 
contributed to the writings of a variety of authors, including Baudelaire and Dumas.  
Around this time the significant physicians of the age supported medicinal use and 
indeed Sir John Russell Reynolds recommended it for various conditions ranging 
from insomnia to dysmenorrhea and indeed prescribed it to Queen Victoria.   
 [6] 
 
By the end of the 19th century it was in widespread use and available in a number of 
formulations.  However, in the 20th century it faced prohibitive legislation across the 
globe.  
 
In the UK it actually remained clinically available until 1971 when it was reclassified 
and banned under the Misuse of Drugs Act. This Act made possession and supply of 
controlled drugs unlawful. Cannabis was included.   
 
There are three Classes of controlled drugs under the Act and the Class determines 
the range of penalties for possession and supply. Class A drugs are deemed the 
most harmful with the highest penalties. That category includes morphine, 
diamorphine (heroin), cocaine and LSD. Class B drugs represent an intermediate 
category including amphetamines and barbiturates, as well as cannabis.  Class C 
drugs are deemed to be the least harmful and thus carry a lesser penalty and include 
anabolic steroids, benzodiazepines and growth hormones.   
 
The Misuse of Drugs Regulations 2001 define the categories of people authorised to 
supply and possess drugs controlled under this Act. Schedule 1, which includes 
drugs such as cannabis, are not conventionally used for medical purposes and are 
deemed to have no medicinal value.  Possession and supply is prohibited without 
specific Home Office approval.  Schedule 2 includes morphine and diamorphine and 
those drugs are subject to special requirements relating to their legal prescription, 
including safe custody and the need to maintain registers.  Nabiximols (Sativex) is 
marketed under Schedule 4, which means that its prescription is not subject to 
special prescription or safe custody requirements.  However, at the moment natural 
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cannabis is still Schedule 1 and remained a Class B drug until 2004 when the 
Advisory Council on the Misuse Drugs recommended it should be reclassified to 
Class C. In 2009 it was reclassified back to Class B.  CBD in isolation is not 
proscribed. THC in certain formulations (nabilone and nabiximols) is also legally 
prescribable. 
 
In 2006 the UK parliamentary Science and Technology Select Committee produced 
a report that said the present classification was arbitrary and unscientific and 
suggested improvements. There has not yet been a change in the law as a result of 
their recommendations 
 
As a Schedule 1 drug it is very difficult, although not impossible, to undertake studies 
of cannabis and clearly, at least in the UK, this has hampered the progression of 
medical cannabis research.  
  
Cannabis has also been restricted in many countries across the globe, although in 
recent years the medical prescription / use of cannabis has been made legal in a 
number of countries, including 11 European countries and currently 24 states in the 
USA.  It is also legal, or partially legal, for medical use in Australia, Canada, Chile, 
Colombia, Ecuador, Israel, Paraguay, Peru, Puerto Rico and Uruguay.   
 
  
 [8] 
 
4. The Scientific Rationale for Medicinal Cannabis 
 
Whilst the medical benefits of cannabis have been known for many centuries, it is 
only in very recent years that a scientific rationale for the effects of cannabis on 
human bodily systems has been developed.  In 1990 Matsuda and colleagues first 
described a cannabinoid receptor in several species, including man (Matsuda et al, 
1990).  Eventually this receptor was called the CB1 receptor and a few years later 
another receptor, called CB2, was also identified (Munro et al 1993).  CB1 receptors 
are present throughout the central nervous system and in some peripheral tissues, 
including the immune system, reproductive and gastrointestinal systems and are 
also found in the heart, lung and bladder.  The CB2 receptors are mainly expressed 
by immune cells.  The discovery of these cannabinoid receptors led to significant 
further studies on what is now termed the endocannabinoid system (ECS).  The 
endocannabinoid system is characterised by the two primary receptors, CB1 and 
CB2, and the chemicals (called lipid ligands) that bind to those receptors and the 
mechanism of their synthesis and metabolism. The key ligands are Anandamide and 
2-Arachidonoylglycerol (2-AG), although others are known. It is thought that the 
phyto-cannabinoids found in the natural cannabis plant (see Section 5) mimic the 
effects of the human cannabinoid receptor ligands, particularly Anandamide and 2-
Arachidonoylglycerol. (Skaper and Di Marzo 2012).  The endocannabinoid system 
has now been identified in many bodily regions, not only the brain but also in the 
digestive tract and bladder (Izzo, et al 2015) and is now known to be involved in a 
number of metabolic (Gatta-Cherifi and Cota 2015) and endocrine (Hillard 2015) and 
immune (Cabral et al 2015) disorders. The ECS also seems to have a role in the 
regulation of tumour growth (Velasco et al 2015).  In neurological terms, the 
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endocannabinoid system is involved in brain protection after damage, modulation of 
pain, regulation of motor activity and has a role in nerve formation (neuro-genesis), 
brain adaptability (plasticity) and the control of some aspects of memory processing 
(Pertwee 2015).     
 
In summary, the medical effects of herbal cannabis in man are very likely to be 
modulated by the phyto-cannabinoids found in the cannabis plant which mimic the 
actions of the naturally occurring cannabinoid receptor ligands.  There is, of course, 
much more to be learnt about the effects of the endocannabinoid system.  It is likely 
that as our knowledge of the human endocannabinoid system develops then we will 
be in a better positon to develop strategies for improving the efficacy of 
cannabinoids. It may, for example, be possible to target specific cannabinoid 
receptors located outside the brain or receptors only expressed by a particular 
tissue. This may allow for better targeting of effects and limitation of side effects. 
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5. Cannabis – The Plant and the Phyto-Cannabinoids 
 
Cannabis is a very hardy plant that grows throughout the world from the equator to at 
least 60o north.  It is thought to be present in three separate species – cannabis 
sativa, cannabis indica and cannabis ruderalis (Schultes et al 1974), although this is 
somewhat controversial in botanical circles.  The plant probably originated in 
Central/Eastern Asia and, along with hops, is a member of the cannabaceae family.  
The plant produces natural cannabinoids called phyto-cannabinoids. The amount of 
phyto-cannabinoid varies among different strains.  The phyto-cannabinoid 
concentration is not uniform throughout the plant.  The phyto-cannabinoids are 
present in the leaves and stems but not the seeds and roots.  However, phyto-
cannabinoids are most abundant in the unfertilised female flower head.  The plant 
stem and leaf is covered in small outgrowths containing resin (the glandular 
trichome) and these have the highest concentration of phyto-cannabinoids and 
indeed when harvested and compacted this constitutes ‘hash’.  The plant has a 
fibrous stem known as the hemp and indeed hemp has been cultivated for centuries 
as a source of building materials, paper and textiles.  It is known from archaeological 
remains in China that hemp seed was being used between 3300 and 2300 BCE.  
Hemp seeds contain a high yield of protein and essential fatty acids.   
 
In 1964 the main psychoactive component of cannabis, tetrahydrocannabinol (THC), 
was isolated and synthesised in Israel (Gaoni and Mechoulam 1964).  This discovery 
was the followed by elucidation of many further phyto-cannabinoids in the plant.  The 
most important, in terms of medical use, in addition to THC, is cannabidiol (CBD).  
There are now over 100 phyto-cannabinoids identified in the natural plant.  Whilst it 
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seems clear that most of the psychoactive properties and some of the medicinal 
usage is secondary to THC, it is also clear that CBD has a number of potential 
medical usages.  It is also possible, as are our knowledge of phyto-cannabinoids and 
human endocannabinoid system develops, that some of the other cannabinoids may 
also have a medical use.  There is interaction between the phyto-cannabinoids and 
indeed it is known that CBD can reduce the psychoactive effects of THC.  As an 
example, nabiximols (Sativex) has a 1:1 ratio of CBD:THC and does not manifest 
psychoactive properties, despite a high concentration of THC.  
 
The ratio of THC:CBD appears to be quite important in terms of medicinal use and 
has a bearing on the side effect profile. It is also possible that the overall efficacy of 
the natural plant in medical terms depends not only on THC and CBD and the other 
phytocannabinoids but also on the “entourage effect” of the other plant chemicals 
that in themselves may not act on the CB receptors (Ben-Shabat et al 1998). 
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6. Cannabinoid Formulations Used in the Efficacy Studies  
 
A major problem with cannabis studies is that a number of different formulations of 
cannabis are available.  Basically, these formulations vary in terms of the relative 
proportion of THC and CBD.  A few studies have used ‘natural’ smoked cannabis or 
a cannabis extract.  However, most studies use the cannabis products that are 
commercially available.  These are: 
 
Nabiximols (Sativex) – GW Pharmaceuticals, UK 
 
This is an oromucosal spray that contains an approximate 1:1 ratio of THC to CBD.  
It is approved in the United Kingdom and is a Schedule 4 Part I controlled drug that 
has been approved for use in patients with moderate to severe spasticity due to 
multiple sclerosis (MS) who have not yet responded adequately to other anti-
spasticity medication and who demonstrate clinically significant improvement in 
spasticity related systems during an initial trial of therapy. Nabiximols must be 
initiated and supervised by a physician with specialist expertise in treating that 
patient population.  It is approved in a number of other European countries.  It also 
has full regulatory approval for spasticity in New Zealand and is approved in Israel 
for MS spasticity and MS associated neuropathic pain.  In Canada it is also approved 
for symptomatic relief from neuropathic pain and as an adjunctive analgesic 
treatment in patients with advanced cancer who still experience moderate to severe 
pain during the highest tolerated dose of strong opioid therapy. 
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GW Pharmaceuticals are also conducting studies in childhood resistant epilepsy 
(Dravets syndrome and Lennox-Gastaut syndrome). The product used in those 
studies is known as Epidiolex and consists purely of the cannabinoid CBD. 
 
Nabilone (Cesamet) – Meda Pharmaceuticals, USA 
 
Nabilone is a synthetic product that was approved (in 1985) by the US Food and 
Drug Administration for treatment of chemotherapy-induced nausea and vomiting 
that has not responded to conventional anti-emetics.  It is also approved in Canada, 
UK and other countries for similar indications.  It is a synthetic cannabinoid analogue 
of THC.  It is formulated as a capsule.   
 
Dronabinol (Marinol) – Solvay Pharmaceuticals, USA 
 
Dronabinol is an isomer of THC and is synthetically manufactured. That means it has 
the same molecular formula but a different chemical structure. It is prescribable in 
the United States and is used to treat nausea and vomiting caused by chemotherapy 
but is also used to treat loss of appetite and weight loss in people who have acquired 
immunodeficiency syndrome (AIDS).  It is formulated as a capsule.  It is not legally 
prescribable in the UK. 
 
Cannabis Extract (Cannador) – IKF, Germany 
 
This is a whole plant extract with a standardised THC/CBD ratio of about 2:1. It is no 
longer widely available.   
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Bedrocan 
 
This is medicinal grade cannabis and made under contract for the Dutch Ministry of 
Health and available for prescription in the Netherlands.  It is also exported for 
medicinal use to various European countries and further afield, including Canada.  It 
is recommended to be vaporised.  The parent company, Bedrocan, has produced six 
strains of medicinal cannabis with varying THC/CBD levels.  These are – 
 
Bedrocan – standardised THC level of 22% with a CBD level below 1%.  It is the 
most widely used cannabis offered by the Dutch Ministry. 
 
Bedrobinol – this is standardised with a THC content of 13.5% with a CBD level 
below 1%. 
 
Bediol – has a standardised THC content at 6.5% with a level of CBD at 8%.  This is 
available in granulated form. 
 
Bedica – has 14% THC with less than 1% CBD.  It is made from a different variety of 
cannabis (cannabis indica) as opposed to the more usual cannabis sativa variety. 
 
Bedrolite – this contains 9% CBD and 0.4% THC and is non-psychoactive.   
 
Bedropuur – is a high THC cannabis indica variety with less than 1% CBD but is only 
available in Canada for research purposes. 
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The Bedrocan products are now widely known but have not been included in any 
major trials of efficacy.   
 
Some studies have used other variable formulations of cannabis extract containing 
difference ratios of THC/CBD and indeed some containing just CBD.   
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7. Forms of Ingestion / Inhalation and Dosage 
 
7.1 Ingestion /Inhalation 
 
The other difficulty of studying cannabis is that, in addition to the different 
formulations, there are also different ways of using cannabis itself.  As noted above, 
two of the licenced products, nabilone and dronabinol come in capsular form.  
Nabiximols is administered as an oromucosal spray.  Natural cannabis is widely 
smoked.  The dried flowers or leaves of the cannabis plant are smoked through a 
pipe, or rolled into a joint (as in a tobacco cigarette) or smoked using a water pipe 
(bong).  However, for medical reasons smoking is not generally recommended as it 
is possible that carcinogens may be inhaled in a similar fashion to tobacco smoking 
(see Side Effect section and Melamede 2005). 
 
Vaporising is a method that extracts the therapeutic ingredients of the cannabis plant 
at a much lower temperature than required for burning.  The individual inhales the 
active ingredient as a vapour instead of smoke.   Vaporising is a more efficient way 
of converting the plant matter into active ingredients and it is likely that more of the 
THC and other cannabinoids are available through vaporisation than through 
smoking.   
 
Edible cannabis can be infused in butter or oil and cooked in food.  The therapeutic 
effect is less certain and it usually takes longer for the effect to be recognised.  
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Cannabis can also be applied topically and includes availability in lotions, balms, 
sprays, oils and creams and also can be available as a tincture which is a 
concentrated form of medical cannabis in an alcohol solution.   
 
Thus, when larger scale studies of cannabis become available with the wider 
legalisation of the plant, the studies will need to be controlled according to the 
method of ingestion/inhalation.  The natural products will have different availabilities 
of the cannabinoids according to which method is used.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 [18] 
 
7.2 Dosage 
 
The other variable in clinical studies is the dosage of cannabis.  The doses used for 
the licenced products (nabilone, dronabinol and nabiximols) are normally quoted in 
the relevant efficacy papers.   
 
However, the dosage of ‘natural’ cannabis will clearly vary according to the form of 
inhalation/ingestion as well as the strength and purity of the product.  The studies 
using natural cannabis, particularly Class III / Class IV evidence, often do not quote 
the dosage taken by the subject.  This clearly has a significant bearing on the 
efficacy of the product.   
 
Smoking cannabis results in a more rapid onset of action and the effect is usually 
noticed within minutes.  Smoking results in higher blood levels of cannabinoids and a 
shorter duration of effects compared to oral administration (Huestis 2007).  
Unfortunately, the amount of THC delivered from cannabis cigarettes is variable.  
There are factors that are difficult to control in a non-licensed setting, including 
source of the plant material and the actual composition of the cigarette - as well as 
the efficiency and method of smoking.  Indeed, studies have demonstrated a large 
variation in bio-availability between 2 and 56% depending on depth of inhalation, puff 
duration and breath hold (Drotenhermen 2003). 
  
Vaporising can also produce a wide variation of blood cannabis levels according to 
the amount and type of cannabis placed in the vaporiser, the vaporising temperature 
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and duration, and the volume of the balloon (in which the vapour is collected prior to 
inhalation).   
 
Oral administration results in slower onset of action, lower peak blood levels of 
cannabinoids and a longer duration of effects compared to smoking or vaporisation. 
Unfortunately, the absorption is unreliable from an oral route. As an example, 
systemic availability of THC from a chocolate cannabis cookie has been estimated to 
be only between 4 and 12% (Agurell et al 1986). The time for peak THC 
concentration is usually 1-2 hours after ingestion but in some people it can take 
several hours for peak levels to be attained.  
 
There is less information about topical (skin) application.  Most cannabinoids are 
highly hydrophobic (dislike water) and that makes topical application across the 
aqueous layer of the skin difficult to achieve.  However, topical application is a better 
method of administration for cannabidiol (CBD), as well as cannabinol (CBN), as it 
has a tenfold higher permeation than THC through the skin (Stinchcomb et al 2004).  
 
Further information on pharmacokinetics and pharmacodynamics of cannabis and 
cannabinoids is found in a useful publication produced by Health Canada in 2013 
(Health Canada 2013).  
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8. Efficacy of Cannabis 
 
This section will review the efficacy of cannabis.  We have reviewed several different 
conditions that have some published evidence and assessed the quality of that 
evidence for each condition.  Each section starts with a brief overview of the 
rationale for cannabis use in that condition before a more detailed review of the 
evidence base.  
 
We wish to emphasise that efficacy is likely to be specific, in evidential terms, to a 
particular cannabis formulation. If, for example, nabiximols is efficacious for 
spasticity this does not necessarily mean that other cannabis formulations will also 
be useful for spasticity. This will depend on many variables, particularly the 
THC:CBD ratio.   
 
The authors draw attention to useful systematic reviews and meta-analyses of 
cannabinoids for medical use in recent publications (Whiting et al 2015; Koppel et al 
2014; Hill 2015). 
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8.1 Pain  
 
Chronic pain is extremely common and has been estimated that 8-46% of the 
population has chronic pain at some point, depending on the definition (Elliott et al 
1999). Severe pain occurs in about 11% of adults and 8% of children. Severe 
chronic pain is known to have adverse effects on many aspects of life including 
employment, daily activities, relationships, mood, sleep and general health. Current 
treatment is often, but not always, effective but can be associated with serious side 
effects. This is particularly the case for the opioids, (see section 9.2) which carry very 
serious risks, including mortality.  
 
Cannabis preparations have been used to treat pain for centuries.  Indeed, in a 
recent survey undertaken for the APPG for Drug Policy Reform, it has been shown 
that pain is one of the leading reasons for medical use of cannabis in the UK.  It is 
known that the endocannabinoid system is one of the key bodily systems that 
regulate pain sensation with actions at all stages of the pain processing pathway.  
Neural signalling through both CB1 and CB2 receptors has a key role in normal pain 
processing and considerable animal model and pre-clinical data on both patients and 
healthy volunteers confirm that modulation of the endocannabinoid system can 
reduce pain (Burston and Woodhams 2014; Woodhams et al 2015). 
 
In terms of the clinical trials most have been carried out using the proprietary 
products nabilone, dronabinol and nabiximols.  These have been used in studies 
both of chronic pain and neuropathic (nerve) pain and cannabis preparations seem 
to have a positive effect on both those pain modalities.  The authors have decided to 
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discuss the clinical trials of cannabis and pain under different headings according to 
the specific available formulation – nabilone / dronabinol / nabiximols and ‘natural’ 
smoked cannabis. We have amalgamated the studies of chronic pain and 
neuropathic pain as there appears to be no significant difference in efficacy between 
these two pain modalities. 
 
8.1.1 Nabilone (Cesamet) and Pain 
 
One of the earliest studies of cannabis and pain was a simple description of the 
experience of 20 adult patients with chronic non-cancer pain published by Berlach 
and colleagues in 2006 (Berlach et al 2006). Fifteen of these patients reported 
subjective overall improvement with nabilone and nine reported reduced pain 
intensity. There were further beneficial effects on sleep and nausea.  Intolerable side 
effects were experienced in three patients (palpitations, urinary retention and dry 
mouth).  The authors concluded that nabilone may be a useful addition to pain 
management strategies and should be further evaluated in randomised controlled 
trials (Class IV).   
 
In the same year Wissel and colleagues (2006) used 1mg per day of nabilone on 
spasticity-related pain in a placebo-controlled, double-blind, crossover trial involving 
just 13 patients – 11 of whom completed the study.  The authors found significant 
decrease of pain with nabilone (p<0.05) with five patients reporting side effects, 
including drowsiness and transient weakness of the legs.  This is a relatively 
underpowered study but nevertheless pointed towards the fact that nabilone could 
assist spasticity-related pain.  Somewhat surprisingly, given the evidence of 
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effectiveness of cannabinoid products in spasticity (see Spasticity section), the 
authors found that spasticity itself did not change (Class II).   
 
Pinsger and colleagues (2006) conducted a placebo-controlled, double-blind pilot 
study divided into a 14-week crossover period with two four-week medication phases 
plus washout phases followed by a 16-week medication switch period.  The principal 
inclusion criterion was chronic therapy resistant pain.  Pain intensity was assessed 
by a visual analogue scale and quality of life scales.  Thirty patients were included 
and the authors found that nabilone treatment was superior to placebo with a 
decrease in the average spinal pain intensity as well as a decrease in average 
headache intensity, an increase in the number of days without headache as well as 
improvements in quality of life.  Patients continued to take their standard treatment 
and the authors concluded that adding nabilone to standard pain treatment produced 
a further positive benefit (Class I).  
 
Skrabek and colleagues (2008) showed improvement with nabilone on pain 
reduction and quality of life in 40 patients with fibromyalgia in a double-blind, 
placebo-controlled trial (see Fibromyalgia section).   
 
Frank and colleagues (2008) conducted an interesting comparative study between 
nabilone and dihydrocodeine for chronic neuropathic pain. This Class II study 
involved 96 patients with chronic pain attending three hospitals in the United 
Kingdom.  It was a straightforward randomised, double-blind, crossover trial of 14-
weeks duration comparing dihydrocodeine and nabilone.  Patients received a mean 
daily dose of 240mg of dihydrocodeine and 2mg of nabilone at the end of an 
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escalating treatment period of six weeks.  There was a two-week washout period.  
The visual analogue scale results showed that nabilone was slightly inferior to 
dihydrocodeine – in other words dihydrocodeine provided somewhat better pain 
relief and had slightly fewer side effects, although there were no major adverse 
events for either drug.   
 
Maida and colleagues (2008) carried out a Class III study using data from 112 
patients and showed that pain scores in the nabilone treated patients were 
significantly lower than those in untreated patients and other parameters also 
improved, including less nausea, less anxiety and overall less distress.  There was a 
borderline improvement in appetite in the nabilone group.  Patients taking nabilone 
had a lower rate of using non-steroidal anti-inflammatory agents, tricyclic 
antidepressants, gabapentin, dexamethasone, metoclopramide and ondansetron, 
with a greater tendency to discontinue those drugs.  Whilst this is not a well-
designed study it does indicate that nabilone does have pain relieving properties but 
also other benefits, particularly less nausea.  Indeed, it should be recalled that 
nabilone is licensed for the treatment of nausea and vomiting in the context of 
chemotherapy (see Nausea and Vomiting section).   
 
In a slightly different context Bestard and Toth (2011) studied nabilone either as 
monotherapy or adjuvant therapy with the first line medication gabapentin in a 
patient population with painful peripheral neuropathy (a condition causing pain in the 
nerve endings in arms and legs).  Patients were permitted to initiate either 
monotherapy (nabilone or gabapentin) or add one of these two medications to their 
existing pain treatment regime in a non-randomised open label study (Class III).  
 [25] 
 
There appeared to be similar benefits between nabilone and gabapentin in terms of 
pain improvement, as well as sleep improvements, anxiety and depression scores 
and sleep adequacy.  They concluded that nabilone appeared comparable to 
gabapentin for the management of such pain.  The same authors, with others, also 
concluded that flexible dosing of nabilone (1-4mg per day) relieved symptoms in 
diabetic peripheral neuropathy as well as improving disturbed sleep, quality of life 
and overall status. Nabilone was well tolerated as an adjuvant treatment in such 
patients (Toth et al 2012) (Class II).  Patients continued regular pain medications and 
were administered a single blinded adjuvant treatment with nabilone for four weeks.  
Those subjects achieving a >30% pain relief were then randomised and treated with 
either flexible dose nabilone or placebo in a further five-week double-blind treatment 
period. Greater than 30% pain relief is a standard measure of pain relief in pain trials 
and is thought to be a meaningful level of improvement for the patient.  
 
In the further indication of headache, Pini and colleagues (2012) studied a total of 30 
patients with medication overuse headache were enrolled in the study which was a 
randomised, double-blind, active-controlled, crossover comparing nabilone 0.5mg/ 
day and ibuprofen 400mg.  Patients received treatment for eight weeks with a one- 
week washout period.  Twenty-six patients completed the study.  The results showed 
that nabilone was more effective than ibuprofen in reducing pain intensity and daily 
analgesic intake and nabilone also was the only drug able to reduce level of 
medication dependence and improve quality of life.  Side effects were uncommon 
and mild and disappeared when nabilone was discontinued.  This is a Class II study 
as the trial was somewhat underpowered to show a difference between the 
compounds (see also Headache section). 
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The most up to date study of nabilone was published in 2015 (Turcotte et al 2015). 
This was a randomised, double-blind, placebo-controlled study involving 15 
relapsing/remitting patients with MS with MS-induced neuropathic pain.  The study 
compared nabilone to gabapentin.  Eligible patients with inadequate pain relief 
stabilised on gabapentin were then administered either nabilone or placebo titrated 
over four weeks followed by a five-week maintenance phase of 1mg oral nabilone or 
placebo twice daily.  The authors concluded that nabilone as an adjunct to 
gabapentin was effective and well tolerated for multiple sclerosis induced 
neuropathic pain (Class II).   
 
8.1.2 Dronabinol (Marinol) and Pain 
 
There is less evidence of the efficacy of the other synthetic THC – dronabinol.  In 
2004 Svendsen and colleagues studied central neuropathic pain in multiple sclerosis 
in a randomised, double-blind, placebo-controlled crossover trial involving 24 
patients (Svendsen et al 2004).  Dronabinol was administered at 10mg daily or 
placebo for three weeks separated by a three-week washout period.  Dronabinol 
showed an improvement in pain intensity compared to placebo as well as higher pain 
relief scores.  On the SF-36 quality of life scale (an accepted quality of life measure) 
the bodily pain and mental health sub scores indicated benefits from dronabinol.  
The authors concluded that dronabinol had a modest but clinically relevant analgesic 
effect on central pain in patients with multiple sclerosis.  There were some adverse 
events, including dizziness but these do not appear to be troublesome (Class II).   
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Dronabinol also seems to have a useful effect as an adjuvant treatment for those 
with chronic pain.  Narang and colleagues (2008) studied 30 patients taking opioids 
for chronic pain. Phase 1 of the study was a randomised, single dose, double-
blinded, placebo-controlled, crossover trial in which subjects were randomly 
administered either 10mg or 20mg of dronabinol or identical placebo.  Phase II was 
an extended open-label titrated trial of dronabinol as add-on medication to those with 
stable doses of opioids.  In phase 1, patients who received dronabinol experienced 
decreased pain intensity and increased satisfaction compared to placebo and there 
were no differences in benefit comparing the 10mg and 20mg dosage.  In phase 2 
titrated dronabinol contributed to significant relief of pain and increased satisfaction 
compared to baseline.  Side effects were relatively mild and dose related (Class I).  
 
8.1.3 Nabiximols (Sativex) and Pain 
 
Nabiximols is licenced for pain relief in a number of countries, including Israel and 
Canada, for the symptomatic relief of neuropathic pain in multiple sclerosis and as 
an adjunctive analgesic treatment in patients with advanced cancer who experience 
moderate to severe pain during opioid therapy.  Thus it is not surprising that there is 
reasonable evidence of efficacy, as the agent has passed regulatory hurdles.   
One of the earlier studies was by Berman and colleagues in 2004 (Berman et al 
2004). Brachial plexus root avulsion is considered a good human model of central 
neuropathic pain. (The brachial plexus is collection of nerves between the neck and 
shoulder and after trauma those nerves can damaged (avulsed). This is a very 
painful condition). In this study 48 patients with at least one avulsed nerve root were 
entered in a randomised, double-blind, placebo-controlled three period crossover 
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study comparing placebo with two formulations of cannabis – nabiximols and a 
further compound prepared by GW Pharmaceuticals (GW2000-02) which contained 
mainly THC.  The primary outcome measure was a mean pain severity score during 
the last seven days of treatment and this outcome measure just failed to show the 
active compound to be significantly better than placebo.  However, both the primary 
outcome measure and measures of sleep did show statistically significant 
improvements and the medications were well tolerated (Class I).   
 
In the following year Rog and colleagues (2005), studied central pain in multiple 
sclerosis in a five-week randomised, double-blind, placebo-controlled, parallel group 
trial in 66 patients. They were treated with nabiximols as an adjunct to analgesic 
treatment, the dose of which could be self-titrated.  The active product was superior 
to placebo in reducing the intensity of pain (p=0.005) and sleep disturbance 
(p=0.003) and was well tolerated (Class I).   
 
In the only study we could identify in the context of pain caused by rheumatoid 
arthritis, Blake and colleagues published the results of a 2006 study (Blake et al 
2006). The authors compared nabiximols to placebo in a randomised, double-blind, 
parallel group study in 58 patients over five weeks of treatment.  In comparison to 
placebo nabiximols produced statistically significant improvements in pain on 
movement, pain at rest, quality of sleep and quality of life measures.  Most of the 
adverse effects were mild to moderate and there were no adverse effect-related 
withdrawals or serious adverse events in the active group (Class I).   
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In a further context nabiximols was shown to improve pain characterised by allodynia 
in a randomised, double-blind, placebo-controlled trial (Nurmikko et al 2007). 
(Allodynia is an increased sensitivity to pain by a stimulus that normally would not 
cause pain). This study was in a good number of patients (125) and consisted of a 
five week randomised, double-blind, placebo-controlled, parallel design study with 
patients remaining on their existing stable analgesia.  A reduction in pain intensity 
scores was greater in those receiving nabiximols compared to placebo.  There were 
also improvements in the neuropathic pain scale, sleep, allodynia scores and the 
disability index.  Sedative and gastrointestinal side effects were reported more 
commonly on those on active medication.  In total of 18% of those on nabiximols and 
3% of those on placebo withdrew from the study (Class I).  An open label extension 
study showed that initial pain relief was maintained without dose escalation or 
toxicity for a further year. 
 
In yet another context Johnson and colleagues (2010) demonstrated the efficacy of 
pain relief in patients with advanced cancer pain that was not fully relieved by strong 
opioids. This study involved a reasonable number of patients (177). They were 
entered into a two week multicentre, double-blind, randomised, placebo-controlled, 
parallel group trial and were randomised either to nabiximols (n=60), a THC extract 
(n=58) or placebo (n=59).  A change from baseline in a mean pain numerical rating 
scale was statistically significant in favour of nabiximols compared to placebo 
whereas the THC group showed no significant change.  Indeed, twice as many 
people taking nabiximols showed a reduction of more than 30% from baseline scores 
when compared to placebo. On the negative side there was a worsening in nausea 
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and vomiting with nabiximols compared to placebo but otherwise drug related 
adverse events were mild or moderate (Class I).   
 
Similar positive results were found by Langford and colleagues in 2013 (Langford et 
al 2013). In this study nabiximols was compared to placebo in a double-blind, 
randomised, placebo-controlled, parallel group study in a total of 339 patients.  
These were individuals who failed to gain adequate analgesia from existing 
medications and they were treated with nabiximols spray or placebo as an add-on 
treatment in a double-blind manner for 14 weeks.  The parallel group phase was 
then followed by an 18 week randomised withdrawal study to investigate time to 
treatment failure and show maintenance of efficacy.  The primary endpoint of 
responder analysis at the 30% level at week 14 was not met - 50% of patients on 
nabiximols spray were classed as responders at 30% level compared to 45% of 
those on placebo.  However, an interim analysis at week 10 did show a statistically 
significant treatment difference in favour of nabiximols spray.  The primary endpoint 
of time to treatment failure in the randomised withdrawal phase was also in favour of 
the active spray.  A change from baseline in pain numerical rating scale and sleep 
quality was also in favour of nabiximols compared to placebo (Class I). 
 
Nabiximols has been shown to be a useful add-on analgesic for those with opioid 
refractory cancer pain and this was confirmed in a study by Portenoy and colleagues 
in 2012 (Portenoy et al 2012). This was a large scale study involving a total of 360 
patients who were randomised in a double-blind, placebo-controlled, graded-dose 
study.  The placebo group was compared to nabiximols at a low dose (1-4 sprays 
per day), medium dose (6-10 sprays per day) and high dose (11-16 sprays per day).  
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Once again the 30% responder pain primary analysis was not significant for 
nabiximols due to a high rate of placebo response.  The secondary responder 
analysis of average daily pain from baseline to end of study did show that the 
proportion of patients reporting analgesia was greater for nabiximols than placebo 
overall and specifically in the low dose and medium dose groups.  Adverse events 
appeared to be dose related and only the high dose group compared unfavourably 
with placebo.  This was a useful study of efficacy but more particularly of safety and 
provided useful dose information for future studies (Class I). 
 
8.1.4 Smoked Cannabis and Pain 
 
In addition to the studies of the synthetic cannabinoids and of nabiximols there have 
been a few studies in the context of pain with ‘natural’ smoked cannabis.  In 2007 
Abrams and colleagues reported a study that involved 50 patients who completed 
the whole trial and used smoked cannabis with random assignment to either smoked 
cannabis (containing 3.56% THC) or identical placebo cigarettes with the 
cannabinoids extracted (Abrams et al 2007). Cigarettes were smoked three times 
daily for five days. Greater than 30% reduction of pain (the accepted measure of 
efficacy in pain trials) was reported in 52% in the cannabis and 24% in the placebo 
group.  No serious adverse events were reported (Class II).   
 
Wilsey and colleagues (2008) conducted a double-blind, placebo- controlled, 
crossover study evaluating analgesic efficacy of smoking cannabis for neuropathic 
pain. Thirty-eight patients with both central and peripheral neuropathic pain 
underwent a standardised procedure for smoking either a high dose (7%) or low 
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dose (3.5%) or placebo cannabis cigarettes.  Pain intensity was a primary outcome 
measure and secondary outcome measures included evoked pain using a heat-pain 
threshold, sensitivity to light touch, psychoactive side effects and neuropsychological 
performance.  The authors confirmed analgesic response to smoking cannabis with 
minimal psychoactive effects and good toleration but with some acute cognitive 
effects, particularly with regard to memory at high doses (Class II). 
 
Ellis and colleagues (2009) studied the effect of smoked cannabis for neuropathic 
pain in HIV in a randomised, crossover clinical trial in patients with HIV-associated 
distal sensory predominant polyneuropathy (DSPN). (This is a painful nerve 
condition focussed in the arms and legs). The subjects had neuropathic pain 
refractory to at least two analgesic classes and they continued on their pre-study 
analgesic regime throughout the trial.  The active cannabis ranged in potency from 1-
8% THC and was smoked four times daily for five consecutive days during each of 
the two treatment weeks separated by a two-week washout period.  The primary 
outcome was a change in pain intensity.  Pain relief was greater with cannabis than 
placebo and the proportion achieving the 30% pain relief with cannabis was 46% 
compared to 18% in the placebo group.  Mood and daily functioning were similar in 
both groups.  Side effects were mild and self-limited (Class III).   
 
A recent study with regard to smoked cannabis and pain was produced in 2010 by 
Ware and colleagues (2010b). This was a study in adults with post-traumatic or post-
surgical neuropathic pain randomly assigned to receive cannabis at four potencies 
(0%, 2.5%, 6% and 9.4%) of THC over four 14 day periods in a crossover trial.  
Participants inhaled a single 25mg dose through a pipe three times daily for five days 
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followed by a nine-day washout period.  Twenty-three patients were recruited and 21 
completed the trial.  The average daily pain intensity was lower at the 9.4% THC 
level compared to placebo.  Preparations at the intermediate potency yielded 
intermediate but non-significant relief compared to placebo.  Those at the higher 
THC dose also reported improved ability to fall asleep and improved quality of sleep. 
There were some drug related adverse events in the high THC group, including 
headaches, dry eyes, burning sensation in areas of neuropathic pain, dizziness, 
numbness and cough (Class III).   
 
8.1.5 Conclusion 
 
This is a difficult literature to summarise as a number of different formulations have 
been used and a number of different types of pain have been studied.  The authors 
are also aware of the considerable literature in terms of anecdotal reports, case 
studies, questionnaires and uncontrolled trials that have also showed efficacy in 
various types of pain with various formulations.   
 
However, nabilone, dronabinol, nabiximols and smoked marijuana have all been 
shown to be efficacious to varying extents in a variety of pain settings in good quality 
studies.  We conclude that there is good evidence for efficacy of cannabis for pain 
relief in various formulations and in a number of settings. 
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8.2 Nausea and Vomiting in the Context of Chemotherapy 
 
Patient experiences that smoked cannabis relieves chemotherapy-induced nausea 
and vomiting (CINV) are widely recognized, and increasing evidence suggests a role 
for the endocannabinoid system in the regulation of nausea and vomiting (Parker et 
al 2010). The mechanism of action seems to be different from other medications and 
so could be used in combination with other anti-emetics to enhance their effect or in 
cases that have not responded to other anti-emetics (Machado Rocha et al 2008). 
 
According to Walsh and colleagues (2003), cannabinoids may be considered for 
controlling nausea and vomiting as a result of chemotherapy and may be effective in 
people with cancer who respond poorly to commonly used agents. They have been 
recommended in international anti-emetic guidelines for the prevention of 
chemotherapy-induced nausea and vomiting (CINV) (Gralla et al 1999). 
 
A recent Cochrane Systematic Review (Smith et al 2015) examined 23 randomised 
controlled trials (RCTs) which compared a cannabis medication with either a placebo 
or with another anti-emetic in adults receiving chemotherapy. The literature showed 
that cannabinoids were more effective than placebo and were similar to conventional 
anti-emetics (metoclopramide and prochlorperazine) for treating chemotherapy-
induced nausea and vomiting.  However, participants were more likely to report 
adverse events with cannabinoids, such as dizziness, dysphoria and sedation.  
Smith and colleagues concluded that cannabinoids may be a useful therapeutic 
option for people with chemotherapy-induced nausea and vomiting who have not 
responded to other anti-emetics (Smith et al 2015). 
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Machado Rocha and colleagues (2008) conducted a literature review on this area 
and found that cannabinoids were significantly more effective than placebo in the 
control of CINV, and the evidence from randomized clinical trials suggested that 
cannabinoids were slightly better than conventional anti-emetics. These findings 
have been corroborated by a recent meta-analysis carried out by Whiting and 
colleagues (2015) that assessed 28 randomised clinical trials into CINV and 
cannabinoid treatment.  Despite the adverse events reported in relation to 
cannabinoids, patients appeared to prefer them to conventional anti-emetics 
(Machado Rocha et al 2008), perhaps because of the sedation and euphoria effects, 
which may be valued by some patients whilst undergoing chemotherapy.   
 
Meiri and colleagues (2007) conducted a randomised controlled trial, which was 
double-blind and placebo-controlled, looking at the efficacy of dronabinol alone and 
in combination with ondansetron (an accepted anti-nausea medication) versus 
ondansetron alone. They found that ondansetron and dronabinol were similarly 
effective for the treatment of CINV and combination therapy was not more effective 
than either agent alone.  A limitation of this study is that it is somewhat 
underpowered with 66 participants (Class 1).   
 
Duran and colleagues (2010) conducted a randomized, double-blind, placebo-
controlled clinical trial which investigated the efficacy of medical cannabis 
(nabiximols in a spray form) in the treatment of CINV. Compared to placebo, 
nabiximols plus standard antiemetic therapy was well tolerated and significantly 
improved CINV.  Despite its robust methodology, this study had small participant 
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numbers and therefore the results would need to be substantiated by studies that are 
higher powered (Class 1).   
 
Another randomized, double-blind, parallel group, multicenter study tested 
dronabinol and prochlorperazine alone and in combination (Lane et al 1991).   They 
found that the combination of drugs was significantly more effective than either 
single agent in controlling CINV.  Only 29% of patients in the drug combination group 
experienced nausea after chemotherapy versus 47% in the dronabinol plus placebo 
group and 60% in the prochlorperazine plus placebo group. In addition, the median 
duration per episode and severity of nausea were significantly less with combination 
therapy (Class II). 
 
Conclusion 
 
In summary, cannabinoids for the management of nausea and vomiting with 
chemotherapy have been shown to produce some adverse effects but they are just 
as effective as established anti-emetics or actually slightly more effective (Whiting et 
al 2015).  Medicinal cannabis could be a useful adjunctive treatment to consider for 
people on moderately or highly emetic chemotherapy who are not responding to 
other anti-emetic treatments (Smith et al 2015). We consider that there is good 
evidence for this indication.  
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8.3 Appetite Stimulation 
 
The ability of cannabis to increase appetite and satiety has been documented for 
many centuries.  It is also known from questionnaire based studies of recreational 
cannabis users that many people actively use cannabis to improve appetite. Indeed, 
controlled laboratory studies with healthy subjects show that inhalation or oral 
ingestion of THC correlates with increase in food consumption, caloric intake and 
body weight (Foltin et al 1988). There is now a reasonable theoretical basis following 
further elucidation of the endocannabinoid system.  It is known there is a high 
concentration of CB1 receptors in brain areas associated with control of food intake 
and satiety.  There is probably a role of the endocannabinoid system not only for 
modulating appetite, food palatability and intake but also a role in energy metabolism 
and modulation of both lipid and glucose metabolism (Farrimond et al 2011).  
 
Studies have been carried out with regard to appetite stimulation and weight gain in 
HIV patients.  There have also been studies to counteract anorexia in cancer 
patients and indeed there are some, albeit more theoretical, studies of use in 
anorexia nervosa.   
 
Much of the work has been carried out with dronabinol, as appetite stimulation in 
various contexts is a licensed indication in some countries. In one study Haney and 
colleagues (2005) showed that experienced HIV+ cannabis smokers benefitted with 
regard to appetite from both dronabinol and also from smoked cannabis cigarettes 
three times per week for a total of eight sessions (Class IV).  
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In a subsequent (Class II) study by the same authors, higher doses of dronabinol (5 
and 10 mg) were alternated with smoked marijuana (2% and 3.9% THC) four times 
per day for four days with a washout period between phases. Both groups showed 
substantial increases in food intake and body weight as well as improvements in 
mood but only the high dose marijuana produced improved sleep (Haney et al 2007).  
 
On the other hand, Timpone and colleagues (1997) found that dronabinol only 
improved weight over 12 weeks of treatment in those with HIV associated wasting 
syndrome in combination with megestrol acetate (an appetite stimulant) but did not 
improve weight by itself (Class III).   
 
The product monograph for dronabinol in Canada summarised a six week 
randomised, double-blind, placebo-controlled trial in 139 patients with AIDS related 
anorexia who received 2.5mg of dronabinol twice a day compared to placebo.  Over 
the treatment period dronabinol significantly increased appetite with a trend towards 
improved body weight and mood as well as a decrease in nausea (Beal et al 1995) 
(Class I study). The main study was followed by an open-label 12-month follow-up 
that showed that dronabinol was safe and continued to be effective for long term use 
of anorexia in such patients.  The dose of dronabinol was 2.5mg twice a day, 
although higher doses (20-40mg per day) have been used (Beal et al 1997). 
 
In terms of cancer and appetite stimulation there have been surprisingly few studies.  
In two early studies (Class III), oral THC in the form of dronabinol did improve 
appetite and food intake in some patients undergoing cancer chemotherapy (Sallan 
et al 1980). In an open label study advanced cancer patients reported an increase in 
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appetite and food intake but limited weight gain (Nelson et al 1994).  In a large study 
by Strasser and colleagues (2006) there were 289 patients screened and 243 were 
randomly assigned to three groups to receive either cannabis extract, THC or 
placebo twice daily for six weeks.  Intention to treat analysis (analysis of all those 
entered into the study) showed no significant difference in the three arms for 
appetite, quality of life or cannabinoid related toxicity.  However, increased appetite 
was reported by 73%, 58% and 69% of patients receiving cannabis extract, THC or 
placebo respectively.  Indeed, the Independent Data Review Board recommended 
termination of recruitment because of insufficient differences between the study arms 
(Class II).   
 
Furthermore, when dronabinol was compared with megestrol it was less efficacious 
in appetite improvement and weight gain for cancer patients (Jatoi et al 2002). 
However, despite relatively modest improvements in cancer patients as opposed to 
HIV patients, cannabinoids may help in terms of quality of life.  A phase II 
randomised, double-blind, placebo-controlled 22-day pilot study (Class II) in adult 
patients with advanced cancer showed that the majority (73%) of dronabinol treated 
patients self-reported an increased overall appreciation of food compared to those 
receiving placebo (30%). A total of 64% of the dronabinol treated patients reported 
increased appetite whereas the majority of people in the placebo group reported 
decreased appetite (50%) or no change (20%). The patients were started at a low 
dose followed by a gradual dose escalation up to a maximum of 7.5mg of dronabinol 
daily (Brisbois et al 2011). 
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Despite the theoretical reason for manipulation of the endocannabinoid system in 
anorexia nervosa there have actually been very few studies, except in animal models 
or small uncontrolled trials in humans (Gross et al 1983). 
 
Conclusion 
 
In summary, we consider there is moderate evidence for improvement in appetite 
and for weight gain in AIDS patients.  There is much less satisfactory evidence for 
similar improvements in cancer patients but nevertheless there is a little patchy 
evidence of efficacy but more and larger studies are required. There is no convincing 
evidence of efficacy for appetite stimulation in anorexia nervosa but adequate 
studies have not been done. 
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8.4 Spasticity 
 
Spasticity is the second most researched indication for various cannabis 
formulations, after chronic pain.  The cannabis-med.org website, for example, lists 
53 spasticity studies using different formulations.  Most of the work has been in the 
context of multiple sclerosis, although there are a few studies on the management of 
spasticity in other conditions, particularly spinal cord injury.  The authors wish to 
emphasise that there is no particular difference in management of spasticity 
whatever the underlying neurological aetiology and if cannabis is deemed to be 
effective in spasticity in multiple sclerosis then there is no reason why it should not 
be effective in other neurological disorders that give rise to spasticity, such as spinal 
cord injury, traumatic brain injury and stroke.   
 
In these cannabis studies we consider it worthwhile to differentiate between the 
different cannabis formulations.  Most of the work has been carried out using 
nabiximols but other formulations have also been studied.  Once again, the authors 
wish to emphasise that if, for example, there is good evidence of efficacy using 
nabiximols then it does not necessarily mean that any cannabis formulation would 
have the same effect on spasticity.  It is likely that the efficacy of cannabis in this, 
and other indications, will depend on the relative ratio of the cannabinoids, 
particularly THC and CBD.  Thus we have summarised the evidence for spasticity 
under the different cannabis formulations. 
 
Spasticity is remarkably common, and a very disabling, symptom in the context of 
many neurological disorders, including multiple sclerosis, stroke, traumatic brain 
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injury, spinal cord injury, motor neurone disease and other neurological disorders.  
Indeed, spasticity can occur after any interruption to the upper motor neural 
pathways.  It is characterised by muscle spasm, particularly in the legs but can also 
occur in the arms or other parts of the body, such as the trunk or neck. The muscle 
spasm impairs coordinated movement giving rise to, for example, difficulties with 
walking, use of the arms, etc.  Often the condition is not only associated with 
incoordination but weakness of the involved muscles.  The spasm can be 
unpredictable and is often painful.  Thus cannabis has a potential dual action in 
patients with spasticity. It can relieve the muscle spasm but also reduce the pain 
associated with the spasm.  There are many treatment modalities for spasticity.  
Physiotherapy is often essential along with provision of appropriate equipment.  
However, from a medical point of view, there are a number of antispastic drugs, such 
as Baclofen, Dantrium, Tizanidine and others.  These are efficacious in terms of 
reduction of spasticity but can often be associated with significant and very 
unsatisfactory side effects, particularly fatigue and weakness. The underlying 
conditions are often already associated with fatigue and weakness and thus the 
antispastic drugs can make the overall situation worse.  Focal treatment can be 
administered, which includes botulinum toxin as a muscle relaxant which is injected 
into the affected muscle.  This is a useful treatment but it is less effective in more 
widespread spasticity, as the number of injections and the total dose of botulinum 
toxin has to be limited. There are surgical treatments, such as the use of intrathecal 
baclofen pumps or more aggressive surgical procedures.  Thus whilst there is an 
array of treatments for spasticity none are entirely satisfactory and there is certainly 
room for additional therapy, either alone or in combination with the existing 
modalities (Barnes and Johnson 2008).   
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8.4.1 Spasticity studies with nabiximols (Sativex) 
 
As we have noted, nabiximols is a licenced product in the UK under Schedule IV of 
the Misuse of Drugs Act.  It is a 1:1 combination of THC and CBD.  It is available as 
an oromucosal spray.  The first randomised controlled study was conducted by Collin 
and others in 2007 (Collin et al 2007). A total of 189 subjects with multiple sclerosis 
and spasticity were randomised to receive daily doses of nabiximols or placebo in a 
double blind study over six weeks.  The primary endpoint was a change of daily self-
recorded Numerical Rating Scale in spasticity.  Secondary endpoints included a 
more objective measure of spasticity (Ashworth Scale – which is an accepted 
objective measure of spasticity) and a subjective measure of spasm.  Primary 
analysis on the intention-to-treat population (this is the population who entered the 
study and the whole group is analysed regardless of drop outs) showed nabiximols 
to be significantly superior.  Secondary efficacy measures were in favour of 
nabiximols but did not achieve statistical significance.  Overall, about 40% of 
subjects achieved a greater than 30% benefit (which is an accepted measure of 
clinically useful improvement).  The product was associated with few serious side 
effects although there were eight withdrawals attributed to adverse events, six from 
the active preparation group and two on placebo (Class I).  
 
The same lead author undertook further work with nabiximols (Collin et al 2010). 
This was a 15 week multicentre, double-blind, randomised, placebo-controlled, 
parallel group study (Class I) in 337 subjects with MS spasticity not fully relieved by 
their current anti spasticity medication.  On this occasion the intention-to-treat 
analysis showed a non-significant improvement in the Numeric Rating Scale in 
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favour of nabiximols.  The per-protocol (analysis of those who completed the study) 
population change in the score and the responder analysis (> or =30% improvement 
from baseline in spasticity) were both significantly superior for nabiximols compared 
to the placebo group.  A carer “Global Impression of Change” (the carer view of the 
degree of improvement) also significantly improved, as did a timed 10 metre walk.  
The authors determined that if the patient was going to respond they had usually 
done so within the first four weeks of treatment.   
 
As a result of this finding, Novotna and colleagues (2011) conducted a redesigned 
trial.  This was a 19-week, follow-up, multicentre, double-blind, randomised, placebo-
controlled, parallel-group study in subjects with multiple sclerosis with resistant 
spasticity.  The subjects were treated with nabiximols as add-on therapy in a single 
blind manner for four weeks and those who achieved an improvement in their 
spasticity of greater than 20% progressed to a 12 week randomised, placebo-
controlled, phase.  The authors felt that this reflected clinical practice.  A total of 272 
out of 572 subjects achieved a greater than 20% improvement after the four week 
single blind phase and 241 were randomised.  The intention-to-treat analysis showed 
a highly significant difference in favour of nabiximols (p=0.0002).  Secondary 
endpoints were responder analysis, spasm frequency scores, sleep disturbance, 
Numeric Rating Scale and carer and clinician global impression of change were all 
significant in favour of nabiximols (Class I).   
 
It is of interest that this preparation is one of the few cannabinoid formulations that 
have been studied for longer term use (Notcutt et al 2012). These authors showed 
maintenance of nabiximols efficacy over a mean duration of usage of 3.6 years with 
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a mean daily dose of 8.25 sprays of the compound.  In a further long term use study 
Serpell and colleagues (2013) followed up, in an open label fashion, 146 patients 
with a mean treatment exposure of 334 days and the patients were administering an 
average of 7.3 sprays per day.  A total of 36% of the patients withdrew in the first 
year, 14% due to side effects and 9% due to lack of efficacy.  Most side effects were 
mild to moderate in severity and the commonest were dizziness and fatigue.  There 
were five patients with more serious side effects, including two psychiatric events 
reported by one patient.  However, no psychosis or withdrawal symptoms seemed to 
occur after abrupt cessation of treatment.  In the long term the baseline spasticity did 
not deteriorate but was maintained to study completion in those who did not 
withdraw.  There was no evidence of tolerance developing. However, this is an open-
label study but nevertheless provides useful long term safety data (Class IV). 
Nabiximols have also been studied in a large patient group in Germany 
(Flachenecker et al 2014). The study involved 335 patients and 276 fitted the 
admission criteria and were included in the effectiveness analysis.  After one month 
nabiximols provided relief of resistant spasticity in the patients in 74.6% of cases, as 
documented by a mean reduction of the spasticity Numerical Rating Scale.  In this 
study after three months 55% of patients had continued to use nabiximols.  A total of 
17% of patients reported some adverse events although the treatment was well 
tolerated.  This is a simple observational prospective study and thus limited 
conclusions can be drawn but nevertheless this further provides useful long term 
safety data and confirms longer term efficacy of the product (Class IV). 
 
Similar results have been confirmed in other open-label long term follow up studies 
(Ferre et al 2016). Further long term evidence of continuing efficacy and safety was 
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recently published by Zettl and colleagues in 2016 (Zettl et al 2016). This study 
confirmed that dizziness and fatigue were the most common treatment related 
adverse events being mostly mild to moderate in severity.  They confirmed 
continuing efficacy and safety in a total of 1600 patients with multiple sclerosis with a 
total of over 1500 patient years.   
 
There are other studies of nabiximols but overall we consider there is good evidence 
of the efficacy of nabiximols for the management of spasticity in multiple sclerosis.  
Some of the studies were not initially convincing although all showed antispastic 
effects in favour of nabiximols.  Later studies have involved analysis after a four-
week open phase to determine responders, which we consider is a reasonable 
approach and reflects clinical practice.  The studies confirm that nabiximols is 
generally well tolerated and efficacy has been shown to be long term, but not in all 
initial responders.  A question arises in this and other cannabis studies of whether 
subjects can be truly blinded (unaware of which treatment they are taking) given that 
the active product is likely to give rise to a ‘high’ whereas placebo does not.  This 
may be the case in studies of herbal cannabis or those with high THC content.  
However, CBD counteracts the effect of the THC ‘high’ and this appears to be the 
case in the nabiximols studies.  Wright and colleagues reanalysed 666 patients, 
included in three phrase III placebo-controlled studies (Wright et al 2012). Two of the 
three trials have been referred to above (Collin et al 2007 and Collin et al 2010). The 
other study was an earlier nabiximols double-blind, randomised, placebo-controlled 
study by Wade and colleagues (2004). The authors concluded that there was no 
evidence to suggest the widespread unblinding to treatment allocation in those three 
studies and they found no evidence that if individuals did become unblinded then this 
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led to bias in the assessment of treatment difference between nabiximols and 
placebo for efficacy, adverse events or dosage.  This is clearly reassuring but is 
obviously only likely to apply to drugs with a high proportion of CBD to THC.  
  
8.4.2 Spasticity Studies with Other Formulations 
 
Other authors have used different cannabis formulations.  Indeed, studies date back 
to 1981 when Petro and Ellenberger described the first use of THC for human 
spasticity (Petro and Ellenberger 1981). Vaney and colleagues (2004) used cannabis 
extract capsules standardised to 2.5mg THC and 0.9mg CBD.  Participants (50) 
received the active compound for 14 days followed by placebo or placebo for seven 
days and active treatment for 14 days.  In the intention-to-treat analysis there was no 
statistically significant difference associated with active treatment compared to 
placebo but there was a trend in favour of active treatment for spasm frequency, 
mobility and getting to sleep.  In the 37 patients who received at least 90% of their 
prescribed dose there were significant improvements in spasm frequency and 
mobility.  Adverse effects seemed to be relatively minor (Class II). 
   
In 2003, Zajicek and colleagues reported on a large study (Class I) of 33 UK centres 
giving oral cannabis extract or THC or placebo over a trial duration of 15 weeks 
(Zajicek et al 2003).  The study noted no treatment effect of cannabinoids on the 
primary outcome measure which was a change in overall spasticity score using the 
Ashworth scale.  There was evidence of treatment effect on patient reported 
spasticity and pain with improvement in spasticity reported in 61% of those on the 
cannabis extract and 60% of those on THC but only 46% of those on placebo.  
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In 2012 Zajicek and colleagues produced a further (Class I) study of oral cannabis 
extract or placebo in 22 UK centres in patients with stable multiple sclerosis and 
spasticity (Zajicek et al 2012).  This was a double-blind, placebo-controlled phase III 
study with a two-week dose titration phase from 5mg to a maximum of 25mg of THC 
daily and a 10-week maintenance phase.  The primary outcome measure in this 
study was a rating scale measuring patient reported change in muscle stiffness and 
further rating scales assessing body pain, spasms and sleep quality.  The relief from 
muscle stiffness after 12 weeks was almost twice as high with cannabis extract than 
with placebo and similar results were found for the secondary outcome measures. 
The authors reported no new safety concerns. 
 
There is one study of smoked marijuana in a randomised, placebo-controlled trial 
(Corey-Bloom et al 2012). Thirty-seven participants were randomised and 30 
completed the study.  The randomisation was either to smoked cannabis once daily 
for three days or placebo cigarettes.  After a washout interval of 11 days participants 
crossed over to the other group.  The primary outcome was a change in the Modified 
Ashworth Scale (similar to the Ashworth scale and still an accepted scale) with 
secondary outcomes of perception of pain, a timed walk, changes in cognitive 
function and ratings of fatigue.  Treatment with smoked cannabis resulted in a 
reduction of patient scores by an average of 2.74 points compared to placebo 
(statistically significant at p < 0.0001).  In addition, pain scores were significantly 
reduced, timed walking did not differ and there were no serious adverse events.  
However, this trial had few participants and there were issues with the study design 
and blinding (Class III). 
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8.4.3 Spinal Cord Injury  
 
There have been few studies other than in multiple sclerosis. One study assessed 
the effect of nabilone on spasticity after spinal cord injury (Pooyania et al 2010). 
There have been other studies of the effect of cannabis formulations on pain in 
spinal cord injury and indeed in multiple sclerosis (see Pain section).  The study by 
Pooyania and colleagues was a double-blind, placebo-controlled, crossover study 
that only involved 11 subjects who either received nabilone or placebo during a four-
week period and after a two-week washout subjects were crossed to the opposite 
arm of the study.  There was a significant decrease on active treatment for the 
Ashworth score in the most involved muscle as well as total Ashworth score.  There 
were no significant differences in secondary measures which included the spasm 
frequency scale and the clinician’s and subject’s global impression of change.  Side 
effects were mild and tolerable (Class III).   
 
8.4.4 Conclusion 
 
In summary, we consider there is good evidence for efficacy of nabiximols for 
reducing patient-reported spasticity symptoms, although there is not firm evidence 
for improvement in objective measures.  We consider there is good evidence of 
safety in the long term and for continued efficacy.  We also consider there is 
moderate evidence for the efficacy of oral cannabis extract for reducing patient-
reported spasticity scores.  There is insufficient evidence to make any 
recommendations with regard to other forms of cannabis.   
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8.5 Movement Disorders 
 
8.5.1 Parkinson’s Disease 
 
Parkinson’s disease is very common and occurs in about 30/10000 of the male 
population and 24/10000 of the female population. This means that there about 
125000 people with Parkinson’s in the UK – mainly, but not exclusively, in the older 
population. It is well known that the symptoms of Parkinson’s disease are largely 
related to the loss of dopaminergic neurones in the basal ganglia of the brain.  The 
basal ganglia is not only a site for dopamine receptors but also cannabinoid 
receptors and there is at least a potential role for the endocannabinoid system to 
control voluntary movement in Parkinson’s disease (Fernandez-Ruis et al 2015). In 
an animal model, for example, a cannabinoid type 1 receptor agonist reduced 
movements induced by levodopa/carbidopa (dopamine products) or apomorphine (a 
dopamine agonist).  It is also known that activation of the CB1 receptor can stimulate 
the dopaminergic system as well as the cannabinoid system and thus cannabinoids 
may have a role to play in the treatment of Parkinson’s disease (Gilgun-Sherki et al 
2003). The dynamics of the cannabinoid and the dopaminergic system in the human 
brain is further discussed in a useful article by Rodriguez De Fonseca and 
colleagues (2001).  Anecdotal evidence has been available for some years and 
indeed in an anonymous questionnaire sent to patients attending the Prague 
Movement Disorder Centre it was shown that 25% of Parkinsonian patients (out of 
339 respondents) had taken cannabis and just less than 50% of those described 
some benefit (Venderova et al 2004). However, few studies have more formally 
analysed the question of whether cannabis is useful in Parkinson’s disease.   
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In 2004 Carroll and colleagues published a four-week dose escalation study which 
assessed the safety and tolerability of cannabis in six Parkinson’s disease patients 
with levodopa induced dyskinesia (Carroll et al 2004). (Dyskinesia is a description for 
involuntary “writhing” movements induced by the dopamine therapy). After this pilot 
study a randomised, placebo-controlled, crossover study was performed in 19 
Parkinson’s disease patients randomised to receive either oral cannabis extract 
followed by placebo or vice versa.  The treatment phase lasted four weeks for the 
two week intervening washout period.  Seventeen patients completed the study and 
cannabis was well tolerated but there was no evidence for a treatment effect on 
levodopa induced dyskinesia as assessed by the Unified Parkinson’s Disease Rating 
Scale (an accepted scale in Parkinson’s disease studies) or any of the secondary 
outcome measures (Class II).  
 
In a relatively small Class III study Lotan and colleagues (2014) studied 22 patients 
in a Parkinson’s clinic both at baseline and after 30 minutes of smoking cannabis 
using a well-recognised Parkinson’s symptom battery.  The Unified Parkinson’s 
Disease Rating Scale improved significantly over the period of time following 
cannabis consumption and analysis of specific motor symptoms also improved, 
including tremor, rigidity, bradykinesia (slowness of movement) and sleep and pain 
scores.  No significant adverse effects were observed.  The authors felt this study 
might indicate that cannabis has a place in the therapy of Parkinson’s disease but 
admitted that larger, controlled studies were clearly needed. Other authors have 
analysed the effect of cannabidiol (CBD).  Chagas and colleagues (2014) selected 
21 Parkinson’s disease patients without dementia and assigned them to three 
groups of seven subjects who were treated with placebo, cannabidiol (CBD) 75mg 
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daily or CBD 300mg daily.  The authors found no statistically significant differences 
in the rating scores or other measures except there was a significant difference (in 
favour of CBD) between the placebo group and the CBD 300mg group with regard to 
a measure of wellbeing and quality of life (Class III). 
 
Conclusion 
 
In summary, whilst there is theoretical evidence that cannabis may assist some 
aspects of Parkinson’s disease there is very limited good quality evidence and whilst 
further studies are justified at the moment there is just some evidence in this 
indication.  
 
8.5.2 Dystonia 
 
Dystonia is a condition characterised by prolonged muscle spasm. It most often 
occurs in just a few muscles, commonly the neck (called torticollis), the face (hemi-
facial spasm) and the hand (writer’s cramp) but sometimes involves the whole body. 
The prevalence is about 15 / 100000 population. The spasms can be painful and 
disabling. The endocannabinoid system is likely to be involved in movement control 
and thus there is a theoretical basis for manipulation of the ECS in the management 
of dystonia. However, there is very limited evidence for efficacy in human studies. 
There are a number of anecdotal and open label studies that suggest there may be 
some benefit using cannabis in dystonia (Consroe et al 1986; Chattergee et al 2002; 
Uribe Roca et al 2005). There are also some animal models that are similarly 
suggestive (Madsen et al 2011). However, there is only one Class III human study - 
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a randomised double-blind placebo-controlled trial (Fox et al 2002). This study used 
a synthetic cannabinoid receptor agonist (nabilone) in patients with generalised and 
segmental primary dystonia but it showed no significant reduction in dystonia 
following treatment.  However, the study was underpowered to detect differences.  
  
Conclusion 
 
In dystonia, whilst there is anecdotal evidence, the data is insufficient to draw any 
conclusions. 
 
8.5.3 Huntington’s Chorea 
 
Huntington’s disease is quite rare (about 5/100000 population) and is a genetic 
disorder characterised by abnormal movements (chorea) and behavioural problems, 
often leading to dementia. Current treatment is very limited and really only manages 
to reduce some symptoms temporarily. Whilst there is a theoretical reason why the 
endocannabinoid system may be involved in Huntington’s disease there is no 
convincing evidence of efficacy in the disorder (Sagredo et al 2011). In an early 
Class III study the authors found no effect of cannabidiol (10mg/kg/day for six 
weeks) compared to placebo in a double-blind, randomised, cross-over trial design. 
However, the study was underpowered and only involved 15 patients with 
Huntington’s disease (Consroe et al 1991). Curtis and colleagues (2009b) studied 
the efficacy of nabilone in Huntington’s disease and conducted a double-blind, 
placebo-controlled, crossover study versus placebo (Class 1).  Forty-four patients 
were involved and either received nabilone 1 or 2 mg followed by placebo or vice 
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versa.  Assessment of both doses of nabilone versus placebo showed a treatment 
difference in favour of nabilone for motor scores, chorea and cognition as well as 
behavioural scores.  However, it was questionable whether the change noted was of 
clinical significance and the study was underpowered but nevertheless was 
promising and larger studies are merited. 
 
Conclusion 
 
In summary, the evidence is sparse for the efficacy of cannabinoids in Huntington’s 
disease but with one modestly positive study and theoretical evidence, further 
studies are warranted.  
 
8.5.4 Tourette’s Syndrome 
 
Tourette’s syndrome is surprisingly common and thought, in variable presentations, 
to affect about 1% of the population at some time. It is characterised by sudden 
movements (tics) and vocal utterances. Treatment is very unsatisfactory.  
The literature is sparse for the efficacy of cannabis in any form for the treatment of 
Tourette’s syndrome.  A single author produced two studies on the subject.  One 
study can be classified as Class II (Muller-Vahl et al 2002) and the other study 
classified as Class III (Muller-Vahl et al 2003).  There are earlier anecdotal reports 
but these provide very limited further information.   
 
In 2002 Muller-Vahl and colleagues performed a randomised double-blind placebo-
controlled crossover single dose trial of THC (in 5mg, 7.5mg or 10mg formulation) 
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(Muller-Vahl et al 2002).  The study was carried out in 12 adult Tourette’s syndrome 
(TS) patients.  Tic severity was assessed using a self-rating scale and an examiner 
rating scale.  These scales are generally accepted as valid measures of severity of 
symptoms.  On one scale (Schapiro Tourette’s Syndrome Symptom List) there was a 
significant improvement of tics (p=0.015) and also in obsessive compulsive 
behaviour (p=0.041) after treatment with THC compared to placebo.  Examiner 
ratings also showed a significant difference with regard to the sub-scale for complex 
motor tics and a trend towards significant improvement for sub-scales of motor tics 
and vocal tics.  There were no serious adverse reactions but five patients 
experienced mild and transient side effects.  The authors concluded that the results 
suggested that a single dose treatment with THC was effective and safe in treating 
tics and obsessive compulsive behaviour in Tourette’s syndrome but they 
recommended that further studies should be carried out to confirm the results.  The 
subject numbers were small and it is lacking in statistical power for reliable 
conclusions to be drawn. 
 
In a second study in 2003 Muller-Vahl and colleagues carried out a slightly larger 
scale study in a randomised double-blind placebo-controlled trial of 24 patients with 
TS who were treated over a six-week period with up to 10mg per day of THC (Muller-
Vahl et al 2003).  Tics were rated at six visits using a standardised Tourette 
Syndrome evaluative measure as well as a video-taped rating scale.  Unfortunately, 
seven patients dropped out of the study or had to be excluded but only one of those 
was due to side effects.  There were significant differences (p<0.05) or a trend 
towards a significant difference (p<0.1) between THC and placebo at visits two, three 
and four of the six-week treatment period on three of the Tourette’s scales and on 
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the video rating scale.  The authors concluded that this study provided more 
evidence that THC was effective and safe in the treatment of tics and further 
postulated that the central cannabinoid receptor system (the endocannabinoid 
system) might play a role in Tourette’s syndrome pathology.  However, the numbers 
in the study were still small and the seven patients dropping out of the study was 
also of some concern.     
 
Conclusion 
 
These two small studies do not provide sufficient evidence to either confirm or refute 
the suggestion that cannabis may be helpful for the treatment of this particular form 
of tic disorder.  The studies were indicative that there may be a therapeutic 
possibility for this indication but clearly further and larger studies are needed.  
Overall, we suggest there is only some evidence of efficacy in Tourette’s syndrome. 
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8.6 Headache 
 
Headache is remarkably common.  The lifetime prevalence of headache (including 
anybody with any form of headache), migraine, and tension-type headache is 93%, 
8% and 69% in men; and 99%, 25% and 88% in women. There are satisfactory 
treatments but a minority of headache sufferers have persistent symptoms despite 
treatment.  
 
Cannabis has been used for centuries for treatment of headache/migraine.  After the 
discovery and elucidation of the endocannabinoid system there is now a theoretical 
basis for such treatment (Russo 1998). It is known that the serotonin system (a 
central neurotransmitter system involved in headache/migraine) can be affected by 
the endocannabinoid system.  Anandamide (cannabinoid receptor ligand) also 
potentiates serotoninergic receptors and it is known that cannabinoids demonstrate 
dopamine blocking and anti-inflammatory properties which may also be relevant in 
terms of migraine.  Indeed, Russo has postulated a clinical endocannabinoid 
deficiency syndrome to explain the therapeutic benefits of cannabis in migraine, as 
well as in fibromyalgia and irritable bowel syndrome (Russo 2008). This concept has 
been further confirmed by Smith and Wagner (2014).   
 
However, despite this theoretical basis there are no Class I or Class II studies of the 
use of cannabis in headache or migraine.  Robbins and colleagues published a 
single case study of the efficacy of recreational marijuana successfully used to abort 
cluster headache refractory to standard medication (Robbins et al 2009). The patient 
subsequently continued to use dronabinol which provided longer term effective pain 
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relief.  Nevertheless, in a larger study of 139 patients with cluster headaches, 
although it was found that just over 45% of the patients had used cannabis, only just 
25% reported efficacy and indeed 22% reported negative effects (Leroux et al 2013).  
A slightly more promising study has recently been published by Rhyne and 
colleagues (2016). One hundred and twenty-one adults with a primary diagnosis of 
migraine headache were recommended migraine treatment or prophylaxis with 
medical marijuana.  Migraine headache frequency decreased from 10.4 to 4.6 
headaches per month with the use of medical marijuana.  This was a statistically 
significant.  Inhaled forms of marijuana were most commonly used.  Fourteen 
patients (11.6%) reported negative effects, including somnolence.  The authors 
suggested that further prospective studies should be carried out (Class IV).   
 
Conclusion 
 
In summary, it is surprising that despite a long history of use in headache and 
migraine there are no good quality randomised clinical trials and thus no conclusion 
can be drawn.  
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8.7 Neuroprotection - Traumatic Brain Injury and Stroke 
 
It is known that the endocannabinoid system is involved in protection of the nervous 
system (neuroprotection) after trauma and other insults.  Thus there is a theoretical 
basis for the use of cannabis as a neuroprotective agent following trauma to the 
brain.  However, there is little convincing evidence that this is the case.  One study 
by Nguyen and colleagues in 2014 described a three-year retrospective review of 
registry data at a level one trauma centre of those who had been admitted with 
traumatic brain injury (Nguyen et al 2014).  Children and patients with a suspected 
non-survivable injury were excluded.  Those with a positive toxicology screen for 
THC were compared to a group who had no such positive toxicology.  Overall there 
were 446 cases meeting the inclusion criteria.  The incidence of a positive THC 
screen was 18.4% in this population.  The mortality in the THC+ group (2 patients) 
were significantly decreased compared to the THC- group (42 patients).  After 
adjusting for differences between the cohorts the THC+ screen was independently 
associated with better survival chances (Class IV).  An early phase II study of a new 
cannabinoid receptor agonist (KN38-7271) has also shown that survival rates within 
one month of the traumatic brain injury were significantly better in the treatment 
group compared to a placebo group.  However, this is a very early study and the 
agonist in question is not commercially available (Firsching et al 2012). 
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Traumatic brain injury - Conclusion 
 
Overall, whilst there is a theoretical basis for cannabinoids to provide 
neuroprotection, there is limited evidence and not yet convincing evidence of efficacy 
in the context of traumatic brain injury.  
 
There is no evidence of neuroprotective effect of cannabis after stroke.  Indeed, 
there is some, albeit limited, evidence that there is a causal link between heavy 
recreational use of cannabis and stroke.  A review in 2015 (Hackan 2015) had found 
34 case reports on 64 patients and in most cases there appeared to be a temporal 
relationship between cannabis exposure and the stroke and 70% of the evaluation 
was sufficiently comprehensive to exclude other sources of stroke.  About a quarter 
(22%) of patients had another stroke after a subsequent re-exposure to cannabis, 
although half of the patients had concomitant stroke risk factors, most commonly 
tobacco (34%) and alcohol (11%) consumption.  Another literature review by 
Desbois and Cacoub (2013) has also shown that in anecdotal cases cannabis usage 
is associated with arterial disease, such as stroke, myocardial infarction and limb 
arteritis.  A recent comprehensive study reviewed all patients in a Nationwide 
Inpatient Sample in 2004 to 2011 with a primary diagnosis of acute ischaemic stroke 
(Rumalla et al 2016). The authors found the incidence of acute ischaemic stroke was 
significantly greater among marijuana users compared to non-users with a relative 
risk of 1.13 (95% confidence intervals of 1.11-1.15).  However, marijuana users were 
also more likely to use other illicit substances.  The authors concluded that amongst 
young adults (marijuana use was most prevalent in younger males) recreational 
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marijuana usage was independently associated with a 17% increased likelihood of 
hospitalisation for acute ischaemic stroke.   
 
Stroke - Conclusion 
 
There is no evidence that there is any neuroprotection offered by cannabis in stroke 
and indeed some, limited, evidence that heavy recreational users have a slightly 
increased risk of stroke. 
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8.8 Dementia 
 
Dementia is a very common chronic condition mainly affecting older adults.  Indeed, 
around 750,000 people in the UK currently live with dementia and the prevalence is 
rising as the population ages.  Current treatment modalities are generally 
unsatisfactory. As the chemical acetylcholine is known to be reduced in the brain in 
various dementias then drugs that can increase the concentration (cholinesterase 
inhibitor drugs) have been shown to improve cognitive symptoms, activities of daily 
living and some aspects of behaviour.  However, the treatment effects are rather 
small and they tend to only delay a decline in cognitive functioning by a period of 
around one year.   
 
In theory the cannabinoids may be helpful for the treatment of dementia.  It is known 
that the cannabinoids are neuroprotective and thus may mitigate the effects of 
neurodegeneration (Gowran et al 2011).  It is also known that some cannabinoid 
receptors can reduce neuro-inflammation, which is also implicated in the aetiology of 
dementia.  Quite recently it was found that THC can reduce the aggregation of 
amyloid, which is a key pathological marker of Alzheimer’s disease (Eubanks et al 
2006). It has also been found that THC can inhibit the enzyme acetylcholinesterase 
and such drugs are known to have an, albeit modest, effect in slowing the 
progression of Alzheimer’s disease.   
 
Despite the theoretical basis for the use of cannabis and cannabinoids in dementia 
there is a paucity of literature on the subject.  A recent Cochrane review (Volicer et al 
1997) found only one placebo-controlled, crossover designed study, which examined 
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the effects of dronabinol on anorexia and disturbed behaviour in patients with 
Alzheimer’s disease. However, this was obviously a symptomatic treatment rather 
than a treatment designed to study the effect on the disease process itself.  Only 11 
patients completed the study period.  The authors found that body weight increased 
during the dronabinol treatment more than during the placebo period and the 
dronabinol treatment decreased the severity of disturbed behaviour and this effect 
persisted during the placebo period in patients who received dronabinol first.  There 
were more adverse reactions in the dronabinol group, including euphoria, 
somnolence and tiredness. However, the study was unsatisfactory in many ways and 
can only be classified as a Class II study. 
 
Recently Shelef and colleagues (2016) have conducted an open label, add-on pilot 
study of the use of medical cannabis oil for behavioural and psychological symptoms 
of dementia. Just 11 patients with Alzheimer’s disease were recruited into this open 
label four-week study.  Ten patients completed the trial.  The authors noted 
significant improvement in aspects of cognition and behaviour, including decreases 
in delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.  
However, the study can only be classified as Class III. 
 
In 2014 Woodward and colleagues reported on a retrospective systematic chart 
review of 40 inpatients with dementia in a neuropsychiatric facility (Woodward et al 
2014).  Dronabinol was added to the treatment regimes.  The addition of dronabinol 
was associated with a significant decrease in agitation and significant improvements 
in global impression scores, sleep duration and percentage of meals consumed 
during the treatment periods.  There were adverse events which were generally mild 
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and none lead to medication discontinuation.  However, the study being uncontrolled 
cannot lead to firm conclusions but is simply indicative that dronabinol may be of 
some assistance in the alleviation of symptoms in this population (Class IV).   
 
A similar effect on agitation was noted in just six patients with severe dementia 
treated with dronabinol (Walther 2006) (Class IV).   
 
The only randomised controlled trial was conducted by van den Elsen and 
colleagues in 2015 (van den Elsen et al 2015). It was a randomised, double-blind, 
placebo-controlled study (Class I).  Individuals were randomly assigned to either 
THC 1.5mg or matched placebo three times daily for three weeks.  Twenty-four 
patients received THC and 26 received placebo.  However, there was no significant 
difference from baseline between THC and placebo, although neuropsychiatric 
symptoms were reduced in both groups.  There were no significant changes in 
scores for agitation or quality of life or activities of daily living.  However, the THC 
was well tolerated.  The authors concluded that oral THC at 4.5mg daily showed no 
benefit in neuropsychiatric symptomatology.  The authors suggested that the 
reasonable tolerance of the compound in this population may lead to studies that 
look at whether higher doses are efficacious.   
 
Conclusion 
 
At the present time we find some evidence that cannabinoids are effective in 
improvement of disturbed behaviour and the treatment of other symptoms in 
dementia. This is in agreement with the Cochrane database systematic reviews on 
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this subject (Krishnan et al 2009). A useful up-to-date review has been published by 
Ahmed and colleagues (2015).   
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8.9 Epilepsy 
 
Epilepsy affects around 1% of the population.  Fortunately, there are a number of 
anticonvulsant drugs and indeed around 80% of epilepsy can be fully controlled 
using a single anticonvulsant.  A minority of people have refractory epilepsy but 
nevertheless the majority of those individuals are controlled on two, or sometimes 
three, anticonvulsants.  However, despite significant progress in anticonvulsant 
research and availability of the newer anticonvulsant drugs there is still a minority of 
individuals who have epilepsy refractory to the currently available compounds.  This 
is particularly the case in various forms of severe childhood epilepsy, such as 
Dravet’s syndrome and the Lennox-Gastaut syndrome.  In addition, anti-epileptic 
drugs often have serious adverse effects, particularly if used in combination.   
It has been known for many years that phytocannabinoids have anticonvulsant 
effects and this has been adequately demonstrated in pre-clinical studies and in 
animal models (Rosenberg et al 2015). However, the situation is complicated. THC 
appears to be anticonvulsant in some circumstances but in other circumstances 
seems to be pro-convulsant.  The main phytocannabinoid with anticonvulsant 
properties is cannabidiol (CBD).  Another phytocannabinoid, cannabidivarin, also 
shows promise as an anticonvulsant (Dos Santos 2015). Unfortunately, human 
studies are limited in number and quality but nevertheless there is emerging 
evidence of the usefulness of both cannabidiol and very early evidence of the 
efficacy of cannabidivarin.  The mode of action of CBD is not known but it seems 
likely that it has effects both within and outside the endocannabinoid system.  It is 
known that it can affect other brain receptors such as the vanilloid system, the 
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5HT1A receptor and the alpha 3 and alpha 1 glycine receptors.  All these may have 
a role to play in the aetiology of epilepsy (Devinsky et al 2014).  
 
A liquid formulation of pure plant derived cannabidiol has been developed by GW 
Pharmaceuticals under the name of Epidiolex.  This compound has been granted 
Orphan Drug Designation by the FDA in the United States for the treatment of 
Dravet’s syndrome and Lennox-Gastaut syndrome. There have been early results of 
the use of Epidiolex in patients with treatment-resistant epilepsy.  Devinsky has 
recently published work in 2016 (Devinsky et al 2016). This is an open label trial with 
patients from 1 to 30 years with severe intractable childhood-onset treatment-
resistant epilepsy who were receiving stable doses of anti-epileptic drugs before the 
study entry.  Enrolment was in 11 epilepsy centres across the United States.  Oral 
cannabidiol was given at 2-5mg per kg per day and then up titrated to intolerance or 
to a maximum dose of 25-50mg per kg.  This was a large study and 214 patients 
were enrolled and 76% of them had at least 12 weeks of follow-up after the first dose 
of cannabidiol and 64% were included in the efficacy analysis.  There were a number 
of different types of epilepsy but 33 patients had Dravet’s syndrome and 31 patients 
had Lennox-Gastaut syndrome.  The drug was reasonably well tolerated and 
adverse events reported in more than 10% of patients were somnolence, decreased 
appetite, diarrhoea, fatigue and convulsion (although the latter may have been 
simply part of the ongoing epilepsy).  Just five patients discontinued treatment 
because of an adverse event.  The median reduction in monthly motor seizures was 
36.5%.  The authors recommended that further randomised, controlled trials were 
warranted to further characterise both the safety profile and the efficacy (Class III).   
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This study was supported by an on-line survey of parents who had administered 
CBD enriched cannabis preparations for the treatment of their children’s epilepsy.  
One hundred and seventeen parents of epileptic children were studied and 85% of 
all parents reported a reduction in seizure frequency and 14% reported complete 
seizure freedom.  The cannabis preparation was mainly used in childhood resistant 
epilepsy, particularly Dravet’s syndrome. The parents reported that the side effects 
were well tolerated and indeed some ‘side effects’ were useful, including 
improvement in sleep (53%), alertness (71%) and mood (63%) (Hussain et al 2015).   
 
Tzadok and colleagues (2016) recently published the current Israeli experience of 
CBD enriched medical cannabis for intractable paediatric epilepsy. This was a 
retrospective study describing the effect of cannabidiol (CBD) enriched medical 
cannabis in children with epilepsy.  There were 74 patients from 1 to 18 years with 
intractable epilepsy resistant to at least seven anti-epileptic drugs.  All the patients 
used medical cannabis oil treatment for at least three months (average six months) 
and the selected formula contained CBD and THC at a ratio of 20:1, dissolved in 
olive oil.  The treatment yielded significant positive effect on seizure load and most 
children (89%) reported a reduction in seizure frequency.  Eighteen percent reported 
75-100% reduction, 34% reported 50-75% reduction and 12% reported 25-50% 
reduction.  Five patients (7%) reported aggravation of seizures which led to CBD 
withdrawal.  Observations of improvement in behaviour and alertness, language, 
communication, motor skills and sleep were also observed.  The drug seemed to be 
well tolerated with the adverse reactions including somnolence, fatigue, 
gastrointestinal disturbance and irritability leading to withdrawal in five cases (Class 
III). 
 [69] 
 
The company is also developing a cannabidivarin (CBDV) cannabinoid treatment 
which, as documented above, has shown anti-epileptic properties in a range of pre-
clinical models.  It is now into a phase II study involving 130 patients with epilepsy.  
In a phase I study in 66 healthy subjects CBDV was tolerated even at the highest 
tested dose with no serious or severe adverse events or any withdrawals due to side 
effects (Hill et al 2012). The current designation of this compound is GWP42006 
(www.gwpharm.com/epilepsy).  GW Pharma estimates that the size of the intractable 
paediatric epilepsy population is approximately 140,000 people in the United States 
and 230,000 people in Europe and thus development of the paediatric epilepsy 
programme is potentially important and may have a significant impact.  The company 
has also recently announced plans to develop epidiolex for a third target indication, 
Tuberous Sclerosis Complex, which is a rare paediatric genetic disorder which is 
associated with significant epilepsy issues.   
 
Conclusion 
 
In summary, whilst there is a theoretical basis and animal model studies and early 
human studies are promising, at the moment robust trials are lacking but further 
results are awaited. There is only limited evidence at the moment. 
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8.10 Sleep 
 
Cannabis in different formulations can cause somnolence and fatigue.  This is a well- 
known effect of the drug.  There is a scientific foundation for this effect, as it is now 
known that the endocannabinoid system has a role to play in regulating sleep (Pava 
et al 2016). The side effects of fatigue and somnolence are well documented in 
many reports, as well as in the historical literature. However, there have been 
surprisingly few studies with the primary purpose of investigating the effect of 
cannabis on sleep disorders.  There is one study which demonstrated the effects of 
nabilone on sleep in fibromyalgia (Ware et al 2010a). This study confirmed that 
nabilone was effective in improving sleep in people with fibromyalgia and was well 
tolerated in a randomised, double-blind, active control equivalency crossover trial, 
which compared nabilone to amitriptyline (Class I) – see also fibromyalgia section.  
Nabilone has also been studied for the treatment of post-traumatic stress disorder 
(PTSD) nightmares (see section on PTSD) (Jetly et al 2015). This small study (10 
subjects – Class II) confirmed relief from PTSD-associated nightmares following the 
administration of nabilone in a double-blind treatment compared to placebo.   
 
Sleep was documented as a secondary outcome (mainly using a numeric rating 
scale) in several of the nabiximols studies of spasticity in multiple sclerosis (see 
Spasticity section) and many reported positive results in terms of sleep.   
 
The authors should also point out that sometimes difficulty sleeping and strange 
dreams are amongst the symptoms reported with both acute and sub-acute cannabis 
withdrawal.  Nevertheless, except for the situation of cannabis withdrawal, cannabis 
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use seems to be clearly associated with sleepiness and facilitation of falling asleep 
(Schierenbeck et al 2008). 
 
Conclusion 
 
It is difficult to quantify and assess the evidence for sleep as it has been very rarely 
used as a primary outcome measure but nevertheless the authors feel that given the 
plethora of literature demonstrating that cannabis promotes somnolence, fatigue and 
sleep then there is moderate evidence that it is likely to be helpful in sleep disorders. 
All formulations of cannabis seem to have the same effect on sleep but obviously 
further research is required to elucidate which particular formulation may be more 
beneficial.  
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8.11 Bladder 
 
A number of studies have demonstrated some efficacy with cannabinoids for the use 
of bladder symptoms in various conditions, particularly multiple sclerosis.  The 
commonest difficulty with bladder functioning in neurological disease is urinary 
frequency and urgency, often associated with urinary incontinence.  This is largely 
due to over-activity of the bladder (detrusor) muscle and often there is additional 
incoordination between bladder contraction and opening of the external urinary 
sphincter (detrusor sphincter dyssynergia).  Bladder difficulties are very common in 
the context of most central nervous system diseases but particularly troublesome in 
multiple sclerosis and spinal cord injury.  There is a scientific rationale for the use of 
cannabinoids on bladder systems as it is now known that both endocannabinoid 
receptors (CB1 and CB2) are located in the lower urinary tract tissues (Ruggieri 
2011; Hedlund 2014). 
 
In the early days of development of nabiximols Brady and colleagues (2004) 
undertook an open label pilot study on bladder dysfunction in advanced multiple 
sclerosis. Patients took cannabis extracts containing THC and cannabidiol for eight 
weeks followed by THC only for a further eight weeks and then entered a long term 
extension part of the study.  Twenty-one patients were recruited and data for 15 
were evaluated.  Urinary urgency, the number and volume of incontinence episodes, 
frequency and nocturia (waking to urinate at night more than considered normal) all 
decreased significantly following treatment.  Patient self-assessment of pain, 
spasticity and quality of sleep also improved.  The authors reported few troublesome 
side effects (Class III).   
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This open pilot study has been followed in the literature by a randomised controlled 
trial (Kavia et al 2010). This was a 10-week double-blind, randomised placebo-
controlled parallel group trial in 135 randomised subjects with multiple sclerosis and 
over-active bladder.  The primary endpoint of the trial (reduction of daily number of 
urinary incontinence episodes) was not different between nabiximols and placebo.  
However, four of the seven secondary endpoints were significantly in favour of 
nabiximols.  These were the number of episodes of nocturia, overall bladder 
condition, number of voids per day and the patient’s global impression of change.  
The number of daytime voids was significantly reduced and in favour of nabiximols.  
The study provides some evidence of improvement in some symptoms associated 
with bladder dysfunction in multiple sclerosis (Class I). 
 
Some other studies that have not been specifically focused on bladder symptoms as 
a primary endpoint have failed to show improvement (Wade et al 2004).   
 
Another group of authors used cannabis extract.  This was a sub-study in the work 
referred to in the spasticity section by Zajicek and colleagues (2003). The CAMS 
study randomised 630 patients to receive the oral cannabis extract or THC or 
placebo.  All three groups showed a significant reduction in episodes of urge 
incontinence but both active treatment arms showed a further significant effect over 
placebo (cannabis extract p=0.005: THC p=0.039) (Freeman et al 2006).  
 
In contrast other studies have shown no effect on self-reported bladder complaints 
(Vaney et al 2004).  
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Conclusion 
 
Thus the evidence for efficacy of cannabis formulations on bladder dysfunction is not 
entirely clear.  However, there does seem to be some evidence of efficacy of 
nabiximols and an oral cannabis extract but clearly further and better designed 
studies are required in larger groups of patients.  Diagnoses other than multiple 
sclerosis also need to be studied. 
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8.12 Glaucoma 
 
Glaucoma is an irreversible eye disease which can slowly progress to blindness due 
to progressive loss of the retinal cells.  It is the second leading cause of blindness in 
the world.  It is characterised by an increased pressure inside the eye and lowering 
of that intraocular pressure can result in reduced progression of the disorder.   
It is now known that the endocannabinoid system is present throughout most ocular 
tissues and it is also known that the intraocular pressure can be lowered by use of 
cannabinoids (Cairns et al 2016). It has been known for many years that marijuana 
can reduce intraocular pressure and thus has a theoretical role in the management 
of glaucoma (Flom et al 1975). There was considerable interest in the scientific 
literature in the use of cannabis and cannabinoids for lowering of the intraocular 
pressure in glaucoma in the 1980s but there were very few properly conducted 
human studies.  The subject was reviewed again in 2002 (Jarvinen et al 2002). The 
authors confirmed the potential efficacy of cannabis and cannabinoids for the 
treatment of glaucoma but proper therapeutic trials were still lacking.  In 2004 
Tomida and colleagues published a further review article (Tomida et al 2004). The 
article once again confirmed the potential efficacy of cannabis and cannabinoids in 
the management of glaucoma and summarised the numerous studies that had 
confirmed that different cannabinoids can reduce the intraocular pressure when 
administered both systemically and topically.  However, controlled and longer term 
studies were still lacking.  The same authors produced a small pilot study in 2006 
(Tomida et al 2006). They performed a randomised, double-blind, placebo-controlled 
four-way crossover study using a cannabis-based medicinal extract of THC and 
CBD.  Six patients received a single sublingual dose either of 5mg of THC or 20mg 
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or 40mg of CBD or placebo.  They found that the administration of THC reduced 
intraocular pressure compared to placebo but CBD did not reduce the pressure and 
indeed the higher dose of CBD actually produced a transient elevation of intraocular 
pressure.  The single dose was well tolerated.  However, given the very small 
numbers this is not a satisfactory study and must be classified as Class III. 
 
Conclusion 
 
In summary, whilst there is a good theoretical basis for the use of cannabis and 
cannabinoids in the treatment of glaucoma there are no satisfactory studies of longer 
term use.  There are a number of single dose studies confirming that the 
cannabinoids can reduce intraocular pressure.  Thus at the present time there is only 
some evidence of efficacy in glaucoma. 
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8.13 Fibromyalgia and “Rheumatic” Diseases 
 
Fibromyalgia is a remarkably common condition and thought to affect about 2-8% of 
the population with a female preponderance of around 8:1. It is characterised by 
chronic widespread pain with a heightened pain response to pressure.  Other very 
common symptoms are overwhelming fatigue, difficulty sleeping and cognitive 
problems, particularly trouble with memory.  It can be associated with a variety of 
other conditions, including irritable bowel syndrome and headaches.  The cause is 
unknown but one hypothesis is that the individual has a lower threshold for pain 
because of increased reactivity of pain sensitive nerve cells.  It is likely there is 
involvement of the endocannabinoid system.  Undoubtedly other neurotransmitter 
systems are involved.  Genetic factors may also have a role to play.  The emerging 
concept of the endocannabinoid deficiency syndrome may provide a partial 
explanation for the aetiology, as discussed under Headache/Migraine (Russo 
2004b). There is also evidence that the endocannabinoid system has some 
involvement in “trigger points” and may play a role in reducing inflammation in 
myofascial tissues, which in turn may give a theoretical basis for use of cannabinoids 
in fibromyalgia.  However, the literature is limited.   
 
Katchan and colleagues (2016) have recently undertaken a systematic review of the 
cannabinoid system and the effect on autoimmune disease and concluded that 
cannabinoids have promising potential as immunosuppresants and anti-fibrotic 
agents in therapy for autoimmune disorders, which includes fibromyalgia.  
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In one small pilot study nine patients with fibromyalgia underwent studies after 
administration of dronabinol (delta-9-tetrahydrocannabiol) (Schley et al 2006).  
Unfortunately, five of the nine patients withdrew due to adverse side effects.  The 
remaining patients’ daily recording of pain significantly reduced and electrically 
induced pain was significantly attenuated after doses of around 10-15mg of delta-9-
THC.  No particular conclusions can be drawn given the small numbers of 
participants (Class III). 
  
In 2011 Fiz and colleagues conducted a questionnaire-based study with 28 
fibromyalgia patients who were cannabis users and 28 non-users (Fiz et al 2011).  
After two hours of cannabis use (the majority were smokers) visual analogue scale 
scores showed a statistically significant reduction of pain and stiffness, enhancement 
of relaxation, increase in somnolence and feeling of well-being. However, whilst this 
study is of interest it is not strong evidence (Class III).   
 
In the context of sleep disturbance in fibromyalgia Ware and colleagues (2010a) 
studied the use of nabilone. This was a randomised, double-blind, active control 
equivalency crossover trial that compared nabilone (0.5-1mg before bedtime) to 
amitriptyline in patients with fibromyalgia and chronic insomnia. Subjects received 
each drug for two weeks with a two-week washout period. The outcome was sleep 
quality measured by the Insomnia Severity Index and the Leeds Sleep Evaluation 
Questionnaire (standard measures).  Thirty-one subjects were involved and 29 
completed the study.  Sleep was improved by both amitriptyline and nabilone but 
nabilone was superior to amitriptyline.  No effects were found on pain, mood or 
quality of life.  Side effects were mostly mild to moderate and the most common side 
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effects with nabilone were dizziness, nausea and dry mouth.  The authors concluded 
that nabilone was effective in improving sleep in patients with fibromyalgia and was 
well tolerated. (Class I) 
 
Nabilone has also been used for the treatment of pain in fibromyalgia (Skrabek et al 
2008). This was a randomised, double-blind, placebo-controlled trial to determine the 
benefit of nabilone in pain management and quality of life improvements in 40 
patients with fibromyalgia.  Nabilone was titrated upwards to 1mg twice daily over 
four weeks or corresponding placebo.  The outcome measure was a visual analogue 
scale for pain and with secondary measures, including the number of tender points, 
average tender point pain threshold and the Fibromyalgia Impact Questionnaire (a 
standard measure).  The authors found significant decreases in the pain scores, the 
FIQ and anxiety scores in the nabilone treated group at four weeks and concluded 
that nabilone appeared to be beneficial and well tolerated for fibromyalgia with 
significant benefits in pain relief and functional improvement (Class I).   
 
Fitzcharles and colleagues (2016) have undertaken a systematic review of 
randomised controlled trials in chronic pain associated with rheumatic diseases, 
which included fibromyalgia as well as back pain, osteoarthritis and rheumatoid 
arthritis. They found four studies that included a variety of aetiologies, including 
fibromyalgia.  Unfortunately, the superiority of cannabinoids over controls was not 
consistent, although cannabinoids were generally well tolerated.  They concluded 
there was insufficient evidence for recommendation of any cannabinoid preparation 
for symptom management in patients with chronic pain associated with rheumatic 
diseases.   
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Conclusion 
 
Overall we consider there is moderate evidence of efficacy for cannabinoid usage in 
fibromyalgia in the context of pain management and sleep. There is insufficient 
evidence for recommendations to be made for other musculoskeletal disorders.   
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8.14 Gastrointestinal Disorders 
 
There have been a few case reports and anecdotal studies of the use of cannabis in 
various gastrointestinal disorders.  However, there have been very few controlled 
trials.  The scientific rationale is the discovery of the involvement of the 
endocannabinoid system in the physiology and pathophysiology of the 
gastrointestinal tract.  CB1 receptors are present in neurones of the enteric nervous 
system and in sensory terminals of the vagal and spinal neurones while CB2 
receptors are located in the immune cells.  Activation of CB1 receptors is known to 
modulate several functions in the gastrointestinal tract, including gastric secretion, 
gastric emptying and intestinal motility (Massa et al 2005). 
 
8.14.1 Crohn’s Disease 
 
The first report of cannabis use in Crohn’s disease in humans was published by 
Naftali and colleagues in 2011 (Naftali et al 2011). This was a retrospective 
observational study in 30 patients who used cannabis.  Of those 30 patients, 21 
improved significantly after treatment with cannabis and the need for other 
medication was significantly reduced.  Little evidence can be drawn from this study 
other than that larger studies are warranted (Class IV).  
 
In a study by Lal and colleagues (2011) a total of 100 patients with ulcerative colitis 
and 191 patients with Crohn’s disease attending an outpatient clinic completed a 
questionnaire on cannabis usage and usage of other alternative medicines.  A 
significant number of ulcerative colitis and Crohn’s disease patients reported lifetime 
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(51%) or current (12%) usage of cannabis, particularly those with a history of 
abdominal surgery or chronic abdominal pain and/or a low quality of life index.  
Obviously little can be extrapolated from this study except to note that presumably 
cannabis has some therapeutic benefit in those who use the drug (Class IV).   
 
We are not aware of any other studies. 
 
8.14.2 Ulcerative Colitis 
 
The study referred to under the Crohn’s disease section above (Lal et al 2011) 
confirms significant use of cannabis amongst patients with ulcerative colitis but 
provides no further useful information.  Thus we can draw no conclusions.   
 
8.14.3 Irritable Bowel Syndrome 
 
In the paper by Lal (see above Lal et al 2011) it was seen that people with Crohn’s 
disease used cannabis to relieve irritable bowel symptoms, including abdominal 
pain, diarrhoea and reduced appetite.  The authors felt that the therapeutic benefits 
of cannabinoid derivatives in irritable bowel disease may warrant further exploration.  
A paper by Lahat and colleagues in 2012 reported a study that included 13 patients 
with irritable bowel disease who completed two questionnaires on quality of life and 
disease activity (Lahat et al 2012).  The patients were advised to smoke cannabis 
cigarettes whenever they felt pain and were provided with 50g of dry cannabis per 
month for this on-demand treatment.  After three months unspecified treatment, 
patients reported improvement in general health, social functioning, ability to work, 
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physical pain and depression.  However, the study is small, uncontrolled and does 
not provide adequate evidence for any recommendation (Class IV).   
 
8.14.4 Gastrointestinal Disorders Conclusion 
 
In summary, there is theoretical evidence of the potential use of cannabis 
formulations in gastrointestinal disease but at the present time there are no 
satisfactory studies that can lead to any recommendation on the subject. 
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8.15 Mental Health Disorders 
 
8.15.1 Anxiety 
 
Cannabis use can both increase and decrease anxiety in humans. CBD has been 
shown to reduce anxiety whereas THC usually has the converse effect.  The precise 
mechanism by which CBD exerts its anxiety-reducing effects is not well established. 
It may act either by decreasing blood flow to brain regions associated with the 
processing of anxiety or fear-based stimuli, or possibly through the modulation of 
serotonergic neurotransmission (Gomes FV et al 2011).   Limited clinical evidence 
indicates that cannabinoid medications may be effective in the treatment of primary 
anxiety or anxiety secondary to chronic illness.  Effective doses of CBD have not 
been established.  However, it does have an adequate safety profile, it has no 
psychoactive effects and does not affect cognition (Schier et al 2012).  
 
Fusar-Poli and colleagues (2009) carried out a randomized, double-blind, placebo-
controlled trial (Class 1) in which participants were studied through functional 
magnetic resonance imaging (fMRI) scanning and electrodermal activity monitoring 
whilst viewing faces that that elicited different levels of anxiety following 
administration of THC, CBD, or a placebo. CBD was found to reduce autonomic 
arousal and subjective anxiety whilst THC was found to increase anxiety.  The same 
participants were used on three occasions and so treatment groups were equivalent 
on baseline characteristics. The results cannot be generalised to females as they 
used a male sample.  
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A recent double-blind, randomized, placebo-controlled clinical study (Class 1) 
showed that orally-administered CBD was associated with a significant reduction in 
anxiety, cognitive impairment, and discomfort in patients suffering from generalized 
social anxiety disorder subjected to a simulated public-speaking test (Bergamaschi 
et al 2011).  
 
A further study carried out by Crippa and colleagues (2011) looked at the effect of 
CBD on anxiety and the brain mechanisms involved (Class1). This double-blind, 
randomized, placebo-controlled study found that CBD significantly decreased anxiety 
and that this was related to its effects on the limbic and paralimbic brain areas.   
 
Woolridge and colleagues (2005) recruited HIV-positive individuals attending a large 
clinic into an anonymous cross-sectional questionnaire study (Class III). Ninety-three 
percent of individuals who completed the questionnaire reported an improvement in 
anxiety levels.  Improved anxiety levels have also been reported in patients suffering 
from chronic neuropathic pain (Ware et al 2010b) 
 
Conclusion 
 
Overall, we consider there is good evidence for CBD use in anxiety. 
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8.15.2 Depression 
 
As reported under the Anxiety section, there is good preclinical and clinical evidence 
that supports an important role for the endocannabinoid system in both anxiety and 
depression.  Animal studies using CB1 receptor agonists show reduced anxiety-like 
behaviour and antidepressant-like responses (Witkin et al 2005). CB1 receptor 
agonists are also known to enhance central serotonergic and noradrenergic 
neurotransmission, which is similar to the actions of antidepressant medication 
(Bambico and Gobbi 2008). However, the clinical situation is not entirely clear, as 
some studies have demonstrated that recreational users are at a slightly higher risk 
than controls for developing depression. The odds ratio for cannabis users for 
developing depression was marginally elevated compared to controls at 1.17 in a 
longitudinal study that screened 57 cannabis articles and included 14 in the final 
analysis with a total of 76,058 subjects.  The odds ratio for heavy cannabis users for 
developing depression was higher at 1.62 compared to non-users or light users.  The 
authors concluded that heavy cannabis use may be associated with an increased 
risk of developing depressive disorders (Lev-Ran et al 2014). However, other 
explanations are possible.  It is conceivable, for example, that some cannabis users 
may have tried the effect of cannabis for pre-existing depression or at least low 
mood.  On the other hand, improvement of mood is a common reason for taking 
recreational or indeed medicinal cannabis.  In a survey conducted for the APPG for 
Drug Policy Reform the commonest use of cannabis was for depression (10.8% of 
users) followed by taking of cannabis for anxiety (9% of users). This was previously 
backed up in a survey by Ware and colleagues (2005).  Those authors studied 2969 
questionnaires in people using cannabis for medical purposes and found that 
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depression was the main use reported by patients (22%) after chronic pain (25%) 
and at a similar level to use for multiple sclerosis (22%).   
 
In terms of clinical trials in a study of HIV+ patients 93% felt there was an 
improvement in anxiety and 86% an improvement in depression (Woolridge et al 
2005). (Class IV).  Some improvements of mood have been reported in studies 
primarily looking at other indications for cannabis, such as multiple sclerosis and 
chronic neuropathic pain (see relevant sections).  It is also possible, and indeed 
likely, that there is alleviation of mood if individuals use cannabis formulations for 
pain, as chronic pain is clearly associated with depression and thus alleviation of 
pain may well produce an improvement in mood.  There is also a tendency for the 
relief of anxiety symptoms to be associated with relief of depression in those 
suffering from both disorders.   
 
Conclusion 
 
Overall, there is still much work to be done in terms of clinical trials to study the 
effect of cannabis formulations on depression.  It is likely that the THC:CBD ratio is 
important in such studies given that THC in isolation can induce anxiety whereas 
CBD in isolation can alleviate anxiety.  At the moment whilst there is considerable 
anecdotal and survey evidence of the use of cannabis formulations for the alleviation 
of depression there is very little convincing trial data on the topic. We can make no 
recommendation. 
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8.15.3 Obsessive Compulsive Disorder 
 
According to research, 40-60% of individuals with obsessive compulsive disorder 
(OCD) do not respond to first-line treatments (Schindler et al 2008). Schindler and 
colleagues (2008) documented two cases in which the cannabinoid dronabinol was 
used and successfully treated OCD symptoms.  However, this is Class IV research 
and, whilst of clinical importance, further research needs to be conducted in this area 
in order to corroborate these findings.  In addition, there is some anecdotal evidence 
that THC may be effective in treating obsessive compulsive behaviour in individuals 
with Gilles de la Tourette Syndrome (GTS) (Curtis et al 2009a). However, this is 
specific to obsessive compulsive behaviours which may not constitute the OCD 
diagnosis.  No recommendation can be made. 
 
8.15.4 Post-Traumatic Stress Disorder 
 
Research suggests that people suffering from PTSD use cannabis in order to 
regulate their symptoms (Bujarski et al 2012).  Evidence is accumulating that 
cannabinoids may play a role in fear extinction (Passie et al 2012).   PTSD is thought 
to be maintained by the amygdala becoming overactive. Cannabis may reduce the 
strength of traumatic memories, “calming” the amygdala and making it easier for 
individuals with PTSD to sleep and causing them to feel less anxious when 
experiencing flashback memories (Passie et al 2012; Neumeister et al 2013).  
Furthermore, endocannabinoids exert an amnesic effect, which may play an 
important part in the extinction of aversive memories (Marco and Viveros 2009).   
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Trezza and Campolongo (2013) suggest the existence of a link between 
endocannabinoids and maladaptive brain changes after trauma exposure. The 
authors note that although SSRIs are the preferred first line to treat the anxiety 
symptoms of PTSD, a large proportion of patients fail to respond to these 
medications. Furthermore, no suitable treatment is currently available to treat the 
maladaptive cognitive features of PTSD and/or to prevent its development.  They 
suggest that endocannabinoid degradation inhibitors may be an ideal therapeutic 
approach to simultaneously treat the emotional and cognitive features of PTSD.   
 
Rabinak and colleagues (2014) conducted an fMRI study using a randomized, 
double-blind, placebo-controlled, between-subjects design (n=14 per group) in order 
to investigate the effect of cannabinoids (oral dronabinol) on extinction memory recall 
in humans (Class II). Results suggested that pre-extinction administration of THC 
facilitates recall of extinction, as demonstrated 24 hours after extinction learning.  
The fMRI scanning showed that the brain areas involved in fear extinction were more 
active during extinction memory recall in the individuals who had received the THC.  
This study represents the first evidence that dronabinol modulates the neural circuits 
involved in fear extinction in humans.   
 
Jetly and colleagues (2015) investigated male Canadian military personnel with 
PTSD in 2015 using a double-blind, placebo-controlled, between-subjects (at one 
time point) and also within-subjects (at two time points) design (n = 10 per group).  
They found that nabilone significantly decreased trauma-related nightmares when 
compared to the placebo group, and the nabilone group had significant global 
improvement (as measured by the Clinical Global Impression-Improvement (CGI-I) 
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scale) and general well-being as compared to placebo. These findings need to be 
replicated in a larger cohort but the study does support nabilone as a clinically 
effective treatment for PTSD (Class II).  Further research needs to establish whether 
nabilone can alleviate other symptoms of PTSD, such as flashbacks and 
hypervigilance, in addition to nightmares.   
 
Cougle and colleagues (2011) conducted a large survey of adults (n = 5,672) from 
the United States in order to look at the relationship between PTSD and cannabis 
use.  They found that individuals with PTSD had a significantly increased use of 
cannabis even when the data were adjusted for confounding variables.  The authors 
reported that there was a strong correlation between severity of PTSD symptoms 
and the amount of cannabis use.  The literature suggests that individuals with PTSD 
are self-medicating with cannabis.  However, this study was cross-sectional and so 
cannot address issues of causality regarding the relationship between cannabis use 
and PTSD (Class III).   
 
Reznik (2012) carried out a naturalistic observational study with the aim of assessing 
and monitoring the effectiveness and safety of medical cannabis use in 
approximately 80 PTSD patients. The medical cannabis used was mostly of the 
sativa species and was supplied from several companies.  The results showed good 
tolerability, an increase in quality of life scores, and improvements in trauma 
symptoms and in CGI-I scores, especially in patients with either pain and/or 
depression comorbidity (Class III).   
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A recent clinical trial to evaluate the effects of nabilone on treatment-resistant 
nightmares in 47 PTSD patients demonstrated that the majority of patients (72%) 
receiving nabilone experienced either cessation of nightmares or a significant 
reduction in nightmare intensity (Fraser 2009). Subjective improvement in sleep time, 
the quality of sleep, and the reduction of daytime flashbacks were also noted by 
some patients. The author relied on self-report measures which have inherent 
limitations, nevertheless the study represents promising results for future 
investigation (Class III).   
 
Cameron and colleagues (2014) conducted a retrospective study of 104 male 
inmates with serious mental illness prescribed nabilone and results indicated a 
significant improvement in symptoms of PTSD.   Although specific to the prison 
population, this study supports the use of nabilone as a safe, effective treatment for 
PTSD (Class III).  Betthauser and colleagues (2015) reviewed the evidence for the 
use of cannabinoids in military veterans with PTSD and found a further four Class III 
studies in support of their use within this population. 
 
Passie and colleagues (2012) described a case in which a male managed and 
reduced his symptoms of PTSD through smoking cannabis (Class IV). 
 
Conclusion 
 
Further larger scale research studies are required within this area in order to 
substantiate observational data and to determine the correct doses, most effective 
method of administration and timing of the exposure in relation to the traumatic event 
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that caused the PTSD.   The studies to date represent encouraging possibilities for 
the use of medical cannabis in the treatment of this debilitating and often hard to 
treat mental disorder. We consider there is moderate evidence of efficacy in PTSD 
for nabilone and dronabinol and some evidence for the use of “natural” cannabis.  
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8.16 Cancer 
 
It has been known for many years that cannabinoids can have antineoplastic (anti-
cancer) activity.  One of the very early papers was published as long ago as 1975 
when it was demonstrated that lung adenocarcinoma cancer growth was retarded by 
the oral administration of THC and other cannabinoids in animal models (Munson et 
al 1975). It is, of course, likely that cannabinoids will not affect all forms of cancer but 
only specific types and very little is known about the mechanism of action at the 
present time. In some cases, cannabinoids can appear to kill specific tumour cells, 
particularly the glioma cells in a specific brain tumour, glioblastoma multiforme 
(Velasco et al 2004).  Another potential specific effect seems to be on prostate 
cancer cells (Sarfaraz et al 2005). However, it is of some potential concern that 
depending on drug concentration cannabinoids can seem to inhibit or stimulate 
cancer cell proliferation.  Thus it is clear that there is still a great deal to be learnt 
about the effect of cannabinoids on different tumour cell types (Bifulco et al 2006).  
 
Another promising line of treatment is the use of cannabinoid receptor agonists in the 
treatment of oestrogen receptor negative breast cancer (Alexander et al 2009). A 
reasonably up to date review of the potential use of cannabinoids in cancer 
management has been published by Cridge and Rosengren (2013).  Nikan and 
colleagues (2016) further reviewed how modulation of the endocannabinoid system 
may be appropriate treatment for several cancer subtypes. 
 
Despite this theoretical anticancer effect there have been very few studies.  In one 
study by Liang and colleagues (2009) the authors studied the relationship between 
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marijuana use and the induction of head and neck squamous cell carcinoma and 
found that 10-20 years of marijuana usage was associated with a significantly 
reduced risk of such cancer.  
 
In humans the most promising therapeutic strategy at the moment seems to be the 
use of THC in patients with recurrent glioblastoma multiforme (a rare and aggressive 
form of brain tumour).  A pilot phase 1 trial of nine patients with recurrent 
glioblastoma multiforme was conducted by Guzman and colleagues in 2006 
(Guzman et al 2006). These patients had previously failed standard therapy, 
including surgery and radiotherapy, and had clear evidence of tumour progression.  
THC was administered directly to the tumour.  The delivery was safe and there were 
no overt psychoactive effects.  The main aim of the study was to determine safety 
rather than efficacy and the technique was deemed safe and may indicate one 
method of improving survival in this aggressive condition.   
 
Conclusion 
 
At the present time there is a reasonable evidence base for the anticancer properties 
of cannabinoids but very limited evidence of actual efficacy in human populations. 
Further studies are needed before any recommendation can be made. 
We emphasise that cannabinoids have a significant role to play in the management 
of appetite loss and nausea and vomiting in the context of cancer chemotherapy.  
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8.17 Other Indications 
 
There are a number of other case reports and anecdotal reports in a variety of other 
indications.  However, none of these indications provide any firm evidence for 
efficacy but nevertheless may point the way to possible future uses.  The indications 
that have been reported in the literature are: 
 
 Attention Deficit Hyperactivity Disorder (ADHD) (Aharonovich et al 2006) 
 Trichotillomania (Grant et al 2011) 
 Tinnitus (Raby et al 2006) 
 Pruritus (Stander et al 2006) 
 Night sweats (Maida V 2008) 
 Isaac’s syndrome (Meyniel et al 2011) 
 Night vision (Russo et al 2004) 
 Asthma (Tashkin et al 1977) 
 Breathlessness (Pickering et al 2011) 
 Hiccups (Gilson and Busalacchi 1998) 
 Amyotrophic lateral sclerosis (motor neurone disease) (Carter and Rosen 
2001) 
 Anti-psychotic effect (CBD) (Iseger and Bossong 2015) 
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9. Side Effects 
 
The majority of the clinical studies discussed in this paper confirm that the side 
effects of cannabis in various formulations are in general mild and well tolerated.  
Many papers have listed the side effects encountered in trials.  We have attempted 
to amalgamate the commonest side effects but we do not claim that this is a 
definitive review of all possible side effects, as a number of rarer problems will arise 
and have been reported.  We felt it was reasonable to differentiate between short 
term effects of cannabis ingestion or inhalation on the one hand and potential longer 
term effects of cannabis on the other hand.  The latter includes a discussion 
regarding concerns of triggering schizophrenia or schizophrenic-like illness in longer 
term users.  We have also discussed the potential cognitive problems that might be 
encountered in the long term.  We include a brief section on driving and cannabis, as 
continued driving in modern society is clearly an important factor for the medical 
usage of cannabis.  We briefly review studies that may show some loss of brain 
volume in long term usage. We also discuss the possibility of respiratory cancers in 
relation to smoked marijuana.  However, we should emphasise in that context that 
most of the publications on medical usage do not use or recommend smoked 
marijuana.   
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9.1 Short Term Effects 
 
Ingestion and inhalation of cannabis is commonly associated with a number of 
effects.  Most studies confirm that these effects are mild and well tolerated and the 
dropout rate from cannabis studies is quite low – usually less than 10%.  This 
compares, for example, to dropout rate in studies of opioids from unacceptable side 
effects of around 33%. In the systematic review by Koppel and colleagues in 2014 
the authors analysed 1619 patients who received cannabinoids for less than six 
months (Koppel et al 2014).  Meta-analysis showed that 6.9% stopped medication 
because of adverse effects.  This compared to 2.2% of the placebo patients in these 
studies that also stopped because of adverse events.  The authors list adverse 
events that occurred in at least two studies as: 
 
 Nausea  
 Increased weakness 
 Behavioural or mood change or both 
 Suicidal ideation or hallucinations or both 
 Dizziness or vasovagal symptoms or both 
 Fatigue 
 Feelings of intoxication 
 
They also reported psychosis, dysphoria (general dissatisfaction, restlessness, low 
mood) and anxiety were generally associated with higher concentrations of THC but 
these side effects were not typical of the studies analysed.   
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The authors point out that there is no definite case of death as a result of overdose 
of cannabis in any formulation.  The paper cites one death ‘possibly related’ to 
treatment which included a seizure followed by fatal aspiration pneumonia. 
 
A further systematic review paper also looked at adverse events reported in 62 
studies (Whiting et al 2015).  These authors produced a useful meta-analysis for the 
number of participants in the studies experiencing any adverse event when 
compared with controls.  The authors point out that no study has evaluated long term 
adverse events of cannabinoids and this is a significant problem with the current 
literature.  The authors obviously confirm that there were more adverse events with 
cannabinoid treatments than with placebo but this is not surprising.  The authors list 
the ‘top 20’ individual adverse events with odds ratio for developing such an event in 
comparison to placebo or with active comparator.  The odds ratio is a measure of the 
increased (or decreased) chance of an event occurring compared to a comparator – 
in this case usually placebo. These ‘leading’ adverse events are as follows – 
 
 Disorientation (Odds ratio (OR) 5.41 – in other words there is a 5.41 
increased chance of disorientation compared to placebo) 
 Dizziness (OR 5.09) 
 Euphoria (OR 4.08) 
 Confusion (OR 4.03) 
 Drowsiness (OR 3.68) 
 Dry mouth (OR 3.50) 
 Somnolence (drowsiness or sleepiness) (OR 2.83) 
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 Balance problems (OR 2.62) 
 Hallucination (OR 2.19) 
 Nausea (OR 2.08) 
 Paranoia (OR 2.05) 
 Asthenia (OR 2.03) 
 Fatigue (OR 2.00) 
 Anxiety (OR 1.98) 
 Vomiting (OR 1.67) 
 Diarrhoea (OR 1.65) 
 Depression (OR 1.32) 
 Psychosis (OR 1.09) 
 
Two adverse events (dyspnoea and seizures) were actually less common in the 
cannabinoid treatment group than the placebo or active comparator group.  This list 
of the commonest ‘short term’ adverse events is entirely compatible with the authors’ 
own analysis of the literature but we have not carried out our own calculation of the 
odds ratios. 
 
Although there were only two studies in their review that evaluated native herbal 
cannabis they found no evidence that the effects of herbal cannabis differed from 
other cannabinoid formulations (such as nabiximols, dronabinol and nabilone) with 
similar THC proportions.  
 
The literature is clear that the ‘high’ associated with cannabis, and one of the main 
reasons for recreational use, is associated with the main psychoactive component – 
 [100] 
 
THC.  Formulations that have a high THC will tend to have more psychoactive side 
effects.  It is also known that CBD will to some extent counteract the effect of THC 
and thus formulations with a relatively high CBD level will have no or few 
psychoactive side effects.  A case in point is nabiximols that has a 1:1 ratio of 
THC:CBD.  This relatively high proportion of CBD will counteract the effect of an 
equally high proportion of THC and users of nabiximols do not experience a ‘high’. 
Thus we must emphasise again that the above side effect profile is characteristic of 
THC. Other formulations, particularly those higher in CBD would not carry this profile 
– as in discussed in several sections of this paper.  
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9.2 Comparison with Opioids 
 
As one of the key uses of cannabis and cannabinoids is for chronic pain relief, then 
the authors have been asked to compare the side effect profile of cannabis and 
different cannabinoid formulations with the side effects of opioids.  Opioids have 
been used for many years to relieve pain.  Opioid is a term that historically refers to 
drugs derived from opium, including morphine.  Other opioids have been produced 
synthetically such as hydrocodone, oxycodone and fentanyl.  Opioids are powerful 
substances and overdose, deliberate or accidental, particularly with concurrent use 
of other depressant drugs, will commonly result in death from respiratory depression.  
Common adverse events include sedation, nausea, vomiting, constipation, urinary 
retention and falls.  Thus there are significant risks in the older populations who may 
be at risk of falls, urinary retention and constipation in any case, as well as the risk 
associated with respiratory depression in the older age group.  Overall, studies 
indicate approximately 0.2% per annum risk of death amongst patients prescribed 
opioids for non-cancer pain over a 10-year period (Gomes T et al 2011). Other, less 
serious, effects include itch, drowsiness, dry mouth, dizziness and other problems 
such as impaired sexual functioning, irregular menstruation, negative effects on the 
immune system and depression.  The opioids are also known for significant 
withdrawal symptoms after cessation of therapy, including severe dysphoria, 
irritability, sweating, nausea, tremor, vomiting and muscle pain, which can often be 
followed by a long phase of depression and insomnia.  Addiction is also a problem 
with opioids.  More infrequent adverse events can also occur, including confusion, 
hallucinations, delirium, changes in body temperature and heart rate, headache and 
muscle spasm.  There is no doubt that opioids are of significant use in medicine, 
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particularly in advanced and chronic pain, but nevertheless there are very significant 
risks associated with opioid therapy.  In general terms there are significantly less 
risks associated with cannabis and cannabis formulations, particularly with regard to 
the very severe side effect of respiratory depression with risk of death. 
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9.3 Long Term Effects 
 
9.3.1 Side Effects in Relation to Schizophrenia and Psychosis  
 
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the 
diagnosis of schizophrenia involves not only positive symptoms (hallucinations, 
delusional thinking, paranoia, thought disorder), but also negative symptoms 
(apathy, poverty of thought, flattened affect and social withdrawal) as well as 
cognitive impairment (impairment in memory function, attention and executive 
functioning) (American Psychiatric Association, 2013).  The majority of the research 
into cannabis and schizophrenia has focused upon the positive symptoms of 
schizophrenia. Therefore, this is a limitation of the research base as a whole. There 
also needs to be clarity around whether we are talking about psychotic symptoms or 
the clinical diagnosis of schizophrenia. The authors will describe the research 
detailing both of these outcomes in relation to side effects of cannabis use. The 
following research is described in categories relating to the classification scheme 
used throughout the report.  
 
Class IV research 
 
D'Souza and colleagues (2009) carried out a literature review on this topic and 
suggested that cannabis use can cause some transient (minutes to hours) psychotic 
symptoms in mentally well individuals.  The research that D’Souza and colleagues 
drew these conclusions from was anecdotal evidence, case reports and surveys and 
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so would fall into Class IV (D’Souza et al 2009).  Furthermore, the research base 
that D’Souza and colleagues used was quite dated and ranged from 1968-1984.   
 
Reilly and colleagues (1998) surveyed 268 long-term cannabis users using a 
structured interview and found that 21% of users reported anxiety, paranoia, and 
depressive symptoms, and 21% reported tiredness, lack of motivation and low 
energy levels.  Although paranoia can be seen as a positive symptom of 
schizophrenia and lack of motivation could be seen as a negative symptom, the 
study had various limitations.  The majority of the participants were regularly drinking 
alcohol and quarter had taken other drugs within the previous month so it is hard to 
ascertain causality of the reported affects.  Furthermore, the participants were from a 
rural area of Australia and so the findings may not generalise to other geographical 
areas.  In addition, the study used a “snowball” sampling method rather than random 
sampling meaning that they may have similar characteristics as they were 
associates of each other.  Another factor that complicated the results was that the 
participants differed in their frequency of use and method of administration.  Despite 
these reported negative effects of cannabis, 61% of the sample reported that the 
main reason that they used cannabis was for its positive effect of relaxation.  
 
Another study within Class IV has been carried out by Thomas (1996) in which 200 
New Zealanders (aged 18-35 years) completed a self-report questionnaire about 
their experiences of the adverse effects of cannabis use.  Fifteen percent of this 
sample reported psychotic symptoms following usage.  However, the chemical 
content of herbal cannabis can vary and the dosage and frequency of usage varied 
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across the sample.  Furthermore, self-report data has inherent limitations as it is 
dependent upon the degree of insight and social desirability within the individual.   
 
The issue of causality between cannabis use and the onset of schizophrenia and 
psychotic symptoms is complex and involves many factors.  McLoughlin and 
colleagues (2014) suggest that other factors need to be considered such as social 
class, additional drug use, and reverse causality whereby an individual starts to use 
cannabis as a means of coping with prodromal symptoms of schizophrenia, such as 
low mood, and consequently the cannabis use is attributed as the cause when the 
illness may have started prior to this drug use (the self-medication hypothesis).  
However, even when taking these factors into account, cannabis has still been 
associated with an increased risk of developing schizophrenia (Matheson et al 
2011).  Despite this increased risk, Hill (2014) points out that within the Western 
world there was a dramatic increase in cannabis use in the 1960s and 1970s and yet 
the prevalence of schizophrenia has largely remained stable.  
 
Henquet and colleagues (2005a) carried out a meta-analysis of seven prospective 
studies into the role of cannabis use and psychosis and they reported an overall 
odds ratio of 2.1.  Within these prospective studies, baseline cannabis use 
consistently increased the risk for psychosis at follow-up.  This effect was not due to 
confounding variables since all studies included in the meta-analysis had 
adjustments made to account for confounding variables.  Confounding variables 
included age, sex, social class, ethnic group, family history of psychiatric illness, 
urbanicity, and use of other drugs.  Henquet and colleagues (2005a) also concluded 
that the association was not due to reverse causality because four of the studies 
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included in the analysis had addressed this issue by either excluding or adjusting for 
participants with predisposition to psychosis or using statistical modelling to 
distinguish the likelihood of causality.  However, a predisposition to psychosis has 
been shown to predict future use of cannabis (Ferdinand et al 2005) and so may 
partly explain the association between cannabis and psychosis.  Therefore, both the 
self-medication hypothesis and the causal hypothesis may be true.  Henquet and 
colleagues (2005a) states that “Causality is generally thought to be plausible if 
studies (i) report an association between the exposure and the outcome consistently 
and with a strong effect size, (ii) show dose-response relationships between the 
exposure and the outcome, (iii) show that the exposure precedes the outcome, and 
(iv) show that there is a plausible biological mechanism linking the exposure and the 
outcome”.  Criteria i-iii were fulfilled by the studies included in the meta-analysis with 
the exception of the large effect size needed to confirm causality.  
 
Various authors have proposed biological mechanisms by which cannabis may 
cause psychosis in terms of neurodevelopment in adolescence (Schneider and Koch 
2003; Veen et al 2004) and dopamine sensitivity (Howes et al 2004). However, this 
is far from established and needs further research.  A limitation of the meta-analysis 
carried out by Henquet and colleagues (2005a) was that the studies included did not 
measure cognitive functioning, which is a core component of the schizophrenia 
diagnosis.  
 
Another large meta-analysis was conducted by Moore and colleagues in 2007 which 
analysed seven longitudinal, population based, studies (Moore et al 2007). The 
authors found a dose-response effect in that there was a greater risk of developing 
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psychosis in people who used cannabis more frequently.  The pooled odds ratio was 
1.41 which had been adjusted for confounding variables and which was independent 
of transient intoxication effects.  The studies attempted to limit reverse causation 
through adjusting for psychotic symptoms or predisposition to psychosis, and 
excluding participants with psychosis at baseline.  Attrition rates were included for six 
out of the seven studies and a limitation of the meta-analysis may have been that 
attrition rates had a small effect on the results.  The authors note that attrition rates 
are higher in individuals who use drugs and in those who develop mental health 
problems and so this would have the effect of underestimating the strength of 
association.   Based on the odds ratio of 1.4, Moore and colleagues (2007) 
estimated that 14% of psychosis cases within the UK were due to cannabis use.   
 
Class III Research 
 
Leweke and colleagues (1999) reported the effects of oral synthetic THC in 17 
healthy males under controlled laboratory conditions.  Reactions amongst the 
participants ranged from mild euphoria to feelings of loss of self-control and body 
distortion suggestive of psychotic symptoms.  One subject went into a two-hour 
psychotic episode and experienced paranoia, persecutory delusions, and delusions 
of thought insertion. These findings cannot be generalised to the female population, 
a control group was not used, and a standardised outcome measure of psychosis 
was not used.   
 
In 2004 D’Souza and colleagues carried out a randomised, double-blind, placebo-
controlled study of 22 healthy control participants (D’Souza et al 2004).  The authors 
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found that THC produced transient positive symptoms of schizophrenia (paranoia, 
perceptual alterations, grandiose delusions, feelings of unreality, depersonalisation 
and derealisation, and disordered thinking), symptoms that are similar to the 
negative symptoms of schizophrenia (blunted affect, psychomotor retardation, and a 
lack of spontaneity), and cognitive difficulties such as impaired immediate and 
delayed verbal memory recall.  Participants were screened for psychiatric disorders 
and family history of those disorders.  Outcomes were assessed by standardised 
measures of psychosis (the Positive And Negative Symptom Scale, PANSS), 
perceptual alterations (the Clinician Administered Dissociative Symptoms Scale) and 
verbal learning and recall (Hopkins Verbal Learning Test, HVLT).  Baseline 
characteristics were not presented in the form of comparison of the different groups 
so we cannot presume that these were equivalent.  In addition, the study did not 
account for attrition rates.   
 
Degenhardt and colleagues (2007) carried out a 10-month prospective study in 2007 
that looked at the relationship between cannabis use and symptoms of psychosis in 
101 individuals with a current diagnosis of schizophrenia. They found that cannabis 
use predicted a small but significant increase in symptoms of psychosis in the 
following month after increased cannabis use.  This effect was present even when 
confounding variables of age, gender, other drug use, medication compliance and 
symptoms of depression were controlled for.  Outcomes were measured using 
standardised assessments but the study was slightly underpowered due to its limited 
sample size.  Despite this small effect, this study indicates that there is a risk of 
increased symptoms within individuals already suffering from schizophrenia following 
cannabis use.   
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Conversely, Casadio and colleagues (2011) found a significant clinical improvement 
in psychotic symptoms following cannabidiol therapy.  
 
Cannabis is often used as a form of self-medication amongst people suffering from 
psychosis with the belief that it reduces psychotic symptoms or reduces the 
unpleasant side-effects of antipsychotic medication (Dixon et al 1990); and the 
prevalence rates of cannabis usage in people diagnosed with schizophrenia are 
much higher than the general population at 40% (McLoughlin et al 2014).  In 2005 
D’Souza and colleagues conducted another randomised, double-blind, placebo-
controlled study similar to the one they carried out in 2004 but this time with a 
population suffering from schizophrenia (D’Souza et al 2005).  They found that THC 
caused a transient increase in positive and negative symptoms of schizophrenia as 
well as cognitive difficulties.  These effects occurred despite the participants being 
stable and compliant with taking antipsychotic medication.  Compared to their 2004 
study on healthy individuals, patients diagnosed with schizophrenia appeared to be 
more sensitive to THC effects as measured by the PANSS and HVLT. However, 
confounding variables may be the effect of the course of the illness itself and its 
impact upon cognitive ability, and the complex effect of some antipsychotics upon 
cognition.  Further research is needed into this population of individuals suffering 
from schizophrenia who are using cannabis in order to ascertain the effects upon 
their positive, negative and cognitive symptoms.  This is particularly merited given 
the increase in THC within street preparations of the drug and a decreasing age of 
first-time exposure to cannabis (Casadio et al 2011)  
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De Hert and colleagues (2011) investigated the influence of cannabis on the age of 
onset of schizophrenia using a regression analysis.  They found that cannabis use 
was associated with a decrease in the age of onset by an average of 1.5 years, 
which was representative of both males and females.  Another study by Ongur and 
colleagues (2009) concluded that lifetime cannabis use was associated with a 
significantly earlier age of onset of psychosis by 3.1 years when compared to non-
users.   
 
A Swedish cohort study carried out over 35 years found an odds ratio of 3.7 for 
schizophrenia, 2.2 for brief psychosis, and 2.0 for non-affective psychoses when 
they compared frequent cannabis users with non-users. (Manrique-Garcia et al 
2012) The study involved 41,943 male Swedes conscripted between the years 1969-
1970, and so cannot be generalised to the female population.  This risk declined 
over time for moderate users but much less so for frequent users, and the 
associations were stronger within the highest consumption category.  The study 
looks at hospitalisation for psychosis and so may have missed those who had still 
experienced psychosis but had managed to function without inpatient care (through 
accessing community mental health services, for example).  The data was adjusted 
for confounding variables which are likely to be related to cannabis use and 
schizophrenia including psychiatric diagnosis at conscription, low IQ, urbanicity, 
cigarette smoking, and ‘disturbed behaviour’ (such as truancy and contact with the 
Police).  However, the study did not account for the confounding variable of other 
drug use.  The authors described 60% of the cases of schizophrenia occurring in the 
first decade compared with 45% in non-users of cannabis, which supports the 
proposition that cannabis can trigger an earlier onset of this mental illness.  
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However, a limitation of this study is that they only have data regarding cannabis use 
at and prior to the date of conscription when the participants were on average 18 
years old and so we do not have information on consumption in subsequent years.  
Furthermore, self-report data is limited because it is reliant on accurate disclosure by 
the individual and conscripts may have under-reported drug use or even over-
reported in an attempt to avoid conscription.  
 
Manrique-Garcia and colleagues (2014) analysed the same data from Swedish 
conscripts as in their 2012 study, in order to determine whether cannabis users had 
a different prognosis compared to non-users. Data from 357 participants were 
analysed.  They found that prognosis was worse in cannabis users in terms of 
significantly longer inpatient stays, a higher rate of readmission to hospital, as well 
as being more likely to have inpatient stays of longer than two years.  Confounding 
variables were controlled for but a limitation of the study is that substance use is 
often associated with poor medication compliance, which would affect the prognosis 
of the illness.   
 
Another longitudinal study by Arseneault and colleagues (2002) found evidence in 
agreement with the Swedish study described above in that using cannabis in 
adolescence increases the likelihood of experiencing symptoms of schizophrenia in 
adulthood. They looked at a birth cohort of 759 individuals born in New Zealand 
between 1972-1973 and assessed their psychotic symptoms at age 11, their drug 
use at ages 15 and 18 and re-assessed these outcomes at age 26.  This study 
controlled for psychosis preceding the cannabis use, which suggests that the 
cannabis use is not secondary to a pre-existing psychosis (evidence against the self-
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medication hypothesis).  In addition, the risk was specific to cannabis use rather than 
to other drugs such as glue, cocaine and opiates.  Furthermore, this research found 
that earlier onset of cannabis use (by age 15) causes a greater risk of later 
developing schizophrenia; indeed they are four times more likely to have this 
diagnosis than controls.  However, Moore and colleagues (2007) points out that the 
increase risk of psychosis if cannabis is used from a younger age may be due to 
increased exposure at this age rather than a sensitive period per se.  
 
Henquet and colleagues (2005b) found that the effect of cannabis use was much 
stronger in those individuals with previous experience of psychotic symptoms than in 
those without this previous experience. The authors analysed data from 2437 young 
participants aged 14-24 years over a four-year period.  The sample was randomly 
drawn from the registry offices of Munich giving a representative population based 
sample.  Psychotic symptoms were measured by diagnostic interview carried out by 
trained psychologists and self-report measures.  They found that cannabis use at 
baseline increased the incidence of psychotic symptoms at follow up four years later 
after confounding variables were controlled for such as age, sex, socioeconomic 
status, urbanicity, childhood trauma, use of other drugs, tobacco, alcohol use, and 
also a predisposition for psychosis at baseline.  These data did not support the self-
medication hypothesis since baseline predisposition for psychosis did not predict 
cannabis use at follow-up.   
 
In terms of studies looking at genetic risk, McGuire and colleagues (1995) found that 
the first degree relatives of patients with psychosis who used cannabis had a 10 
times higher risk for developing schizophrenia (at 7.1%) than the relatives of patients 
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who were non-users (at 0.7%). The findings suggested that the development of 
psychosis in the context of cannabis use may be associated with a genetic 
predisposition to schizophrenia.  In support of this finding, Henquet and colleagues 
(2005b) reported that the risk of developing psychotic symptoms was 21% in 
individuals without genetic predisposition to psychosis and 51% in individuals with a 
genetic predisposition, with both groups using cannabis (more detail of this study is 
described above).  Power and colleagues (2014) studied the genetics of 2082 
healthy individuals and suggested that the association between schizophrenia and 
cannabis is due to a shared genetic aetiology; the same genes that increase 
psychosis risk may also increase risk of cannabis use. Their results suggested that 
individuals with an increased predisposition to schizophrenia are more likely to use 
cannabis.  This study implied that the association between cannabis use and 
psychosis could be bidirectional, in which case the risks of cannabis use in causing 
schizophrenia could be overestimated within the research.   Indeed, a recent study 
by Giordano and colleagues (2015) indicated that population-based estimates of 
cannabis-schizophrenia comorbidity substantially overestimate their causal 
association. There is strong evidence for genetic contributions to both schizophrenia 
and cannabis use (Giordano et al 2015), and so part of this association may be 
confounded by genetics.  The authors studied a sibling-pair group who were 
discordant in their cannabis use alongside a general population sample in order to 
control for this potential confounder variable.  Sibling pairs are a natural experiment; 
they share 50% of their parents’ genes and often share similar environmental 
factors.  Once familial confounding was controlled for, the risk of later developing 
schizophrenia substantially reduced within the cannabis users.  Although this latest 
research supports the earlier findings that cannabis use has a causal impact on the 
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risk for developing schizophrenia, this risk is likely to have been overestimated in the 
previous literature and when familial confounding is controlled for, this risk reduces 
by approximately two thirds.  A limitation of the Giordano and colleagues (2015) 
study is that it used individuals admitted to hospital or convicted of cannabis use and 
so their findings may not generalise to individuals with lower levels of cannabis use 
and less severe psychosis.  
 
Class I and II Research 
 
Randomised controlled trials of cannabis and schizophrenia are clearly difficult to 
undertake. This is partly because the synthetic preparations of the drug differ from 
the recreational drug and therefore studies using synthetic (legal) cannabinoids may 
not help to address the issue of causality.  The relatively short follow-up period of 
randomised controlled trials may also limit the results.  
 
Conclusion 
 
We have seen that cannabinoids can induce transient symptoms similar to the 
positive, negative, and cognitive symptoms of schizophrenia in healthy individuals.  
However, these are short-lived symptoms and do not constitute a psychiatric 
condition.  The research suggests that cannabinoids can exacerbate symptoms 
within individuals already suffering from psychosis and the use of herbal cannabis 
has been shown to reduce the age of onset of psychosis.  In addition to these 
findings, the prognosis of the course of the illness has been shown to be worse 
within individuals who have used cannabis, as indicated by longer inpatient stays 
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and more readmissions.  Furthermore, people who have a genetic predisposition to 
developing psychosis are more likely to develop psychotic symptoms following 
cannabis use.   
 
However, the direction of the causal link between cannabis use and psychosis has 
not been fully established as yet and this association is likely to have been 
overestimated in the earlier research papers. Hickman and colleagues (2009) 
considered how many cannabis users would need to stop the habit in order to 
prevent one case of schizophrenia or psychosis. These estimates are considerable, 
ranging, for men aged 20–24, from 2800 for heavy cannabis users to more than 
10000 for light cannabis users; and, for women aged 20–24, from 7700 for heavy 
cannabis users to 29000 for light cannabis users.  These figures demonstrate that 
the actual clinical risk of cannabis causing schizophrenia is very low and this needs 
to be considered, holding in mind the risks and benefits that all pharmaceutical 
medicines share.   
 
A limitation of the research base in this area is that studies do not often measure 
cognitive functioning or negative symptoms, which are core components of the 
schizophrenia diagnosis, and rather the focus has been on positive symptoms.  
Furthermore, the literature needs to be clear about whether we are hypothesising a 
link between cannabis and the symptoms of psychosis or the diagnosis of 
schizophrenia, or both. In addition, the literature would benefit from a consistent way 
of measuring either psychosis or schizophrenia; the DSM-5 has rarely been used in 
these studies as a standardised clinical diagnostic tool.   Another difficulty within this 
area of research is that it is impossible to ascertain the balance of THC and CBD 
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within the herbal recreational cannabis that the participants consumed.   The more 
recent studies are also more likely to include individuals who have used herbal 
cannabis with a higher level of THC since street preparations are increasingly using 
a higher concentration of this chemical (Casadio et al 2011).    
 
In conclusion, the majority of the literature gives support for a causal hypothesis 
between cannabis use and psychosis, particularly if usage starts at an early age 
(young adolescence) and if the individual has a genetic predisposition to psychosis.  
We know that it is unlikely that any one environmental factor (such as cannabis use) 
or any one gene can cause schizophrenia on its own.  It appears that cannabis is a 
component cause in the development of symptoms of schizophrenia and the onset of 
this mental illness depends upon many interacting factors.  However, it is also 
important to remember that most people who use cannabis do not develop 
schizophrenia, and most people with schizophrenia have never used cannabis.  
 
The authors wish to emphasise that it is likely that THC is the main cannabinoid 
which triggers schizophrenia and psychosis. CBD on the other hand is known to be 
anti-psychotic and may have a therapeutic role as an anti-psychotic agent although 
further studies are required (Iseger and Bossong 2015). 
 
9.3.2 Dependence 
 
Dependence on cannabis is actually quite unusual and the generally accepted figure 
is that about 9% of those who use cannabis develop dependence.  Most of the 
studies have been done in recreational users.  Dependence has been defined in the 
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International Classification of Diseases and Health Problems (ICD10) as ‘a cluster of 
physiological, behavioural, and cognitive phenomena in which the use of a 
substance or a class of substances takes on a much higher priority for a given 
individual than other behaviours that once had greater value’.  A central 
characteristic is a strong desire or sense of compulsion to take the substance.  There 
are difficulties in controlling the substance-taking behaviour and a physiological 
withdrawal state on cessation of the drug is also characteristic.  In an article in the 
Lancet in 2007 a scale was developed to assess the harm of drugs of potential 
misuse (Nutt et al 2007). Heroin was highest on the list of both psychological and 
physical dependence following by cocaine, tobacco, barbiturates, alcohol, 
benzodiazepines and amphetamine.  Cannabis was eighth on this list.  The 
dependency rate of around 9% compares to a dependence rate of alcohol of around 
15%, cocaine of around 17%, heroin 23% and tobacco 32%. We do not wish to 
underplay the potential problem of dependency in some individuals but nevertheless 
the risk is reasonably small and is less likely to be the case in medical usage, as 
prescription, formulation and use is likely to be more controlled than in recreational 
usage.   
 
9.3.3 Driving and Cannabis  
 
Driving is an important component of modern society.  Individuals taking cannabis for 
medical reasons will need to be given advice on whether they should or should not 
drive whilst taking the drug.  Such advice is, of course, common in prescriptions of all 
psychoactive drugs.  Studies tend to confirm that a single ‘dose’ of cannabis does 
impair driving and indeed that effect is exaggerated when combined with alcohol.  
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THC has been shown to impair both psychomotor function and actual driving 
performance in a dose related manner (Ramaekers et al 2004). The degree of 
impairment of performance in experimental studies has shown that a dose of THC of 
up to 300 mcg / kg produces equivalent impairment to alcohol concentration of 
0.05g/dl which is the legal limit for driving in many European countries.  Studies have 
also shown that detectable THC in the blood at the time of accident means that 
those drivers are three to seven times more likely to be responsible for their crash 
compared to drivers who do not use drugs or alcohol.  However, the authors wish to 
emphasise that such studies have mainly been carried out on illegal cannabis users 
and the cannabis attained is likely to be high in THC and may contain impurities.  We 
also point out that non-psychoactive cannabinoids, such as CBD, are not likely to 
carry any risk with regard to driving.  The importance of determining the safety in 
regard to the specific formulation is confirmed in a study by Friedel and colleagues 
(Friedel et al 2015) which showed no effect on driving performance in relation to 
nabiximols.  
 
Thus there should be no ‘blanket’ ban on driving with concomitant cannabis 
medicinal usage but it would be dependent on the circumstances and type of 
cannabis taken.  However, doctors prescribing cannabis should be aware of the 
need to caution patients with regard to driving (and probably using machinery) whilst 
taking the medication. 
 
A useful summary article on the effects of cannabis and driving skills has recently 
been published by Hartman and Huestis (2013). 
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9.3.4 Respiratory Cancer and Cannabis 
 
The commonest form of recreational intake of cannabis is by smoking.  However, the 
great majority of cannabis trials for medical use do not involve smoking the natural 
product.  Either the product is taken in capsular form (nabilone and dronabinol) or by 
oromucosal spray (nabiximols) or if cannabis extract/herbal cannabis is used then 
other forms of ingestion/inhalation are recommended, such as vaporisation.  Thus 
the number of studies of medicinal use by smoking cannabis is very limited.  If 
cannabis is legalised in the UK for medical use, then smoking is unlikely to be the 
recommended route and thus the risk of lung cancer is minimal.  The problem with 
epidemiological studies on this subject is that many recreational cannabis smokers 
also smoke tobacco which is, of course, a known carcinogen for lung and upper 
respiratory/throat/mouth cancers.  Some studies have shown no connection between 
marijuana smoking and lung (or colorectal cancer) and indeed some studies have 
shown that compounds found in cannabis have an anticancer effect (see Cancer 
section above).  Thus the effect of cannabinoids is complex and indeed sometimes 
contradictory.  Nevertheless, smoke from both tobacco and cannabis contains many 
of the same carcinogens.  In a review of the subject (Melamede 2005) the author 
concludes that both tobacco smoke and cannabis smoke contain carcinogens but 
the THC inhibits the enzyme necessary to activate some of the carcinogens found in 
the smoke.  The author points out a number of other differences between tobacco 
smoke and cannabis smoke and concludes that the current evidence does not 
suggest that cannabis smoke will have a carcinogenic potential comparable to that 
resulting from exposure to tobacco smoke.  He also makes the point that 
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development of cannabis vaporisers largely eliminates the carcinogenic potential of 
smoking cannabis. 
 
As long as smoked cannabis is not the recommended route then the risk of 
respiratory cancer seems very small or non-existent.   
 
9.3.5 Cognition and Cannabis Use 
 
A number of conditions that may benefit from cannabis prescription are associated 
with cognitive deficits – such as multiple sclerosis, traumatic brain injury, Parkinson’s 
disease, etc.  Thus if cannabis in any formulation caused additional cognitive 
impairment then this would be of some concern.  There is a considerable literature 
on this subject and it is not the purpose of this paper to review that literature in detail.  
Most of the neuropsychological studies have been carried out on recreational 
cannabis users and thus, whilst of relevance, are not necessarily applicable to those 
who use cannabis in more controlled form for medical reasons.   
 
There are many studies of the neuropsychological effect on acute intoxication with 
cannabis, usually in the form of the smoked product.  The evidence is reasonably 
clear that cannabis, particularly the THC component, impairs psychomotor 
performance and cognition.  Most attention has focused on deficits of episodic 
memory.  (episodic memory is autobiographical memory for time, places, associated 
emotions, etc.) There are also deficits noted in attention and concentration and some 
elements of higher executive functioning, including decision making and abstract 
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reasoning (Crane et al 2013). As we have seen the short term effects are usually 
mild. 
 
In terms of the longer term medical usage, it is more relevant to look at the potential 
cumulative cognitive effects of cannabis intake.  Some studies have indicated 
residual effects after several hours to several days of abstinence and some studies 
have shown longer term effects after several weeks of abstinence whilst other 
studies have shown no clear evidence for residual or long term neuropsychological 
deficits amongst cannabis users (Crean et al 2011). Studies differ on whether there 
are long term effects on attention, concentration and working memory.  Some 
confirm that there are documentable deficits after weeks of abstinence whilst others 
refute the suggestion.  There is some evidence that the neurocognitive deficits have 
a greater impact if cannabis is started at a young age (during adolescence) when 
relevant parts of the brain are still developing.  There is also evidence that the effect 
is dose related in that heavy users have more cognitive deficits than lighter users.  In 
terms of patient use there is some evidence that, in multiple sclerosis, cannabis use 
can worsen the cognitive deficits that already exist in such patients (Pavisian et al 
2014). There is further evidence that the THC component in cannabis has more 
negative neurocognitive effects than the cannabis formulations relatively high in 
CBD. The formulation of cannabis is very likely to be important. A study by Vachova 
and colleagues (Vachova et al 2014), for example, has shown no long term cognitive 
effects following nearly one year of nabiximols usage in 121 patients in a placebo 
controlled, double blind study in MS spasticity.  
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There are very few studies indeed that have followed individuals in the longer term 
and studied their ongoing cognitive functioning. At the present time the authors 
conclude there is no firm evidence that would suggest that the possible cognitive 
problems of cannabis use are of sufficient severity to give rise to concern but it may 
be sensible to suggest that prescription in adolescence should be given with more 
caution than in adults, given the probable susceptibility of the developing brain 
(Jacobus and Tapert 2014). 
 
The historical literature on cannabis has emphasised that an “amotivational” 
syndrome can occur in cannabis users. This syndrome is well known in 
neuropsychological terms and usually, but not always, reflects specific damage to 
the frontal lobe of the brain. It is characterised by lack of initiation, apathy, passivity 
and, incorrectly, is often labelled as “laziness”. It is quite common after traumatic 
brain injury.  It is still thought by some to be a cannabis-related issue and indeed 
features in a recent publication by the National Institute of Drug Abuse in the US (US 
Department of Health and Human Services 2014). However, there is no convincing 
evidence that this is the case. A thorough review (Barnwell, Earleywine and Wilcox 
2006) failed to show any difference in motivation between cannabis users and non-
users. In the short term, cannabis can induce a state of “relaxation” and indeed this 
is the desired result in many recreational, and medicinal, users. Some actually find 
this effect helpful in terms of their ability to cope in stressful social situations 
(Buckner and Zvolensky 2014). However, we find no convincing evidence of longer 
term social detriment.  
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Clearly more studies are required, particularly in a medical population that may 
already have cognitive deficits, in order to determine the longer term possible 
cognitive deficits and whether brains already damaged by various pathologies are 
more prone to further damage from cannabis use or whether there is no such 
correlation.   
 
9.3.6 Brain Volume and Cannabis 
 
There has been some concern in the literature that cannabis may give rise to 
reduced brain volume, particularly in long term heavy recreational users.  In one 
study 15 long term (> 10 years) and heavy (> five joints daily) users showed bilateral 
reduced volume of the hippocampus and the amygdala (central parts of the brain - 
Yucel et al 2008). Other neuroimaging studies have failed to show such change.  In 
a review by Lorenzetti et al (2010) the authors identified 13 structural neuroimaging 
studies and found that no study noted global structural change in cannabis users but 
six studies reported regional alterations, particularly in the hippocampus and the 
para-hippocampal region.  However, these findings were inconsistent across the 
studies.  The authors suggested that the overall evidence was that THC exposure 
does affect brain morphology but given the small literature and the limitation of the 
studies further research was required.  Those studies that have shown changes in 
the hippocampus have tended to be in the heavy recreational user.   
 
The main problem with these studies is that even if it is shown that regional brain 
volume is affected in long term users, then the importance of such findings is entirely 
unknown.  Is such a reduced volume of relevance in the long term and might it lead, 
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for example, to cognitive decline or mental health issues?  At the moment there is no 
evidence that brain volume loss, if it occurs, is associated with any such longer term 
issue.  Recent authors have shown a lack of such brain volume changes with regard 
to CBD usage and have suggested that if THC is associated with loss of volume then 
such potential harm is minimised by the additional use of CBD and that such 
changes can be reversed by extended periods of abstinence (Yucel et al 2016). 
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10.  Impact of Potential Legalisation of Cannabis in the United Kingdom 
 
The authors see a number of potential benefits of legalisation of cannabis in the 
United Kingdom but one also has to recognise some potential drawbacks.   
 
It is clear from the literature and from presentations to the APPG for Drug Policy 
Reform that there is widespread use of cannabis in the United Kingdom for medicinal 
purposes.  Legalisation would take many tens of thousands of people, currently 
using cannabis for medical purposes, out of the criminal justice system.  At the 
moment such individuals are exposed to the illegal trade with the concern of putting 
potentially vulnerable people in potentially hazardous situations – and risking 
prosecution. 
 
Cannabis obtained illegally can be highly variable in terms of the quality of the 
product.  We see, from a medical point of view, that a significant advantage of 
legalisation is that there could be far better quality control.  Such quality control now 
occurs in a number of US states. In many states there are licenced producers who 
are subject to strict quality control measures.  The supply by the Dutch Ministry of 
Health of the various bedrocan products is a further example of an improvement in 
quality control that can be obtained through a legal system.   
 
It is also clear from the evidence presented in this paper that a key factor in the 
efficacy of cannabis is the ratio between the THC content and the CBD content.  If 
the products are produced by licenced and quality checked growers, then this ratio 
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can also be controlled.  This is the case with the various bedrocan products and also 
the case with the nabiximols oromucosal spray.   
 
The authors recognise that even if production is controlled then there is a risk of 
diversion of the product into the recreational market.  This is known to be the case in 
some of the US states, such as Oregon.  Indeed, Oregon growers produce a total of 
approximately 408,000lbs of medical marijuana each year, yet it has been estimated 
that Oregon’s medical marijuana patients should only require about 85,000lbs per 
year (Privateer Holdings 2015). The authors of that paper assume that the excess 
production is diverted into the illegal market.  However, in states where the supply 
chain is fully controlled, then the diversion rate is much less.  An early study in 
Colorado in 2012 demonstrated that 74% of adolescents had used someone else’s 
medical marijuana (Salomonsen-Sautel et al 2012). This study, as well as other 
political and social pressures, led to tightening of the supply chain in Colorado with 
the creation of licenced pharmacy premises.  In most of the US states which have 
legalised marijuana, a physician has to approve an individual patient as being able to 
access the product – usually against a number of allowed medical indications.  This 
also reduces the diversion rate and secures the supply chain as far as possible.  
 
The authors particularly recognise the benefit of legalisation of cannabis in terms of 
improving the evidence base for the efficacy and safety of the product.  As will have 
been clear from this paper, many of the studies into the efficacy of cannabis have, 
not surprisingly, involved only the licenced products nabilone, dronabinol and 
nabiximols.  There is limited evidence of efficacy, at least in formal academic studies, 
of the efficacy of the ‘natural’ product.  Legalisation would allow such studies to be 
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undertaken in large and meaningful numbers for the different indications and in a 
controlled format.  This paper has demonstrated there are many applications that 
have a theoretical basis and have some evidence of efficacy but such evidence is 
limited.  Legalisation, over a period of time, would clearly correct this defect in our 
knowledge.  The other key factor that could be properly studied is the incidence of 
the short and long term side effects of the product.  Most of the studies of side 
effects of cannabis have been in recreational users and have not been properly 
controlled in the medical context.  It is just as important to determine the short and 
long term safety of the product as it is to determine the overall evidence of efficacy in 
different indications.  Indeed, it would be possible, as was the case for disease 
modifying drugs in multiple sclerosis, for medical users to be automatically entered 
into an appropriate long term study, particularly with regard to side effect profile.  
 
Have we seen advantages, from a medical viewpoint, of legalisation in US States? 
Obviously, at a personal level many individuals will have been assisted by the 
medical legalisation process in many US States. However, it would appear that these 
States have not initiated any coordinated research programme to monitor the impact, 
in medical terms, of such legalisation. Formal studies are hampered by the fact that 
the US Food and Drug Administration (FDA) still views cannabis as an illegal drug 
under the Controlled Substances Act, whereas 24 states and the District of Columbia 
approve and regulate its medical use. This confusion makes coordinated research 
difficult as it is the FDA that has to approve the safety and efficacy of any 
prescription drug. There is wide variation between States in the conditions approved 
and in the production chain. Some States allow growth of the plant by the individual 
whereas others only allow production by licensed growers and supply through 
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licensed dispensaries. It so far appears that the opportunity for proper, large scale 
studies of efficacy and safety is being missed in the US, although some studies are 
underway and results are awaited. 
 
In summary, from the patient point of view, legalisation of medical cannabis would 
take individuals outside the criminal justice system. It seems preferable for the 
growth and supply of cannabis to be formally regulated so that the quality of the 
product, and particularly the THC:CBD ratio, can be controlled.  The supply chain 
should be secured as far as possible to reduce diversion into the recreational 
market. Patients using cannabis could be entered into proper studies both of the 
efficacy of the product and also of the short and long term side effects.  
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11. Conclusions 
 
Cannabis has been used as a medicinal product for centuries.  However, it is only in 
recent decades that neuroscientists have discovered that humans have natural 
cannabinoid receptors and natural chemicals that bind to those receptors.  This is 
known as the endocannabinoid system.  It is now known the endocannabinoid 
system is not only found throughout the brain but also in many other regions of the 
body, including the digestive tract, the bladder and the metabolic, endocrine and 
immune systems.  The endocannabinoid system is involved in modulation of pain, 
regulation of motor activity and has a role to play in brain plasticity, protection of 
brain cells and aspects of memory processing.  It seems to have a role in the 
regulation of tumour growth.  Our knowledge of the endocannabinoid system is 
rapidly expanding and it is clear that it is an important regulator of many bodily 
functions.  It is also becoming clear that manipulation of the endocannabinoid system 
can have an important role in the management of many common diseases and 
disorders.   
 
It is thought that the natural phytocannabinoids found in the cannabis plant are able 
to interact with the human endocannabinoid system and thus modulate the effects of 
that system.  Thus there is now a good scientific rationale for the mode of action of 
cannabis in many diseases.   
 
This paper has demonstrated the depth and breadth of evidence for cannabis in a 
number of different disease states.  The scientific literature has focussed on the 
cannabis products that are legally available.  In the UK nabilone (Cesamet) is legally 
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prescribable for nausea and vomiting and nabiximols (Sativex) is legally prescribable 
for management of resistant spasticity.  The former is a synthetic form of THC, which 
is the most widely occurring phytocannabinoid.  The latter is 1:1 mixture of THC and 
the second most common phytocannabinoid – cannabidiol (CBD).  In the United 
States further work has been carried out on another synthetic form of THC – 
dronabinol (Marinol).  The studies on ‘natural’ cannabis and cannabis extracts are 
not surprisingly limited by the fact that in most countries the product is illegal.  
However, despite these difficulties there is evidence for the efficacy of cannabis in a 
number of different indications.   
 
This paper has shown that there is good evidence for the efficacy of at least one 
formulation of cannabis in: 
 Pain – both chronic pain and neuropathic pain 
 Spasticity – mainly in multiple sclerosis but there is no reason why it should 
not be just as efficacious in spasticity secondary to other neurological 
disorders 
 Nausea and vomiting – particularly in the context of chemotherapy 
 Anxiety 
 
We find there is moderate evidence for efficacy in: 
 Parkinson’s disease 
 Sleep disorders 
 Fibromyalgia  
 Post-traumatic stress disorder 
 Appetite stimulation – most of that evidence in the context of HIV infection 
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There is some limited evidence of efficacy, but clearly further studies are required, 
in: 
 Epilepsy (particularly the drug resistant childhood epilepsies) 
 Bladder dysfunction in the context of neurological disorders, especially 
multiple sclerosis 
 Glaucoma 
 Control of agitation in dementia 
 Tourette’s syndrome  
 
We have found that there is a reasonable theoretical base but so far no convincing 
evidence for efficacy in dystonia, a neuroprotective effect in traumatic brain injury, 
Huntington’s disease, headache, depression, obsessive compulsive disorder, 
gastrointestinal disorders, as an anti-psychotic agent (CBD). We find no convincing 
evidence so far for an effect on cancer. 
 
Obviously some of these recommendations are drug specific, as the studies have 
only been done in the context of the licenced products.   
 
There is clearly a considerable amount of work yet to be done to further determine 
the efficacy in these, and probably other, indications and also to determine the best 
dose of the product and, in particular, which type of cannabis, especially in terms of 
the THC:CBD ratio, best helps each specific condition. 
 
We know a considerable amount about the short term effects of cannabis, which are 
generally mild and well tolerated.  We know less about long term effects.  The most 
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studied possible long term effect is with regard to schizophrenia.  Our conclusion is 
that the majority of literature gives support for a causal link between cannabis use 
and psychosis in certain circumstances, particularly if usage starts in adolescence 
and if the individual has a genetic predisposition to psychosis.  If cannabis is 
legalised it may be preferable for caution to be exercised in prescription for those 
with a personal history or family history of schizophrenia.  There is a small risk of 
dependency with “natural” cannabis use in the order of 9% but this favourably 
compares to higher levels of dependency in, for example, alcohol and tobacco users.  
Caution needs to be expressed with regard to using cannabis in the context of 
driving or using heavy machinery but we consider from the evidence there should be 
no overall ban on driving with concomitant cannabis medical usage, as it depends on 
the circumstances and the type of cannabis taken.   There may be, although far from 
proven, a carcinogenic risk from smoking cannabis but nevertheless the medical 
recommendation would be that cannabis should not be taken as a smoked product 
as there are safer ways of administration, such as vaporisation, oromucosal spray or 
taken in food or even topically applied.  Further studies are clearly required on the 
best route of administration.  We have documented some cognitive difficulties, at 
least in the short term and, in a similar fashion to prescription in schizophrenia, it 
may be wise to avoid prescription in adolescence given the probable susceptibility of 
the developing brain.   
 
Most of the side effects are secondary to the THC component. CBD has less side 
effects and indeed may counteract some of the THC effects. 
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We should not forget that whilst there are alternative medications for most of the 
indications we have studied in this paper, many of the alternative medical treatments 
do give rise to significant, and often troublesome, side effects.  This is particularly the 
case with regard to the prescription of opioids for pain.   
 
Overall, there is good evidence for the use of cannabis in many important conditions 
that effect many thousands of disabled people in the UK. Generally, cannabis and 
cannabis products are safe and well tolerated.  It is clear from this review that 
cannabis does have medicinal value and continuing placement of cannabis under 
Schedule 1 of the Misuse of Drugs Act, which thus states it is of no medicinal value, 
is inaccurate and misleading.  We consider that the evidence firmly suggests that 
cannabis should be a legal product for medicinal use, as long as the quality of the 
product is guaranteed and the supply chain secured and that medical users are, as 
far as possible and practicable, entered into proper long term studies of both efficacy 
and side effects.   
  
 [134] 
 
12. References 
 
Abrams DI, Jay CA, Shade SB, et al.  Cannabis in painful HIV-associated sensory 
neuropathy: a randomized placebo-controlled trial.  Neurology 2007; 68: 515-521 
 
Agurell S, Halldin M, Lindgren JE, et al.  Pharmacokinetics and metabolism of delta 
1-tetrahydrocannabinol and other cannabinoids with emphasis on man.  Pharmacol 
Rev 1986; 38: 21-43 
 
Aharonovich E, Garawi F, Bisaga A, et al.  Concurrent cannabis use during 
treatment for comorbid ADHD and cocaine dependence: effects on outcome. Am J 
Drug Alcohol Abuse 2006; 32: 629-635 
 
Ahmed A, van der Marck MA, van den Elsen G, Olde Rikkert M.  Cannabinoids in 
late-onset Alzheimer’s disease.  Clin Pharmacol Ther 2015; 97: 597-606 
 
Alexander A, Smith PF, Rosengren RJ.  Cannabinoids in the treatment of cancer.  
Cancer Lett 2009; 285: 6-12 
 
American Psychiatric Association. Diagnostic and statistical manual of mental 
disorders: DSM-5. 2013. Washington, D.C: American Psychiatric Association 
 
Arseneault L, Cannon M, Poulton R, et al. Cannabis use in adolescence and risk for 
adult psychosis: longitudinal prospective study. BMJ 2002; 325:1212–1213 
 
 [135] 
 
Bambico FR, Gobbi G.  The cannabinoid CB1 receptor and the endocannabinoid 
anandamide: possible antidepressant targets.  Exp Opin Ther Targets 2008; 12: 
1347-1366 
 
Barnes MP, Johnson GR.  Upper motor neurone syndrome and spasticity: clinical 
management and neurophysiology. 2nd Edition 2008, Cambridge University Press, 
Cambridge, UK 
 
Barnwell SS, Earleywine M, Wilcox R. Cannabis, motivation, and life satisfaction in 
an internet sample. Subst Abuse Treat Prev Policy 2006; 1: 2 
 
Beal JE, Olson R, Laubenstein L, et al.  Dronabinol as a treatment for anorexia 
associated with weight loss in patients with AIDS.  J Pain Symptom Manage 1995; 
10: 89-97 
 
Beal JE, Olson R, Lefkowitz L, et al.  Long-term efficacy and safety of dronabinol for 
acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom 
Manage 1997; 14: 7-14 
 
Ben-Shabat S, Fride E, Sheskin T et al. An entourage effect: inactive endogenous 
fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J 
Pharmacol 1998; 353: 23-31 
 
 [136] 
 
Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety 
induced by simulated public speaking in treatment-naive social phobia patients. 
Neuropsychopharmacology. 2011; 36: 1219-1226  
 
Berlach DM, Shir Y, Ware MA.  Experience with the synthetic cannabinoid nabilone 
in chronic noncancer pain.  Pain Med 2006; 7: 25-29 
 
Berman JS, Symonds C, Birch R.  Efficacy of two cannabis based medicinal extracts 
for the relief of central neuropathic pain from brachial plexus avulsion: results of a 
randomised controlled trial.  Pain 2004; 112: 299-306 
 
Bestard JA, Toth CC.  An open-label comparison of nabilone and gabapentin as 
adjuvant therapy or monotherapy in the management of neuropathic pain in patients 
with peripheral neuropathy.  Pain Pract 2011; 11: 353-368 
 
Betthauser K, Pilz J, Vollmer L. Use and effects of cannabinoids in military veterans 
with posttraumatic stress disorder. Am J Health-Syst Pharm 2015; 72: 1279-1284 
 
Bifulco M, Laezza C, Pisanti S, Gazzerro P.  Cannabinoids and cancer: pros and 
cons of an antitumour strategy.  Br J Pharmacol 2006; 148: 123-135 
 
Blake DR, Robson P, Ho M, et al.  Preliminary assessment of the efficacy, tolerability 
and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused 
by rheumatoid arthritis.  Rheumatology (Oxford) 2006; 45: 50-52 
 
 [137] 
 
Brady CM, DasGupta R, Dalton C, et al.  An open-label pilot study of cannabis-
based extracts for bladder dysfunction in advanced multiple sclerosis.  Mult Scler 
2004; 10: 425-433 
 
Brisbois TD, de Kock IH, Watanabe SM, et al.  Delta-9-tetrahydrocannabinol may 
palliate altered chemosensory perception in cancer patients: results of a randomized, 
double-blind, placebo-controlled pilot trial.  Ann Oncol 2011; 22: 2086-2093 
 
Buckner JD, Zvolensky MJ. Cannabis and related impairment: the unique roles of 
cannabis use to cope with social anxiety and social avoidance. Am J Addict 2014; 
23: 598-603. 
 
Bujarski SJ, Feldner MT, Lewis SF, et al. Marijuana use among traumatic event-
exposed adolescents: posttraumatic stress symptom frequency predicts coping 
motivations for use. Addict Behav 2012; 37: 53-59 
 
Burston JJ, Woodhams SG.  Endocannabinoid system and pain: an introduction.  
Proc Nutr Soc 2014; 73: 106-117 
 
Cabral GA, Ferreira GA, Jamerson MJ.  Endocannabinoids and the immune system 
in health and disease.  Handb Exp Pharmacol 2015; 231: 185-211 
 
Cairns EA, Baldridge WH, Kelly NEM.  The endocannabinoid system is a therapeutic 
target in glaucoma.  Neurol Plast 2016;2016:9364091. doi: 10.1155/2016/9364091. 
Epub 2016 Jan 12 
 [138] 
 
Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional 
population for posttraumatic stress disorder-related insomnia and nightmares, 
chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin 
Psychopharmacol 2014; 34: 559-564  
 
Carroll CB, Bain PG, Teare L, et al.  Cannabis for dyskinesia in Parkinson disease: a 
randomized double-blind crossover study. Neurology 2004; 63: 1245-1250 
 
Carter GT, Rosen BS.  Marijuana in the management of amyotrophic lateral 
sclerosis.  Am J Hosp Palliat Care 2001; 18: 264-270 
 
Casadio P, Fernandes C, Murray RM, Di Forti M. Cannabis use in young people: the 
risk for schizophrenia. Neurosci Biobehav Rev 2011: 35: 1779-87 
 
Chagas MH, Zuardi AW, Tumas V, et al. The effects of cannabidiol in the treatment 
of patients with Parkinson’s disease: an exploratory double-blind trial.  J 
Psychopharmacol 2014; 28: 1088-1098 
 
Chattergee A, Almahrezi A, Ware M, Fitzcharles MA.  A dramatic response to 
inhaled cannabis in a woman with central thalamic pain and dystonia.  J Pain 
Symptom Manage 2002; 24: 4-6 
 
Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.  
Randomized controlled trial of cannabis-based medicine in spasticity caused by 
multiple sclerosis.  Eur J Neurol 2007; 14: 290-296 
 [139] 
 
Collin C, Ehler E, Waberzinek G, et al.  A double-blind, randomized, placebo-
controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity 
due to multiple sclerosis.  Neurol Res 2010; 32: 451-459 
 
Consroe P, Sandyk R, Snider SR.  Open label evaluation of cannabidiol in dystonic 
movement disorders. Int J Neurosci 1986; 30: 277-282 
 
Consroe P, Laquna J, Allender J, et al.  Controlled clinical trial of cannabidiol in 
Huntington’s disease.  Pharmacol Biochem Behav 1991; 40: 701-708 
 
Corey-Bloom J, Wolfsen T, Gamst A, et al.  Smoked cannabis for spasticity in 
multiple sclerosis: a randomized, placebo-controlled trial.  CMAJ 2012; 184: 1143-
1150 
 
Cougle JR, Bonn-Miller M, Vujanovic AA, et al. Posttraumatic stress disorder and 
cannabis use in a nationally representative sample. Psychol Addict Behav 2011; 25: 
554-558 
 
Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R.  Effects of cannabis on 
neurocognitive functioning: recent advances, neurodevelopmental influences and 
sex differences.  Eur Psychol Rev 2013; 23: 117-137 
 
Crean RD, Crane NA, Mason BJ.  An evidence based review of acute and long-term 
effects of cannabis use on executive cognitive functions.  J Addict Med 2011; 5: 1-8 
 [140] 
 
Cridge BJ, Rosengren RJ.  Critical appraisal of the potential use of cannabinoids in 
cancer management.  Cancer Manag Res 2013; 5: 301-313 
 
Crippa JA, Derenusson GN, Ferrari TB, et al.  Neural basis of anxiolytic effects of 
cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J 
Psychopharmacol. 2011; 25 :121-30  
 
Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's Syndrome. Cochrane 
Database Sys Rev 2009a, 4. Art. No.: CD006565. 
DOI:10.1002/14651858.CD006565.pub2  
 
Curtis A, Mitchell I, Patel S, et al.  A pilot study using Nabilone for symptomatic 
treatment in Huntington’s disease.  Mov Disord 2009b; 24: 2254-2259 
 
D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of 
intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for 
psychosis. Neuropsychopharmacology 2004; 29: 1558–1572 
 
D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects 
in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 
2005; 57: 594-608  
 
D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: 
human studies. Eur Arch Psychiatry Clin Neurosci 2009: 259: 413-31 
 
 [141] 
 
Degenhardt L, Tennant C, Gilmour S, et al. The temporal dynamics of relationships 
between cannabis, psychosis and depression among young adults with psychotic 
disorders: findings from a 10-month prospective study. Psychol Med 2007; 37: 927–
934 
 
De Hert M, Wampers M, Jendricko T, et al. Effects of cannabis use on age at onset 
in schizophrenia and bipolar disorder. Schizophr Res 2011; 126: 270-276  
 
Desbois AC, Cacoub P.  Cannabis-associated arterial disease.  Ann Vasc Surg 
2013; 27: 996-1005 
 
Devinsky O, Cilio MR, Cross H, et al.  Cannabidiol: pharmacology and potential 
therapeutic role in epilepsy and other neuropsychiatric disorders.  Epilepsia 2014; 
55: 791-802 
 
Devinsky O, Marsh E, Friedman D, et al.  Cannabidiol in patients with treatment-
resistant epilepsy: an open label interventional trial.  Lancet Neurol 2016; 15: 270-
278 
 
Dixon L, Haas G, Wedien PJ, et al. Acute effects of drug abuse in schizophrenic 
patients: clinical observations and patients' self-reports. Schizophr Bull 1990; 16: 69-
79 
 
dos Santos RG, Hallak JE, Lite JP, et al.  Phytocannabinoids and epilepsy.  J Clin 
Pharm Ther 2015; 40: 135-143 
 [142] 
 
Drotenhermen F.  Pharmacokinetics and pharmacodynamics of cannabinoids.  Clin 
Pharmacokinet 2003; 42: 327-360 
 
Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an 
oromucosal standardized cannabis extract in chemotherapy-induced nausea and 
vomiting. Br J Clin Pharmacol 2010; 70: 656-663 
 
Elliott AM, Smith BH, Penny KI, et al. The epidemiology of chronic pain in the 
community. Lancet 1999; 354: 1248 – 1252. 
 
Ellis RJ, Toperoff W, Vaida F, et al.  Smoked medicinal cannabis for neuropathic 
pain in HIV: a randomized, crossover clinical trial.  Neuropsychopharmacology 2009; 
34: 672-680 
 
Eubanks LM, Rogers CJ, Beuscher AE, et al.  A molecular link between the active 
component in marijuana and Alzheimer’s disease pathology.  Mol Pharm 2006; 3: 
773-777 
 
Farrimond JA, Mercier MS, Whalley BJ, Williams CM.  Cannabis sativa and the 
endogenous cannabinoid system: therapeutic potential for appetite regulation. 
Phytother Res 2011; 25: 170-188 
 
Ferdinand RF, Sondeijker F, Van der Ende J, et al. Cannabis use predicts future 
psychotic symptoms; and vice versa. Addiction 2005; 100: 612–618 
 
 [143] 
 
Ferre L, Nuara A, Pavan G, et al.  Efficacy and safety of nabiximols (Sativex(®) on 
multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci 2016; 
37: 235-242 
 
Fernandez-Ruis J, Romero J, Ramos JA. Endocannabinoids and Neurodegenerative 
disorders: Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease and 
Others.  Handb Exp Pharmacol 2015; 231: 233-259 
 
Firsching R, Piek J, Skalej M, et al. Early survival of comatose patients after severe 
traumatic brain injury with the dual cannabinoid CB1/CB2 receptor agonist KN38-
7271: a randomised, double-blind, placebo-controlled phase II trial.  J Neurol Surg A 
Cent Eur Neurosurg 2012; 73: 204-216  
 
Fitzcharles MA, Baerwald C, Ablin J, Hauser W.  Efficacy, tolerability and safety of 
cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia 
syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of 
randomized controlled trials. Schmerz 2016; 30: 47-61 
 
Fiz J, Duran M, Capella D, et al.  Cannabis use in patients with fibromyalgia: effect 
on symptoms relief and health-related quality of life. PLoS One 2011; 6: e18440. doi: 
10.1371/journal.pone.0018440 
 
Flachenecker P, Henze T, Zettl UK.  Nabiximols (THC/CBD oromucosal spray, 
Sativex®) in clinical practice--results of a multicenter, non-interventional study 
(MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014; 71: 271-279 
 [144] 
 
Flom MC, Adams AJ, Jones RT.  Marijuana smoking reduced pressure in human 
eyes: drug action or epiphenomenon?  Invest Opthalmol 1975; 14: 52-55 
 
Foltin RW, Fischman MW, Byrne MF.  Effects of smoked marijuana on food intake 
and body weight of humans living in a residential laboratory.  Appetite 1988; 11: 1-14 
 
Fox SH, Kellett M, Moore AP, et al.  Randomised, double-blind, placebo-controlled 
trial to assess the potential of cannabinoid receptor stimulation in the treatment of 
dystonia.  Mov Disord 2002; 17: 145-149 
 
Frank B, Serpell MG, Hughes J, et al.  Comparison of analgesic effects and patient 
tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, 
crossover, double blind study.  BMJ 2008; 336: 199-201 
 
Fraser GA. The use of a synthetic cannabinoid in the management of treatment-
resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 
2009; 15: 84–88 
 
Freeman RM, Adekanmi O, Waterfield MR, et al.  The effect of cannabis on urge 
incontinence in patients with multiple sclerosis: a multicentre randomised, placebo-
controlled trial (CAMS-Luts).  Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 636-
641 
 
Friedel M, Tiel-Wilck K, Schreiber H et al. Drug resistant MS spasticity treatment with 
Sativex add-on and driving ability. Acta Neurol Scand 2015; 131: 9-16 
 [145] 
 
Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9- 
tetrahydrocannabinol and cannabidiol on neural activation during emotional 
processing. Arch Gen Psychiatry 2009; 66: 95-105  
 
Gaoni Y, Mechoulam R.  Isolation, structure and partial synthesis of an active 
constituent of hashish.  J Am Chem Soc 1964; 86: 1646-1647 
 
Gatta-Cherifi B, Cota D.  Endocannabinoids and metabolic disorders.  Handb Exp 
Pharmacol 2015; 231: 367-391 
 
Gilgun-Sherki Y, Melaned E, Mechoulam R, Offen D.  The CB1 cannabinoid receptor 
agonist, HU210, reduces levodopa induced rotations in 6-hydroxydopamine-lesioned 
rats.  Pharmacol Toxicol 2003; 93: 66-70 
 
Gilson I, Busalacchi M.  Marijuana for intractable hiccups.  Lancet 1998; 351: 267 
 
Giordano GN, Ohlsson H, Sundquist K, et al. The association between cannabis 
abuse and subsequent schizophrenia: A swedish national co-relative control study. 
Psychological Medicine 2015; 45: 407-414 
 
Gomes FV, Resstel LB, Guimaraes FS. The anxiolytic-like effects of cannabidiol 
injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A 
receptors. Psychopharmacology (Berl) 2011; 213: 465-473  
 
 [146] 
 
Gomes T, Mamdani MM, Dalla IA, et al.  Opioid dose and drug-related mortality in 
patients with nonmalignant pain.  Arch Intern Med 2011; 171: 686-691 
 
Gowran A, Noonan J, Campbell VA. The multiplicity of action of cannabinoids: 
implications for treating neurodegeneration.  CNS Neurosci Ther 2011; 17: 637-644 
 
Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: 
evidence-based, clinical practice guidelines. American Society of Clinical Oncology.  
J Clin Oncol 1999; 17: 2971-94 
 
Grant JE, Odlaug BL, Chamberlain SR, Kim SW.  Dronabinol, a cannabinoid agonist, 
reduces hair pulling in trichotillomania: a pilot study.  Psychopharmacology (Berl) 
2011; 218: 493-502 
 
Gross H, Ebert MH, Faden VB, et al.  A double-blind trial of delta-9-
tetrahydrocannabinol in primary anorexia nervosa.  J Clin Psychopharmacol 1983; 3: 
165-171 
 
Guzman M, Duarte MJ, Blazquez C et al.  A pilot clinical study of delta9-
tetrahydrocannabionol in patients with recurrent glioblastoma multiforme.  Br J 
Cancer 2006; 95: 197-203 
 
Hackan DJ.  Cannabis and stroke: systematic appraisal of case reports.  Stroke 
2015; 46: 852-856 
 
 [147] 
 
Haney M, Rabkin J, Gunderson E, Foltin RW.  Dronabinol and marijuana in HIV(+) 
marijuana smokers: acute effects of caloric intake and mood.  Psychopharmacology 
(Berl) 2005; 181: 170-178 
 
Haney M, Gunderson EW, Rabkin J, et al.  Dronabinol and marijuana in HIV-positive 
marijuana smokers.  Caloric intake, mood and sleep.  J Acquir Immune Defic Syndr 
2007; 45: 545-554 
 
Hartman RL, Huestis MA.  Cannabis effects on driving skills.  Clin Chem 2013; 59: 
478-492 
 
Health Canada.  Information for health care professionals.  Cannabis (marihuana 
and marijuana) and the cannabinoids.  Health Canada, Ottawa, Canada. February 
2013 
 
Hedlund P.  Cannabinoids and the endocannabinoid system in lower urinary tract 
function and dysfunction.  Neurourol Urodyn 2014; 33: 46-53 
 
Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the 
role of cannabis use. Schizophr Bull 2005a; 31: 608–612 
  
Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis 
use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 
2005b; 330: 11 
 
 [148] 
 
Hickman M, Vickerman P, Macleod J, et al. If cannabis caused schizophrenia--how 
many cannabis users may need to be prevented in order to prevent one case of 
schizophrenia? England and Wales calculations. Addiction. 2009; 104: 1856-1861  
 
Huestis MA.  Human cannabinoid pharmacokinetics.  Chem Biodivers 2007; 4: 1770-
1804 
 
Hill MN. Clearing the smoke: what do we know about adolescent cannabis use and 
schizophrenia? J Psychiatry Neurosci 2014; 39: 75-77 
 
Hill KP.  Medical marijuana for treatment of chronic pain and other medical and 
psychiatric problems: a clinical review.  JAMA 2015; 313: 2474-2483 
 
Hill AJ, Mercier MS, Hill TD, et al.  Cannabidivarin is anticonvulsant in mouse and 
rat.  Br J Pharmacol 2012; 167: 1629-1642 
 
Hillard CJ.  Endocannabinoids and the endocrine system in health and disease.  
Handb Exp Pharmacol 2015; 231: 317-339 
 
Howes OD, McDonald C, Cannon M, et al. Pathways to schizophrenia: the impact of 
environmental factors. Int J Neuropsychopharmacol 2004; 7: S7–S13 
 
Hussain SA, Zhou R, Jacobson C, et al.  Perceived efficacy of cannabidiol-enriched 
cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile 
spasms and Lennox-Gastaut syndrome.  Epilepsy Behav 2015; 47: 138-141 
 [149] 
 
Iseger TA, Bossong MG. A systematic review of the anti-psychotic properties of 
cannabidiol in humans. Schizophr Res 2015; 162: 153-161 
 
Izzo AA, Muccioli GG, Ruggieri MR, Schicho R.  Endocannabinoids and the digestive 
tract and bladder in health and disease.  Handb Exp Pharmacol.  2015; 231: 423-447 
 
Jacobus J, Tapert SF.  Effects of cannabis on the adolescent brain.  Curr Pharm Des 
2014; 20: 2186-2193 
 
Jarvinen T, Pate DW, Laine K.  Cannabinoids in the treatment of glaucoma. 
Pharmacol Ther 2002; 95: 203-220 
 
Jatoi A, Windschitl HE, Loprinzi CL, et al.  Dronabinol versus megestrol acetate 
versus combination therapy for cancer-associated anorexia: a North Central Cancer 
Treatment Group study.  J Clin Oncol 2002; 20: 567-573 
 
Jetly R, Hever A, Fraser G, Boisvert D.  The efficacy of nabilone, a synthetic 
cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary 
randomized, double-blind, placebo-controlled cross-over design study.  
Psychoneuroendocrinology 2015; 51: 585-588 
 
Johnson JR, Bernell Nugent M, Lossignol D, et al.  Multicenter, double-blind, 
randomized, placebo-controlled, parallel group study of the efficacy, safety and 
tolerability of THC:CBD extract and THC extract in patients with intractable cancer-
related pain.  J Pain Symptom Manage 2010; 39: 167-179 
 [150] 
 
Katchan V, David P, Shoenfeld Y.  Cannabinoids in autoimmune diseases: a 
systematic review.  Autoimmun Rev 2016; Feb 11. pii: S1568-9972(16)30034-9. doi: 
10.1016/j.autrev.2016.02.008. [Epub ahead of print] 
 
Kavia RB, De Ridder D, Constantinescu CS, et al.  Randomised controlled trial of 
Sativex to treat detrusor activity in multiple sclerosis.  Mult Scler 2010; 16: 1349-
1359 
 
Koppel BS, Brust JCM, Fife T, et al.  Systematic review: efficacy and safety of 
medical marijuana in selected neurologic disorders: report of the Guideline 
Development Subcommittee of the American Academy of Neurology.  Neurology 
2014; 82: 1556-1563 
 
Krishnan S, Cairns R, Howard R.  Cannabinoids for the treatment of dementia.  
Cochrane Database Syst Rev 2009 Apr 15;(2):CD007204 
 
Lahat A, Lang A, Ben-Horin S.  Impact of cannabis treatment on the quality of life, 
weight and clinical disease activity in inflammatory bowel disease patients: a pilot 
prospective study.  Digestion 2012; 85: 1-8 
 
Lal S, Prasad N, Ryan M, et al.  Cannabis use amongst patients with inflammatory 
bowel disease.  Eur J Gastroenterol Hepatol 2011; 23: 891-896 
 
 [151] 
 
Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in 
combination for treatment of cancer chemotherapy-induced nausea and vomiting. J 
Pain Symptom Manage1991; 6: 352-359  
 
Langford RM, Mares J, Novotna A, et al.  A double-blind, randomized, placebo-
controlled, parallel-group study of THC/CBD oromucosal spray in combination with 
the existing treatment regimen, in the relief of central neuropathic pain in patients 
with multiple sclerosis. J Neurol 2013; 260: 984-997 
  
Leroux E, Taifas I, Valade D, et al.  Use of cannabis among 139 cluster headache 
sufferers.  Cephalalgia 2013; 33: 208-213 
 
Lev-Ran S, Roerecke M, Le Foll B, et al.  The association between cannabis use 
and depression: a systematic review and meta-analysis of longitudinal studies. 
Psychol Med 2014; 44: 797-810 
 
Leweke FM, Schneider U, Thies M, et al. Effects of synthetic delta9-
tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in 
man. Psychopharmacology (Berl) 1999; 142: 230–235 
 
Liang C, McClean MD, Marsit C, et al.  A population-based case-control study of 
marijuana use and head and neck squamous cell Cancer Prev Res (Phila) 2009; 2: 
759-768 
 
 [152] 
 
Lorenzetti V, Lubman DI, Whittle S, et al.  Structural MRI findings in long-term 
cannabis users: what do we know?  Subst Use Misuse 2010; 45: 1787-1808 
 
Lotan I, Treves TA, Roditi Y, Djaldetti R.  Cannabis (medical marijuana) treatment for 
motor and non-motor symptoms of Parkinson disease: an open-label observational 
study.  Clin Neuropharmacol 2014; 37: 41-44 
 
McGuire PK, Jones P, Harvey I, et al. Morbid risk of schizophrenia for relatives of 
patients with cannabis-associated psychosis. Schizophr Res, 1995; 15: 277–281 
 
McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. 
Cochrane Database Syst Rev 2014: 10. Art. No.: CD004837. DOI: 
10.1002/14651858.CD004837.pub3. 
 
Machado Rocha FC, Stefano SC, De Cassia, Haiek R, et al. Therapeutic use of 
Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer 
patients: systematic review and meta-analysis. Eur.J.Cancer Care (Engl) 2008; 17: 
431-443  
 
Madsen MV, Peacock LP, Werge T, et al.  Effects of cannabinoids CB1 receptor 
agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced 
dystonia in Cebus apella monkeys.  Neuropharmacology 2011; 60: 418-422 
 
Maida V. Nabilone for the treatment of paraneoplastic night sweats: a report of four 
cases.  J Palliat Med 2008; 11: 929-934 
 [153] 
 
Maida V, Ennis M, Irani S, et al.  Adjunctive nabilone in cancer pain and symptom 
management: a prospective observational study using propensity scoring.  J Support 
Oncol 2008; 6: 119-124 
 
Manrique-Garcia E, Zammit S, Dalman C, et al. Cannabis, schizophrenia and other 
non-affective psychoses: 35 years of follow-up of a population-based cohort. 
Psycholl Med 2012; 42: 1321-1328  
 
Manrique-Garcia E, Zammit S, Dalman C, et al. Prognosis of schizophrenia in 
persons with and without a history of cannabis use. Psychol Med 2014; 44: 2513-
2521 
 
Marco EM, Viveros MP. The critical role of the endocannabinoid system in emotional 
homeostasis: avoiding excess and deficiencies. Mini Rev Med Chem 2009; 9: 1407-
1415  
 
Massa F, Storr M, Lutz B.  The endocannabinoid system in the physiology and 
pathophysiology of the gastrointestinal tract. J Mol Med (Berl) 2005; 83: 944-954 
 
Matheson SL, Shepherd AM, Laurens KR, Carr VJ. A systematic meta-review 
grading the evidence for non-genetic risk factors and putative antecedents of 
schizophrenia. Schizophr Res 2011; 133: 133-42 
 
Matsuda LA, Lolait SJ, Brownstein MJ, et al.  Structure of a cannabinoid receptor 
and functional expression of the cloned cDNA.  Nature 1990; 346: 561-564 
 [154] 
 
Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in 
combination with ondansetron versus ondansetron alone for delayed chemotherapy-
induced nausea and vomiting. Curr Med Res Opin 2007; 23: 533-43 
 
Melamede R.  Cannabis and tobacco smoke are not equally carcinogenic.  Harm 
Reduct J 2005; 2: 21 
 
Meyniel C, Ollivier Y, Hamidou M, et al.  Dramatic improvement of refractory Isaacs’ 
syndrome after treatment with dronabinol.  Clin Neurol Neurosurg 2011; 113: 323-
324 
 
Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic 
or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-328 
 
Muller-Vahl KR, Schneider U, Koblenz A, et al.  Treatment of Tourette’s syndrome 
with Delta-9-tetrahydrocannabinol (THC): a randomised crossover trial.  
Pharmacopsychiatry 2002; 35: 57-61  
 
Muller-Vahl KR, Schneider U, Prevedel H, et al.  Delta-9-tetrahydrocannabinol (THC) 
is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.  
J Clin Psychiatry 2003; 64: 459-465  
 
Munro S, Thomas KL, Abu-Shaar M.  Molecular characterization of a peripheral 
receptor for cannabinoids.  Nature 1993; 365: 61-65 
 
 [155] 
 
Munson AE, Harris LS, Friedman MA et al.  Antineoplastic activity of cannabinoids. J 
Natl Cancer Inst 1975; 55: 597-602 
 
Naftali T, Lev LB, Yablecovitch D, et al. Treatment of Crohn’s disease with cannabis: 
an observational study.  Isr Med Assoc J 2011; 13: 455-458 
 
Narang S, Gibson D, Wasan AD, et al.  Efficacy of dronabinol as an adjuvant 
treatment for chronic pain patients on opioid therapy.  J Pain 2008; 9: 254-264 
 
Nelson K, Walsh D, Deeter P, Sheehan F.  A phase II study of delt-9-
tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.  J Palliat 
Care 1994; 10: 14-18 
 
Neumeister A , Normandin MD , Pietrzak RH , et al. Elevated brain cannabinoid CB1 
receptor availability in post-traumatic stress disorder: a positron emission 
tomography study. Mol Psychiatry 2013; 18: 1034-1040 
 
Nguyen BM, Kim D, Bricker S, et al.  Effective marijuana use on outcomes in 
traumatic brain injury.  Am Surg 2014; 80: 979-983 
 
Nikan M, Nabavi SM, Manayi A.  Ligands for cannabinoid receptors, promising 
anticancer agents.  Life Sci 2016; 146: 124-130 
 
 
 [156] 
 
Notcutt W, Langford R, Davies P, et al.  A placebo-controlled, parallel-group, 
randomized withdrawal study of subjects with symptoms of spasticity due to multiple 
sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 2012; 18: 
219-228 
 
Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-
controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®), as add-
on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J 
Neurol 2011; 18: 1122-1131 
 
Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic 
pain characterised by allodynia: a randomised, double-blind, placebo-controlled 
clinical trial.  Pain 2007; 133: 210-220 
 
Nutt D, Keen LA, Saulsbury W, Blakemore C. Development of a rational scale to 
assess the harm of drugs of potential misuse.  Lancet 2007; 369: 1047-1053 
 
Ongur D, Lin L, Cohen BM. Clinical characteristics influencing age at onset in 
psychotic disorders. Compr Psychiatry 2009; 50: 13-19 
 
Parker LA, Rock E, Limebeer C. Regulation of nausea and vomiting by 
cannabinoids. Br.J.Pharmacol 2010; 163: 1411-1422  
 
 [157] 
 
Passie T, Emrich HM, Karst M, et al. Mitigation of post-traumatic stress symptoms by 
Cannabis resin: a review of the clinical and neurobiological evidence. Drug Test Anal 
2012; 4: 649-659 
 
Pava MJ, Makriyannis A, Lovinger DM.  Endocannabinoid signaling regulates sleep 
stability.  PLoS One 2016; Mar 31;11(3):e0152473. doi: 10.1371/ journal. 
pone.0152473. eCollection 2016 
 
Pavisian B, MacIntosh BJ, Szilagyi G, et al.  Effects of cannabis on cognition in 
patients with MS: a psychometric and MRI study.  Neurology 2014; 82: 1879-1887 
 
Pertwee RG.  Endocannabinoids and their pharmacological actions.  Handb Exp 
Pharmacol 2015; 231: 1-37 
 
Petro DJ, Ellenberger C Jr. Treatment of human spasticity with delta 9-
tetrahydrocannabinol. J Clin Pharmacol 1981; 21(8-9 Suppl): 413S-416S 
 
Pickering EE, Semple SJ, Nazir MS, et al.  Cannabinoid effects on ventilation and 
breathlessness: a pilot study of efficacy and safety.  Chron Respir Dis 2011; 8: 109-
118 
 
Pini LA, Guerzoni S, Cainazzo MM, et al.  Nabilone for the treatment of medication 
overuse headache: results of a preliminary double-blind, active-controlled, 
randomized trial.  J Headache Pain 2012; 13: 677-684 
 
 [158] 
 
Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the 
synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized 
controlled trial.  Wien Klin Wochenschr 2006; 118: 327-335 (article in German) 
 
Pooyania S, Ethans K, Szturm T et al.  A randomized, double-blinded, crossover 
pilot study assessing the effect of nabilone on spasticity in persons with spinal cord 
injury.  Arch Phys Med Rehabil 2010; 91: 703-707 
 
Portenoy RK, Ganae-Motan ED, Allende S, et al.  Nabximols for opioid-treated 
cancer patients with poorly-controlled chronic pain: a randomized, placebo-
controlled, graded-dose trial.  J Pain 2012; 13: 438-449 
 
Power R, Verweij K, Martin N, et al. Genetic predisposition to schizophrenia 
associated with increased use of cannabis. Mol Psychiatry 2014; 19: 1201-1204 
 
Privateer Holdings.  Diversion of medical marijuana in Oregon.  A Privateer Holdings 
Whitepaper.  April 15, 2015 
 
Rabinak CA, Angstadt M, Lyons M, et al. Cannabinoid modulation of prefrontal-limbic 
activation during fear extinction learning and recall in humans. Neurobiol Learn Mem 
2014; 113: 125-134 
 
Raby WN, Modica PA, Wolintz RJ, Murtaugh K.  Dronabinol reduces signs and 
symptoms of idiopathic intracranial hypertension.  A case report.  J Ocul Pharamcol 
Ther 2006; 22: 68-75 
 [159] 
 
Ramaekers JG, Berghaus G, van Laar M, Drummer OH.  Dose related risk of motor 
vehicle crashes after cannabis use.  Drug Alcohol Depend 2004; 73: 109-119 
 
Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users 
in an Australian rural area. Addiction 1998; 93: 837–846 
 
Reznik I. Post-traumatic stress disorder and medical cannabis use: a naturalistic 
observational study. Eur Neuropsychopharm 2012; 22: S363-S364 
 
Rhyne DN, Anderson SL, Gedde M, Borgelt LM.  Effects of medical marijuana on 
migraine headache frequency in an adult population.  Pharmacotherapy 2016 Jan 9. 
doi: 10.1002/phar.1673. [Epub ahead of print]  
 
Robbins MS, Tarshish S, Solomon S, Grosberg BM.  Cluster attacks responsive to 
recreational cannabis and dronabinol.  Headache 2009; 49: 914-916 
 
Rodriguez De Fonseca F, Gorriti MA, Bilbao A, et al.  Role of the endogenous 
cannabinoid system as a modulator of dopamine transmission: implications for 
Parkinson’s disease and schizophrenia.  Neurotox Res 2001; 3: 23-35 
 
Rog DJ, Nurmikko TJ, Friede T, Young CA.  Randomised, controlled trial of 
cannabis-based medicine in central pain in multiple sclerosis.  Neurology 2005; 65: 
812-819 
 
 [160] 
 
Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. 
Neurotherapeutics 2015; 12: 747-768 
 
Ruggieri MR Sr.  Cannabinoids: potential targets for bladder dysfunction.  Handb 
Exp Pharmacol 2011; 202: 425-451 
 
Rumalla K, Reddy AY, Mittal MK.  Recreational marijuana use and acute ischaemic 
stroke: a population-based analysis of hospitalised patients in the United States.       
J Neurol Sci 2016 May 15; 364: 191-6. doi: 10.1016/j.jns.2016.01.066. Epub 2016 
Feb 4. 
 
Russo E.  Cannabis for migraine treatment: the once and future prescription? An 
historical and scientific review.  Pain 1998; 76: 3-8 
 
Russo E.  History of cannabis as a medicine.  In: The Medicinal Uses of Cannabis 
and Cannabinoids.  Eds: Guy GW, Whittle BA, Robson PJ.  Pharmaceutical Press 
2004a, London 
 
Russo EB.  Clinical endocannabinoid deficiency (CECD): can this concept explain 
therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome 
and other treatment-resistant conditions?  Neuro Endocrinol Lett 2004b; 25: 31-39 
 
Russo EB, Merzouki A, Mesa J, et al.  Cannabis improves night vision: a case study 
of dark adaptometry and scotopic sensitivity in kif smokers of the Rif mountains of 
northern Morocco.  J Ethnopharmacol 2004; 93: 99-104 
 [161] 
 
Russo EB.  Clinical endocannabinoid deficiency (CECD): can this concept explain 
therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome 
and other treatment-resistant conditions?  Neuro Endocrinol Lett 2008; 29: 192-200 
 
Sagredo O, Pazos MR, Satta V, et al.  Neuroprotective effects of phytocannabinoid-
based medicines in experimental models of Huntington’s disease.  J Neurosci Res 
2011; 89: 1509-1518 
 
Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving 
chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol 
and prochlorperazine.  N Engl J Med 1980; 302: 135-138 
 
Salomonsen-Sautel S, Sakai JT, Thurstone C, et al.  Medical marijuana use among 
adolescents in substance abuse treatment.  J Am Acad Child Adolesc Psychiatry 
2012; 51: 694-702 
 
Sarfaraz S, Afaq F, Adhami VM, Mukhtar H.  Cannabinoid receptor as a novel target 
for the treatment of prostate cancer.  Cancer Res 2005; 65: 1635-1641 
 
Schier AR, Ribeiro NP, Silva AC, et al. Cannabidiol, a Cannabis sativa constituent, 
as an anxiolytic drug. Rev Bras Psiquiatr, 2012; 34: S104-110 
 
Schierenbeck T, Riemann D, Berger M, Hornyak M.  Effect of illicit recreational drugs 
upon sleep: cocaine, ecstasy and marijuana.  Sleep Med Rev 2008; 12: 381-389 
 
 [162] 
 
Schindler F, Anghelescu I, Regen F, Jockers-Scherubl, M. Improvement in refractory 
obsessive compulsive disorder with dronabinol. Am J Psychiatry 2008; 165: 536-537 
 
Schley M, Legler A, Skopp G, et al.  Delta-9-THC based monotherapy in fibromyalgia 
patients on experimental induce pain, axon reflex flare and pain relief.  Curr Med Res 
Opin 2006; 22: 1269-1276 
 
Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment 
impairs sensorimotor gating, recognition memory, and the performance in a 
progressive ratio task in adult rats. Neuropsychopharmacol 2003; 28: 
1760–1769 
 
Schultes RE, Klein WN, Plowman T, Lockwood TE.  Cannabis: an example of 
taxonomic neglect.  Botanical Museum Leaflets, Harvard University 1974; 23: 337-
367 
 
Serpell MG, Notcutt W, Collin C.  Sativex long-term use: an open-label trial in 
patients with spasticity due to multiple sclerosis.  J Neurol 2013; 260: 285-295 
 
Shelef A, Barak Y, Berger U, et al.  Safety and efficacy of medical cannabis oil for 
behavioral and psychological symptoms of dementia: an open label add-on pilot 
study.  J Alzheimers Dis 2016; 51: 15-19 
 
 [163] 
 
Skaper SD, Di Marzo V.  Endocannabinoids in nervous system health and disease: 
the big picture in a nutshell.  Philos Trans R Soc Lond B Biol Sci 2012; 367: 3193-
3200 
 
Skrabek RQ, Galimova L, Ethans K, Perry D.  Nabilone for the treatment of pain in 
fibromyalgia.  J Pain 2008; 9: 164-173 
 
Smith SC, Wagner MS.  Clinical endocannabinoid deficiency (CECD) revisited: can 
this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, 
irritable bowel syndrome and other treatment resistant conditions?  Neuro Endocrinol 
Lett 2014; 35: 198-201 
 
Smith LA, Azariah F, Lavender VTC, et al. Cannabinoids for nausea and vomiting in 
adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015 Nov 
12;11:CD009464. doi: 10.1002/14651858.CD009464.pub2 
 
Stander S, Reinhardt HW, Luger TA.  Topical cannabinoid agonists: an effective new 
possibility for treating chronic pruritus.  Hautarzt 2006; 57: 801-807 
 
Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR.  Human skin permeation of 
delta8-tetrahydrocannabidol, cannabidiol and cannabinol.  J Pharm Pharmacol 2004; 
56: 291-297 
 
 
 [164] 
 
Strasser F, Luftner D, Possinger K, et al.  Comparison of orally administered 
cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-
related anorexia – cachexia syndrome: a multicenter, phase III, randomized, double-
blind, placebo-controlled, clinical trial from the Cannabis-in-Cachexia-Study-Group. J 
Clin Oncol 2006; 24: 3394-3400 
 
Svendsen KB, Jensen TS, Bach FW.  Does the cannabinoid dronabinol reduce 
central pain in multiple sclerosis? Randomised double blind placebo controlled 
crossover trial.  BMJ 2004; 329: 253 
 
Tashkin DP, Reiss S, Schapiro BJ, et al.  Bronchial effects of aerosolized delt-9-
tetrahydrocannabinol in healthy and asthmatic subjects.  Am Rev Respir Dis 1977; 
115: 57-65 
 
Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol 
Depend. 1996; 42: 201–207  
 
Timpone JG, Wright DJ, Li N, et al.  Safety and pharmacokinetics of single-agent 
and combination therapy with megestrol acetate and dronabinol for the treatment of 
HIV wasting syndrome. The DATRI 004 Study Group.  Division of AIDS Treatment 
Research Initiative.  AIDS Res Hum Retroviruses 1997; 13: 305-315 
 
Tomida I, Pertwee RG, Azuara-Blanco A.  Cannabinoids and glaucoma.  Br J 
Ophthalmol 2004; 88: 708-713  
 
 [165] 
 
Tomida I, Azuara-Blanco A, House H, et al.  Effect of sublingual application of 
cannabinoids on intraocular pressure: a pilot study.  J Glaucoma 2006; 15: 349-353 
 
Toth C, Mawani S, Brady S, et al.  An enriched-enrolment, randomized withdrawal, 
flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of 
nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain.  Pain 
2012; 153: 2073-2082 
 
Trezza V, Campolongo P. The endocannabinoid system as a possible target to treat 
both the cognitive and emotional features of post-traumatic stress disorder (PTSD). 
Front Behav Neurosci 2013; 7: 100  
 
Turcotte D, Doupe M, Torabi M, et al.  Nabilone as an adjunctive to gabapentin for 
multiple sclerosis-induced neuropathic pain: a randomized controlled trial.  Pain Med 
2015; 16: 149-159 
 
Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for 
intractable paediatric epilepsy: the current Israeli experience.  Seizure 2016; 35: 41-
44 
 
Uribe Roca MC, Micheli F, Viotti R.  Cannabis sativa and dystonia secondary to 
Wilson’s disease.  Mov Disord 2005; 20: 113-115 
 
US Department of Health and Human Services. Marijuana: Facts parents need to 
know. NIH Publication 2014; 14-4036.  
 [166] 
 
Vachova M, Novotna A, Mares J et al. A multicentre, randomised, parallel-group, 
placebo-controlled study of effect of long term Sativex treatment on cognition and 
mood of patients with spasticity due to multiple sclerosis. J Mult Scler 2014; 1: 2-8 
 
van den Elsen GA, Ahmed AL, Verkes RJ, et al.  Tetrahydrocannabinol for 
neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology 
2015; 84: 2338-2346 
 
Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al.  Efficacy, safety and tolerability of 
an orally administered cannabis extract in the treatment of spasticity in patients with 
multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. 
Mult Scler 2004; 10: 417-424 
 
Veen ND, Selten JP, van der Tweel I, et al. Cannabis use and age at onset of 
schizophrenia. Am J Psychiat 2004; 161: 501–506 
 
Velasco G, Galve-Roperh I, Sanchez C et al.  Hypothesis: cannabinoid therapy for 
the treatment of gliomas? Neuropharmacology 2004; 47: 315-323 
 
Velasco G, Sanchez C, Guzman M.  Endocannabinoids and cancer.  Handb Exp 
Pharmacol 2015; 231: 449-472 
 
Venderova K, Ruzicka E, Vorisek V, Visnovsky P.  Survey on cannabis use in 
Parkinson's disease: subjective improvement of motor symptoms.  Mov Disord 2004; 
19: 1102-1106 
 [167] 
 
Volicer L, Stelly M, Morris J, et al.  Effects of dronabinol on anorexia and disturbed 
behavior in patients with Alzheimer’s disease.  Int J Geriatr Psychiatry 1997; 12: 913-
919 
 
Wade DT, Makela P, Robson P, et al.  Do cannabis-based medicinal extracts have 
general or specific effects on symptoms in multiple sclerosis? A double-blind, 
randomized, placebo-controlled study on 160 patients.  Mult Scler 2004; 10: 434-441 
 
Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic 
applications of cannabinoids in oncology. Supportive Care in Cancer 2003; 11: 137-
43 
 
Walther S, Mahlberg R, Eichmann U, Kunz D.  Delta-9-tetrahydrocannabinol for 
nighttime agitation in severe dementia. Psychopharmacology 2006; 185: 524-528 
 
Ware MA, Adams H, Guy GW.  The medicinal use of cannabis in UK: results of a 
nationwide survey. Int J Clin Pract 2005; 59: 291-295 
 
Ware MA, Fitzcharles MA, Joseph L, Shir Y.  The effects of nabilone on sleep in 
fibromyalgia: results of a randomized controlled trial.  Anesth Analg 2010a; 110: 604-
610 
 
Ware MA, Wang T, Schapiro S, et al.  Smoked cannabis for chronic neuropathic 
pain: a randomized controlled trial.  CMAJ 2010b; 182: E694-701 
 
 [168] 
 
Whiting PF, Wolff RF, Deshpande S, et al.  Cannabinoids for medical use: a 
systematic review and meta-analysis.  JAMA 2015; 313: 2456-2473 
 
Wilsey B, Marcotte T, Tsodikov A, et al.  A randomized, placebo-controlled, 
crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9: 506-521 
 
Wissel J, Haydn T, Muller J, et al.  Low dose treatment with the synthetic 
cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind 
placebo-controlled cross-over trial.  J Neurol 2006; 253: 1337-1341 
 
Witkin JM, Tzavara ET, Nomikos GG.  A role for cannabinoid CB1 receptors in mood 
and anxiety disorders.  Behav Pharmacol 2005; 16: 315-331 
 
Woodhams SG, Sagar DR, Burston JJ, Chapman V.  The role of endocannabinoid 
system in pain.  Handb Exp Pharmacol 2015; 227: 119-143 
 
Woodward MR, Harper DG, Stolyar A, et al.  Dronabinol for the treatment of agitation 
and aggressive behavior in acutely hospitalized severely demented patients with 
noncognitive behavioral symptoms. Am J Geriatr Psychiatry 2014; 22: 415-419 
 
Woolridge E, Barton S, Samuel J, et al.  Cannabis use in HIV for pain and other 
medical symptoms.  J Pain Symptom Manage 2005; 29: 358-367 
 
 [169] 
 
Wright S, Duncombe P, Altman DG.  Assessment of blinding to treatment allocation 
in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: 
a new approach. Trials 2012; 13: 189 
 
Yucel M, Solowij N, Respondek C, et al.  Regional brain abnormalities associated 
with long-term heavy cannabis use. Arch Gen Psychiatry 2008; 65: 694-701 
 
Yucel M, Lorenzetti V, Suo C, et al.  Hippocampal harms, protection and recovery 
following regular cannabis use.  Transl Psychiatry 2016; Jan 12;6:e710. doi: 
10.1038/tp.2015.201 
 
Zajicek J, Fox P, Sanders H, et al.  Cannabinoids for treatment of spasticity and 
other symptoms related to multiple sclerosis (CAMS study): multicentre randomised 
placebo-controlled trial.  Lancet 2003; 362: 1517-1526 
 
Zajicek JP, Hobart JC, Slade A et al.  Multiple sclerosis and extract of cannabis: 
results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012; 83: 1125-1132 
 
Zettl UK, Rommer P, Hipp P, Patejdl R.  Evidence for the efficacy and effectiveness 
of THC-CBD oromucosal spray in symptom management of patients with spasticity 
due to multiple sclerosis. Ther Adv Neurol Disord 2016; 9: 9-30 
 
